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A B S T R A C T
Background
Chlorpromazine, formulated in the 1950s, remains a benchmark treatment for people with schizophrenia.
Objectives
To review the effects of chlorpromazine compared with placebo, for the treatment of schizophrenia.
Search methods
We searched the Cochrane Schizophrenia Group’s Trials Register (15 May 2012). We also searched references of all identified studies
for further trial citations. We contacted pharmaceutical companies and authors of trials for additional information.
Selection criteria
We included all randomised controlled trials (RCTs) comparing chlorpromazine with placebo for people with schizophrenia and non-
affective serious/chronic mental illness irrespective of mode of diagnosis. Primary outcomes of interest were death, violent behaviours,
overall improvement, relapse and satisfaction with care.
Data collection and analysis
We independently inspected citations and abstracts, ordered papers, re-inspected and quality assessed these. We analysed dichotomous
data using risk ratio (RR) and estimated the 95% confidence interval (CI) around this. We excluded continuous data if more than 50%
of participants were lost to follow-up. Where continuous data were included, we analysed this data using mean difference (MD) with
a 95% confidence interval. We used a fixed-effect model.
Main results
We inspected over 1100 electronic records. The review currently includes 315 excluded studies and 55 included studies. The quality
of the evidence is very low. We found chlorpromazine reduced the number of participants experiencing a relapse compared with
placebo during six months to two years follow-up (n=512, 3 RCTs, RR 0.65 CI 0.47 to 0.90), but data were heterogeneous. No
difference was found in relapse rates in the short, medium or long term over two years, although data were also heterogeneous. We
found chlorpromazine provided a global improvement in a person’s symptoms and functioning (n=1164, 14 RCTs, RR 0.71 CI 0.58
to 0.86). Fewer people allocated to chlorpromazine left trials early ( n=1831, 27 RCTs, RR 0.64 CI 0.53 to 0.78) compared with
placebo. There are many adverse effects. Chlorpromazine is clearly sedating (n=1627, 23 RCTs, RR 2.79 CI 2.25 to 3.45), it increases
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a person’s chances of experiencing acute movement disorders (n=942, 5 RCTs, RR 3.47 CI 1.50 to 8.03) and parkinsonism (n=1468,
15 RCTs, RR 2.11 CI 1.59 to 2.80). Akathisia did not occur more often in the chlorpromazine group than placebo. Chlorpromazine
clearly causes a lowering of blood pressure with accompanying dizziness (n=1488, 18 RCTs, RR 2.38 CI 1.74 to 3.25) and considerable
weight gain (n=165, 5 RCTs, RR 4.92 CI 2.32 to 10.43).
Authors’ conclusions
The results of this review confirm much that clinicians and recipients of care already know but aim to provide quantification to support
clinical impression. Chlorpromazine’s global position as a ’benchmark’ treatment for psychoses is not threatened by the findings of this
review. Chlorpromazine, in common use for half a century, is a well-established but imperfect treatment. Judicious use of this best
available evidence should lead to improved evidence-based decision making by clinicians, carers and patients.
P L A I N L A N G U A G E S U M M A R Y
Chlorpromazine versus placebo for schizophrenia
For previous plain language summary please see Appendix 3.
People with schizophrenia often hear voices or see things (hallucinations) and have strange beliefs (delusions). The main treatment
for these symptoms of schizophrenia is antipsychotic drugs. Chlorpromazine was one of the first drugs discovered to be effective in
the treatment of schizophrenia during the 1950s. It remains one of the most commonly used and inexpensive treatments even today.
However, being an older drug (‘typical’ or first generation) it also has serious side effects, such as blurred vision, a dry mouth, tremors
or uncontrollable shaking, depression, muscle stiffness and restlessness.
An update search was carried out in 2012 and the review now includes 55 studies that assess the effects of chlorpromazine in treating
schizophrenia compared with no active treatment (‘dummy’ treatment or placebo). Evidence was, in the main, rated by the review
authors as low quality. There is some evidence to suggest that chlorpromazine reduces relapse and improves people’s mental health,
symptoms and functioning. However, the side effects of chlorpromazine are severe and debilitating. Chlorpromazine causes sleepiness
and sedation. It also causes movement disorders (such as tremors and uncontrollable shaking), considerable weight gain and lowering
of blood pressure with accompanying dizziness.
Chlorpromazine is low-cost and widely available. Despite its many side effects, chlorpromazine is likely to remain a benchmark drug
and one of the most widely used treatments for schizophrenia worldwide.
It should be noted that the quality of evidence from the 55 included studies was low and in addition to this, 315 studies were excluded
because of flaws in the reporting of information or data and in research design and methods. Larger, better conducted and reported
trials should focus on important outcomes such as quality of life, levels of satisfaction, relapse, hospital discharge or admission and
number of violent incidents.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
CHLORPROMAZINE versus PLACEBO for schizophrenia
Patient or population: pat ients with schizophrenia
Settings: hospital and community
Intervention: CHLORPROMAZINE versus PLACEBO
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control CHLORPROMAZINE
versus PLACEBO
Death
Follow-up: 5 weeks
See comment See comment Not est imable 14
(1 study)
⊕©©©
very low1,2
One study specif ically
reported mortality and
there were no deaths
in either the chlor-
promazine or placebo
group. There were no
reports of death in any
other study
Relapse
Follow-up: 6 months to
2 years
710 per 1000 461 per 1000
(334 to 639)
RR 0.65
(0.47 to 0.90)
512
(3 studies)
⊕©©©
very low3,4
2 trials report this out-
come at 0-8 weeks fol-
low-up, 3 trials at 6
months to 2 years, and
2 trials 2-5 years, none
showed a signif icant
dif f erence
Global state: no overall
improvement
(psychiatrist - rated)
Follow-up: 9 weeks to 6
months
897 per 1000 637 per 1000
(520 to 772)
RR 0.71 (0.58 to 0.90) 1164
(14 studies)
⊕©©©
very low5,6,7
13 trials also reported
on this outcome at 0-
8 weeks follow-up and
showed a signif icant re-
sult in favour of chlor-
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promazine
Leaving the study early
Follow-up: 9 weeks to 6
months
200 per 1000 128 per 1000
(106 to 156)
RR 0.64
(0.53 to 0.78)
1831
(27 studies)
⊕⊕©©
low8
17 trials reported on
this outcome at 0-8
weeks follow-up and
showed signif icant re-
sults in favour of chlor-
promazine. 2 trials re-
ported on this outcome
at 6 months to 2 years
follow-up, and 1 trial
at 2-5 years, and there
was no signif icant dif -
ference
Satisfaction with treat-
ment - not reported
See comment See comment Not est imable - See comment No studies reported on
this outcome.
Behaviour: dete-
riorated/ disturbed/un-
cooperative
Follow-up: 9 weeks to 6
months
471 per 1000 231 per 1000
(113 to 471)
RR 0.49
(0.24 to 1.00)
1040
(8 studies)
⊕©©©
very low4,9
2 trials reported on this
outcome at 0-8 weeks
follow-up and found no
signif icant dif f erence
Cost of care - not re-
ported
See comment See comment Not est imable - See comment No studies reported on
this outcome.
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval; RR: Risk rat io
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
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1 Serious risk of bias: the study had an unclear risk of bias for random sequence generat ion, allocat ion concealment and other
bias as the drugs were provided by a pharmaceut ical company.
2 Very serious imprecision: there are very few part icipants and no events for this outcome.
3 Serious risk of bias: all studies had an unclear risk of bias for random sequence generat ion, allocat ion concealment, blinding
of assessors and incomplete data. One also had an unclear risk of other bias as the drugs were provided by a pharmaceut ical
company.
4 Very serious inconsistency: there was very high heterogeneity in the pooled results.
5 Serious risk of bias: one study had a high risk of bias for random sequence generat ion and in eleven studies it was unclear.
Twelve studies had an unclear risk of bias for allocat ion concealment. Blinding of part icipants and personnel was unclear in
seven studies and blinding of assessors was unclear in twelve. Four studies also had a high risk of other bias as they were
funded by industry.
6 Serious inconsistency: there was high heterogeneity in the pooled results.
7 Strongly suspected publicat ion bias: the funnel plot suggests that there may be studies without stat ist ically signif icant
ef fects that have not been included in this analysis.
8 Very serious risk of bias: twenty four of the studies had an unclear risk of bias for random sequence generat ion, and all but
one for allocat ion concealment. Twelve studies had an unclear risk of bias for blinding of part icipants and personnel and in
23 studies it was unclear whether assessors were blinded. Six studies also had a high risk of other bias as they were part ly
funded by industry.
9 Serious risk of bias: all studies had an unclear risk of bias for random sequence generat ion, and all but one for allocat ion
concealment. Three studies had an unclear risk of bias for blinding of part icipants and personnel, and in all studies it was
unclear whether assessors were blinded. Two studies also had a high risk of other bias as they were part ly funded by industry.
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B A C K G R O U N D
Description of the condition
Approximately 24millionpeople currently suffer from schizophre-
nia (WHO 1998), the majority of whom live in low- or mid-
dle-income countries. Chlorpromazine remains one of the most
commonly used and inexpensive treatments for people with
schizophrenia (Odejide 1982), despite its well-documented ad-
verse effects and the advent of a new generation of antipsychotic
drugs. It is one of the essential drugs listed by the World Health
Organization (WHO 2003). Chlorpromazine is commonly pre-
scribed in India, and in South East Asia, the older generation
of antipsychotics are used to treat the majority of people with
schizophrenia (Chong 2004). In 2003, chlorpromazine was the
most frequently prescribed of the first generation ’typical’ antipsy-
chotic drugs in the UK at a time when the ’typical’ group of an-
tipsychotics accounted for 44% of all antipsychotic prescriptions
(PPA, 2003).
Description of the intervention
Chlorpromazine, a drug developed in 1951 for reducing allergic
reactions (an antihistamine) began to be used as part of a cocktail
of drugs in order to induce a state of ’artificial hibernation’ for
surgical procedures (Laborit 1951). Its ability to reduce psychic
stress led researchers to demonstrate its effectiveness for treating
certain psychiatric disorders (Delay 1952). Chlorpromazine was
hailed as a major discovery for schizophrenia, an illness for which
few treatment options existed (Davis 1978). The impact of this
drug has been so great, that according to one author, it has been
heralded as the second revolution in psychiatry (the first being psy-
choanalysis) (Grozier 1973). Chlorpromazine is the first of many
drugs to be classed as a ’neuroleptic’ (literally translated: to grasp
the nerve), a term coined by two of its first protagonists (Delay
1952). Early trials of chlorpromazine for schizophrenia indicated,
that in comparison with placebo, it hastened clinical recovery, fa-
cilitated improvements in social functioning and was effective at
preventing relapse.
How the intervention might work
The antipsychotic effect of chlorpromazine results from its action
on particular areas within specific cells of the brain (Sedvall 1995).
It is thought to affect how receptive these cells are to dopamine.
However, chlorpromazine is not specific to one site of actionwithin
the body. Consequently, it is known to cause adverse effects rang-
ing from dry mouth, blurred vision and urinary retention as well
as restlessness, tremors, facial rigidity, shuffling gait and repetitive
movements of the face and/or trunk which can be difficult to re-
verse (APA 1992). Chlorpromazine has also been linked to depres-
sive symptoms that may be caused by the drug itself (neuroleptic
dysphoria, Awad 1993). In addition, the use of chlorpromazine
has been associated with a potentially fatal disturbance of blood
pressure, temperature and muscle control (neuroleptic malignant
syndrome, APA 1994).
Why it is important to do this review
There are questions relating to the differential response to drugs
between certain groups of people with schizophrenia. For example,
there may be differences in the effects of treatment for men and
women (Hambrecht 1992; Kendler 1995; Szymanski 1995), for
children, adults or the elderly (Kaplan 1990; Rosen 1990), or
for people who are experiencing their first episode as opposed to
those with a longer illness duration (Hill 1992; Szymanski 1996).
When prescribing drugs for schizophrenia dosage is important
in order to obtain optimal response with minimal adverse effects
(Bollini 1994; Kane 1985). There also remains debate about the
applicability of research findings to the ’real world’ of clinicians
(Jenicek 1990). For example, trials undertaken on highly selected
groups of people with schizophrenia may be of very limited use
in the ’everyday’ situation. We attempted to investigate whether,
for the primary outcomes of interest (see: Methods, Types of
outcomemeasures), a real difference exists for those with diagnoses
of schizophrenia made with operational ’checklists’ as opposed
to those with less rigorous diagnoses. A final question we posed
was whether the effects of chlorpromazine were different between
patients treated recently (1990-2002) to those treated in earlier
decades (1951-1989).
New trials often use chlorpromazine as the ’benchmark’ or ’con-
trol’ drug rather than a placebo when a new treatment is being
evaluated. The aim of this review is to evaluate this ’benchmark’
in comparison to placebo. This is an update of a Cochrane Re-
view first published in 1998, Issue 1 of The Cochrane Database
of Systematic Reviews (Thornley 1998a) and updated in 2003
(Thornley 2003) and 2007 (Adams 2007).
O B J E C T I V E S
To review the effects of chlorpromazine compared with placebo,
for the treatment of schizophrenia.
It was expected that several subgroup analyses could be undertaken
within this review (see Subgroup analysis and investigation of
heterogeneity).
M E T H O D S
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Criteria for considering studies for this review
Types of studies
We sought all relevant randomised controlled trials. Where a trial
was described as ’double blind’ but it was implied that the study
was randomised, we included these trials in a sensitivity analysis.
If their inclusion did not result in a substantive difference, they
remained in the analyses. If their inclusion did result in statistically
significant differences, we did not add the data from these lower
quality studies to the results of the better quality trials, but pre-
sented these within a subcategory. We excluded quasi-randomised
studies, such as those allocating by alternate days of the week.
Types of participants
We included people with schizophrenia and other types of
schizophrenia-like psychoses (schizophreniform and schizoaffec-
tive disorders) however diagnosed, irrespective of age, sex or sever-
ity of illness.
Types of interventions
1. Chlorpromazine: any dose or mode of administration
(oral or by injection)
2. Placebo (active or inactive) or no treatment
Types of outcome measures
We categorised outcomes as short term (zero to eight weeks),
medium term (nine weeks to six months) and long term (six
months to two years).
Primary outcomes
We classified these outcomes as primary outcomes for the 2002
update to help minimise the potential for multiple statistical test-
ing that could be undertaken within sensitivity analyses. We tried
to choose these on the grounds of clinical importance and were
helped in this by inclusion of a new co-reviewer, JR, who was not
as familiar with the data as the previous authors. We have used
the same outcomes but rearranged into new sub-headings for this
2012 update.
1. Death - suicide and natural causes
2. Relapse - as defined by each study
3. Global state
3.1 Overall improvement*
4. Leaving the study early
5. Satisfaction with treatment - participant/carer
6. Behaviour
6.1 Specific behaviours (e.g. aggressive or violent behaviour)
7. Economic
7.1 Cost of care
Secondary outcomes
1. Global state
1.1 Duration of hospital stay
1.2 Re-admission
1.3 Severity of Illness
2. Mental state
2.1 General symptoms
2.2 Specific symptoms
2.2.1 Positive symptoms (delusions, hallucinations, disordered
thinking)
2.2.2Negative symptoms (avolition, poor self-care, blunted affect)
2.2.3 Mood - depression
3. Behaviour
3.1 General behaviour
3.2 Social functioning
3.3 Employment status during trial (employed/unemployed)
3.4 Occurrence of violent incidents (to self, others or property)
4. Adverse effects
4.1 General
4.2 Specific
4.2.2Movement disorders (extrapyramidal side effects, specifically
tardive dyskinesia and neuroleptic malignant syndrome)
4.2.3 Sedation
4.2.4 Dry mouth
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5. ’Summary of findings’ table
Weused theGRADEapproach to interpret findings (Schünemann
2008) and GRADE profiler (GRADEPRO) to import data from
Review Manager 5 ( Review Manager) to create a ’Summary of
findings’ table. These tables provide outcome-specific informa-
tion concerning the overall quality of evidence from each included
study in the comparison, the magnitude of effect of the interven-
tions examined, and the sum of available data on all outcomes we
rate as important to patient-care and decision making. We have
selected the following main outcomes for inclusion in the ’Sum-
mary of findings’ table.
1. Death - suicide and natural causes
2. Overall improvement
3. Relapse - as defined by each study
4. Leaving the study early
5. Satisfaction with treatment - participant/carer
6. Specific behaviours (e.g. aggressive or violent behaviour)
7. Cost of care
Search methods for identification of studies
Electronic searches
For previous searches please see Appendix 2.
1. Cochrane Schizophrenia Group Trials Register (May 2012)
The Trials Search Co-ordinator searched the Cochrane
Schizophrenia Group’s Trials Register (15 May 2012).
The Cochrane Schizophrenia Group’s Trials Register is compiled
by systematic searches of major databases, handsearches of relevant
journals and conference proceedings (see group module).
Searching other resources
1. Reference searching
We inspected the references of all identified studies for further
studies.
2. Personal contact
For this update, we didnot contact the first author of each included
study for information regarding unpublished trials.
3. Pharmaceutical companies
In previous versions of this review, we contacted pharmaceutical
companies for any unpublished and published trials. Approaches
have been made to Rhone Poulenc Rorer, the original develop-
ers of chlorpromazine, for access to archive material. Dr R.A Par-
giter of Hobart, Tasmania very kindly donated a series of reports
from May and Baker (the pharmaceutical company which origi-
nally produced chlorpromazine) that listed presentations of work
relevant to chlorpromazine and schizophrenia, dating from 1955
to 1973. We (BT, CEA and JR) handsearched these for further
studies.
Data collection and analysis
Methods used in data collection and analysis for this 2012 update
are below; for previous methods please see Appendix 3.
Selection of studies
For this 2012 update, theCochrane Schizophrenia group provided
Enhance Reviews a database of relevant abstracts; the Enhance
Reviews team inspected full articles of the abstracts meeting the
inclusion criteria.
Data extraction and management
1. Extraction
For this 2012 update, two members of the Enhance Reviews team
extracted data from included studies. In addition, Jun Xia (JX)
extracted data for all Chinese studies. We extracted data presented
only in graphs and figures whenever possible. In the previous ver-
sions of the review, when further information was necessary, we
contacted authors of studies in order to obtain missing data or
for clarification. If studies were multi-centre, where possible, we
extracted data relevant to each component centre separately.
2. Management
2.1 Forms
We extracted data onto standard, simple forms, created in a web-
based software ( www.systematic-review.ca).
2.2 Scale-derived data
We included continuous data from rating scales only if:
a. the psychometric properties of the measuring instrument have
been described in a peer-reviewed journal (Marshall 2000); and
b. the measuring instrument had not been written or modified by
one of the trialists for that particular trial.
Ideally, the measuring instrument should either be i. a self-report
or ii. completed by an independent rater or relative (not the ther-
apist). We realise that this is not often reported clearly; we have
noted whether or not this is the case in Description of studies.
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2.3 Endpoint versus change data
There are advantages of both endpoint and change data. Change
data can remove a component of between-person variability from
the analysis. On the other hand, calculation of change needs two
assessments (baseline and endpoint), which can be difficult in
unstable and difficult tomeasure conditions such as schizophrenia.
We decided primarily to use endpoint data, and only use change
data if the former were not available. We combined endpoint and
change data in the analysis as we used mean differences (MD)
rather than standardised mean differences throughout (Higgins
2011, Chapter 9.4.5.2).
2.4 Skewed data
Continuous data on clinical and social outcomes are often not
normally distributed. To avoid the pitfall of applying parametric
tests to non-parametric data, we aimed to apply the following
standards to all data before inclusion:
a) standard deviations (SDs) and means are reported in the paper
or obtainable from the authors;
b) when a scale starts from the finite number zero, the SD, when
multiplied by two, is less than the mean (as otherwise the mean is
unlikely to be an appropriate measure of the centre of the distri-
bution (Altman 1996));
c) if a scale started from a positive value (such as the Positive and
Negative Syndrome Scale (PANSS, Kay 1986) which can have
values from 30 to 210), we modified the calculation described
above to take the scale starting point into account. In these cases
skew is present if 2 SD > (S-S min), where S is the mean score and
S min is the minimum score.
Endpoint scores on scales often have a finite start and end point
and these rules can be applied. We entered skewed endpoint data
from studies of fewer than 200 participants in additional tables
rather than into an analysis. Skewed data pose less of a problem
when looking at the mean if the sample size is large; we entered
such endpoint data into syntheses.
When continuous data are presented on a scale that includes a
possibility of negative values (such as change data), it is difficult
to tell whether data are skewed or not, we entered skewed change
data into analyses regardless of the size of the study.
2.5 Common measure
To facilitate comparison between trials, we intended to convert
variables that can be reported in different metrics, such as days in
hospital (mean days per year, per week or permonth) to a common
metric (e.g. mean days per month).
2.6 Conversion of continuous to binary
Where possible, we made efforts to convert outcome measures
to dichotomous data. This can be done by identifying cut-off
points on rating scales and dividing participants accordingly into
’clinically improved’ or ’not clinically improved’. It is generally
assumed that if there is a 50% reduction in a scale-derived score
such as the Brief Psychiatric Rating Scale (BPRS, Overall 1962)
or the PANSS (Kay 1986), this could be considered as a clinically
significant response (Leucht 2005; Leucht 2005a). If data based
on these thresholds were not available, we used the primary cut-
off presented by the original authors.
2.7 Direction of graphs
Where possible, we entered data in such a way that the area to
the left of the line of no effect indicated a favourable outcome for
chlorpromazine.
Assessment of risk of bias in included studies
For this 2012 update, two members of the Enhance Reviews team
worked independently by using criteria described in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011) to
assess trial quality for the new included studies and all previously
included studies. This new set of criteria is based on evidence of
associations between overestimate of effect and high risk of bias of
the article such as sequence generation, allocation concealment,
blinding, incomplete outcome data and selective reporting.
Where inadequate details of randomisation and other character-
istics of trials were provided, we did not contact authors of the
studies in order to obtain additional information.
We have noted the level of risk of bias in both the text of the review
and in the Summary of findings for the main comparison.
Measures of treatment effect
1. Binary data
For binary outcomes we calculated a standard estimation of the
risk ratio (RR) and its 95% confidence interval (CI). It has been
shown that RR is more intuitive (Boissel 1999) than odds ratios
and that odds ratios tend to be interpreted as RR by clinicians
(Deeks 2000).
2. Continuous data
For continuous outcomes we estimatedmean difference (MD) be-
tween groups. We would prefer not to calculate effect size mea-
sures (standardised mean difference (SMD)). However, if scales of
very considerable similarity were used, we presumed there was a
small difference in measurement, and we would have calculated
effect size and transformed the effect back to the units of one or
more of the specific instruments.
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Unit of analysis issues
1. Cluster trials
Studies increasingly employ ’cluster randomisation’ (such as ran-
domisation by clinician or practice), but analysis and pooling of
clustered data poses problems. Authors often fail to account for in-
tra-class correlation in clustered studies, leading to a ’unit of anal-
ysis’ error (Divine 1992) whereby P values are spuriously low, con-
fidence intervals unduly narrow and statistical significance overes-
timated. This causes type I errors (Bland 1997; Gulliford 1999).
We did not include any cluster trials in this review. If we had, where
clustering was not accounted for in primary studies, we would
have presented data in a table, with a (*) symbol to indicate the
presence of a probable unit of analysis error.Where clustering was
incorporated into the analysis of primary studies, we would have
presented these data as if from a non-cluster randomised study,
but adjusted for the clustering effect.
In subsequent versions of this reviewwewill seek to contact first au-
thors of studies to obtain intra-class correlation coefficients (ICC)
for their clustered data and to adjust for this by using accepted
methods (Gulliford 1999).
We have sought statistical advice and have been advised that the
binary data as presented in a report should be divided by a ’de-
sign effect’. This is calculated using the mean number of partici-
pants per cluster (m) and the ICC [Design effect=1+(m-1)*ICC]
(Donner 2002). If the ICC was not reported it was assumed to be
0.1 (Ukoumunne 1999).
If cluster studies have been appropriately analysed taking into ac-
count ICCs and relevant data documented in the report, synthe-
sis with other studies would have been possible using the generic
inverse variance technique.
2. Cross-over trials
A major concern of cross-over trials is the carry-over effect. It oc-
curs if an effect (e.g. pharmacological, physiological or psycho-
logical) of the treatment in the first phase is carried over to the
second phase. As a consequence, on entry to the second phase
the participants can differ systematically from their initial state
despite a wash-out phase. For the same reason cross-over trials are
not appropriate if the condition of interest is unstable (Elbourne
2002). As both effects are very likely in severe mental illness, we
only used data of the first phase of cross-over studies.
3. Studies with multiple treatment groups
Where a study involvedmore than two treatment arms, if relevant,
we presented the additional treatment arms in the comparisons. If
data were binary, we simply added these and combined within the
two-by-two table. If data were continuous, we combined data fol-
lowing the formula in section 7.7.3.8 (Combining groups) of the
Cochrane Handbook for Systemic reviews of Interventions (Higgins
2011).Where the additional treatment arms were not relevant, we
did not reproduce these data.
Dealing with missing data
1. Overall loss of credibility
At some degree of loss of follow-up, data must lose credibility (Xia
2009). We chose that, for any particular outcome, should more
than 50% of data be unaccounted for, we did not reproduce these
data or use them within analyses. If, however, more than 50% of
those in one arm of a study were lost, but the total loss was less
than 50%, we marked such data with (*) to indicate that such a
result may well be prone to bias.
2. Binary
In the case where attrition for a binary outcome was between 0%
and 50%, we presented data for the total number of participants
randomised for studies that used an intention-to-treat (ITT) anal-
ysis; where studies did not use an ITT analysis, we presented com-
pleter only data.
3. Continuous
3.1 Attrition
In the case where attrition for a continuous outcome was between
0% and 50%, and data only from people who completed the study
to that point were reported, we presented and used these data.
3.2 Standard deviations
If standard deviations (SDs) were not reported, we first tried to
obtain the missing values from the authors. If not available, where
there are missing measures of variance for continuous data, but
an exact standard error (SE) and confidence intervals (CIs) avail-
able for group means, and either P value or T value available for
differences in mean, we can calculate them according to the rules
described in the Cochrane Handbook for Systemic reviews of Inter-
ventions (Higgins 2011). When only the SE is reported, SDs are
calculated by the formula SD=SE * square root (n). Chapters 7.7.3
and 16.1.3 of the Cochrane Handbook for Systemic reviews of Inter-
ventions (Higgins 2011) present detailed formulae for estimating
SDs from P values, T or F values, CIs, ranges or other statistics. If
these formulae do not apply, we would calculate the SDs according
to a validated imputation method which is based on the SDs of the
other included studies (Furukawa 2006). Although some of these
imputation strategies can introduce error, the alternative would be
to exclude a given study’s outcome and thus to lose information.
We did not impute any SDs, if we had we would have examined
the validity of the imputations in a sensitivity analysis excluding
imputed values.
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3.3 Last observation carried forward
We anticipated that in some studies themethod of last observation
carried forward (LOCF) would be employed within the study
report. As with all methods of imputation to deal with missing
data, LOCF introduces uncertainty about the reliability of the
results (Leucht 2007). Therefore, where LOCF data have been
used in the trial, if less than 50% of the data have been assumed,
we reproduced these data and indicated that they are the product
of LOCF assumptions.
Assessment of heterogeneity
1. Clinical heterogeneity
We considered all included studies initially, without seeing com-
parison data, to judge clinical heterogeneity. We simply inspected
all studies for clearly outlying people or situations which we had
not predicted would arise. When such situations or participant
groups arose, we fully discussed these.
2. Methodological heterogeneity
We considered all included studies initially, without seeing com-
parison data, to judge methodological heterogeneity. We simply
inspected all studies for clearly outlyingmethodswhichwe had not
predicted would arise. When such methodological outliers arose,
we fully discussed these.
3. Statistical heterogeneity
3.1 Visual inspection
We visually inspected graphs to investigate the possibility of sta-
tistical heterogeneity.
3.2 Employing the I2 statistic
We investigated heterogeneity between studies by considering the
I2 method alongside the Chi2 P value. The I2 provides an estimate
of the percentage of inconsistency thought to be due to chance
(Higgins 2003). The importance of the observed value of I2 de-
pends on i. magnitude and direction of effects and ii. strength
of evidence for heterogeneity (e.g. P value from Chi2 test, or a
confidence interval for I2). An I2 estimate greater than or equal to
around 50% accompanied by a statistically significant Chi2 statis-
tic was interpreted as evidence of substantial levels of heterogene-
ity (Higgins 2011). When substantial levels of heterogeneity were
found in the primary outcome, we explored reasons for the het-
erogeneity (Subgroup analysis and investigation of heterogeneity).
If data were heterogeneous we used a random-effects model.
Assessment of reporting biases
Reporting biases arise when the dissemination of research findings
is influenced by the nature and direction of results (Egger 1997).
These are described in Section 10 of the Cochrane Handbook for
Systemic reviews of Interventions (Higgins 2011). We are aware that
funnel plots may be useful in investigating reporting biases but
are of limited power to detect small-study effects. We did not use
funnel plots for outcomes where there were 10 or fewer studies,
or where all studies were of similar sizes. In other cases, where
funnel plots were possible, we sought statistical advice in their
interpretation.
Data synthesis
We understand that there is no closed argument for preference for
use of fixed-effect or random-effects models. The random-effects
method incorporates an assumption that the different studies are
estimating different, yet related, intervention effects. This often
seems to be true to us and the random-effects model takes into
account differences between studies even if there is no statistically
significant heterogeneity. There is, however, a disadvantage to the
random-effects model: it puts added weight onto small studies,
which often are the most biased ones. Depending on the direction
of effect, these studies can either inflate or deflate the effect size.
We chose the fixed-effect model for all analyses. The reader is,
however, able to choose to inspect the data using the random-
effects model.
Subgroup analysis and investigation of heterogeneity
1. Subgroup analyses - only primary outcomes
1.1 Clinical state, stage or problem
We proposed to undertake this review and provide an overview
of the effects of chlorpromazine for people with schizophrenia in
general. In addition, however, we tried to report data on subgroups
of people in the same clinical state, stage andwith similar problems.
We also undertook subgroup analyses comparing the results for
the following:
• men versus women; under 18 years of age versus 18-65
years old versus older than 65;
• acutely ill people (< one-month in duration) versus people
who have been ill for longer;
• high dose (> 501 mg/day) versus low doses (1-500 mg/day);
• people diagnosed according to any operational criteria
versus those who have not been diagnosed using operational
criteria;
• studies published before 1990 versus studies published
between 1990 and the present.
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2. Investigation of heterogeneity
If inconsistency was high, we have reported this. First, we inves-
tigated whether data had been entered correctly. Second, if data
were correct, we visually inspected the graph and successively re-
moved outlying to see if homogeneity was restored.
When unanticipated clinical or methodological heterogeneity was
obvious we simply stated hypotheses regarding these for future
reviews or versions of this review.Wedonot anticipate undertaking
analyses relating to these.
Sensitivity analysis
We applied sensitivity analyses to the primary outcomes of this
review.
1. Implication of randomisation
We aimed to include trials in a sensitivity analysis if they were de-
scribed in some way so as to imply randomisation. For the primary
outcomes we included these studies and if there was no substan-
tive difference when the implied randomised studies were added
to those with better description of randomisation, then we entered
all data from these studies.
2. Assumptions for lost binary data
Where assumptions had to bemade regardingpeople lost to follow-
up (see Dealing with missing data), we compared the findings of
the primary outcomeswhenwe use our assumption/s andwhenwe
used data only from people who completed the study to that point.
A sensitivity analysis was undertaken to test how prone results
were to change when completer-only data only were compared
to the imputed data using the above assumption. If there was a
substantial difference, we reported results and discussed them but
continued to employ our assumption.
3. Risk of bias
We analysed the effects of excluding trials that were judged to be
at high risk of bias across one or more of the domains of randomi-
sation (implied as randomised with no further details available):
allocation concealment, blinding and outcome reporting for the
meta-analysis of the primary outcome. If the exclusion of trials at
high risk of bias did not substantially alter the direction of effect
or the precision of the effect estimates, thenwe included data from
these trials in the analysis.
4. Imputed values
Had we included any cluster-randomised trials, we would have
undertaken a sensitivity analysis to assess the effects of including
data from trials where we used imputed values for ICC in calcu-
lating the design effect in cluster-randomised trials.
If we noted substantial differences in the direction or precision of
effect estimates in any of the sensitivity analyses listed above, we
did not pool data from the excluded trials with the other trials
contributing to the outcome, but presented them separately.
R E S U L T S
Description of studies
Please see Characteristics of included studies and Characteristics
of excluded studies.
Results of the search
The original searches in 1995 yielded over 600 references, and after
initial appraisal we selected 201 studies for further inspection of
the full papers. An additional 50 papers were also identified from
the reference lists. We were able to include 45 relevant studies.
For the July 2002 update, we found 106 citations and were able
to include just one additional study, and four additional reports
of already included studies. In addition, May and Baker’s files of
reports of chlorpromazine studies, kindly supplied by Dr Pargiter
ofHobart, Tasmania, were handsearched by BT,CA and JR. These
files yielded 37 more records that met the review criteria. Three
of these reports were previously unknown studies that could be
included. Thirty-four were excluded. We are very grateful to Dr
Pargiter, who kept those files for so long and then, knowing that
they could at last be usefully employed, donated them. For the
January 2007 update search, we found 317 references from 142
studies. We were able to include one additional study (Xiong
1994).
The May 2012 update search identified a total of 21 new relevant
studies. Five trials met the inclusion criteria for this review and
there are now55 studies included in the latest version of this review
(see Figure 1). A total of 315 studies are now excluded. There are
no studies awaiting assessment and no ongoing studies have been
identified.
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Figure 1. Study flow diagram.
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Included studies
We included 55 studies.
1. Methods
Four included studies were cross-over trials (Baker 1959;
Letemendia 1967; Nishikawa 1982; Shepherd 1956), two had a
factorial design (Hamilton 1960; Hogarty 1973), and the remain-
der were parallel studies. All studies were either stated to be ran-
domised or implied randomisation.
2. Length of trials
The most common study length was six to 12 weeks but the range
was considerable with two trials being just over 24 hours in dura-
tion, whilst the two longest were over a period of three years.
3. Participants
It was reported in all trials that the participants suffered from
schizophrenia (with the exception of Vaughan 1955 who ran-
domised people with mental illnesses who were ’chronic and in-
tractable’ with motor restlessness, psychomotor agitation, and ex-
citement andHankoff 1962 who did not clearly state the diagnoses
but included psychiatric outpatients who were ’schizophrenic
and non-schizophrenic’, with the majority having schizophrenia).
Only 14 of the 55 trials described the diagnostic criteria used, or
the symptoms required for people to be included.Otherwise, entry
to most included studies was on a clinical diagnosis of schizophre-
nia. A total of 5506 participants are now included in this review.
4. Setting
Most studies were hospital-based with only a few of the studies
being undertaken in the community.
5. Study size
Themean number of participants was 99, ranging from 21 (Payne
1960) to 838 (Prien 1968).
6. Intervention
6.1 Chlorpromazine: The doses of chlorpromazine in these studies
ranged from 25 mg/day (Reschke 1974) to 2400 mg/day (Dean
1958). The mean dose was 574 mg/day (SD 446).
6.2 Placebo: All trials compared chlorpromazine with placebo or
no treatment. Kurland 1961 used a ’positive’ placebo (phenobar-
bital) and a ’negative’ placebo, the results of which were combined
in this review. Clark 1968a randomised participants to placebo
and a no-drug group, which were also combined in this review.
Prien 1968, however, randomised to a placebo group and a ’rou-
tine conventional hospital treatment’ group. These groups were
not combined because the latter had the opportunity to receive
any medication that the treating physicians felt appropriate (pre-
sumably including chlorpromazine). Prien 1968 also included two
arms, one with lower doses and the other with higher doses. We
pooled data from these arms in the main analysis and conducted
subgroup analyses.
6.3 Other drug treatment arms: Thirty-eight of the trials also
included at least one more drug treatment arm in addition to
placebo and chlorpromazine. Data were not included from these
treatment arms.
7. Outcomes
The following outcomes were reported by the included studies:
death, relapse, global impression, mental state, behaviour, leaving
the study early and adverse effects. None of the included studies
attempted to quantify levels of satisfaction, or quality of life and
there is no evidence of any direct economic evaluation of chlor-
promazine. Most outcomes analysed were dichotomous, and pre-
sented as such, or were ordinal data that could be dichotomised.
7.1 Outcome scales
The following scales provided continuous data for the analysis.
7.1.2 Mental state
i. Brief Psychiatric Rating Scale (Overall 1962)
A brief rating scale used to assess the severity of a range of psychi-
atric symptoms, including psychotic symptoms. The original scale
has 16 items, but a revised 18-item scale is commonly used. Each
item is defined on a seven-point scale varying from ’not present’ to
’extremely severe’, scoring from zero to six or one to seven. Scores
can range from zero to 126, with high scores indicating more se-
vere symptoms. Tetreault 1969 reported data from this scale.
ii. Global impression
4.7.2.1 Clinical Global Impression (Guy 1976)
A rating instrument commonly used in studies on schizophrenia
that enables clinicians to quantify severity of illness and overall
clinical improvement. A seven-point scoring system is usually used
with low scores indicating decreased severity and/or greater recov-
ery. Borison 1991 reported data from this scale.
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7.1.3 Behaviour
i. Modified Rosenthal Rating Scale (Rosenthal 1963)
A scale for nurses to rate the behaviour of psychiatric patients.
Lower scores indicate improved behaviour. Tetreault 1969 re-
ported data from this scale.
ii. Parkside Behaviour Rating Scale (Schmidt 1957)
A rating scale in which six behavioural characteristics are rated on a
five-point scale. The worst possible behaviour would carry a rating
of six points, as against amaximum of 30 points for unproblematic
behaviour. Baker 1959 reported data from this scale.
iii. Fergus Falls rating scale (Lucero 1951)
The L-M Fergus Falls Behavior Rating Scale is a method of rating
the behaviour of patients in mental hospitals, which measures 11
aspects of behaviour, and the changes in one patient over a length
of time. Ramu 1999a reported data from this scale.
7.1.4. Adverse effects
i. Extrapyramidal Bilan scale (Tetreault 1969a)
A nine-item rating scale for use by neurologists, to measure sever-
ity of symptoms such as facial mask, tremor, rigidity, akathisia,
dystonia, dyskinesia and others. Each item can be scored from zero
to three, such that the overall score can range from zero (no symp-
toms) to a possible 27 (severe symptoms of all types). Tetreault
1969 reported data from this scale.
Excluded studies
We have now excluded 315 studies. The studies listed in the ’Ex-
cluded studies’ section had to be inspected in hard copy in order
to make the final decision. Nearly half were not randomised, did
not imply randomisation or did not describe the allocation proce-
dure used. In several studies, participants were not suffering from
schizophrenia. Another sizeable proportion of the trials did not
compare chlorpromazine with placebo, but in combination with
other treatments. A few were chlorpromazine withdrawal studies
investigating the effects of instigation of treatment, which are not
relevant to this review. We will include these withdrawal studies in
a later review. Eighty-eight studies had no usable outcomes. Either
data did not have clear clinical implications, for example EEG
recordings, or genuinely relevant clinical data were not adequately
reported. Frequently the numbers of participants in each group
were not specified, means or standard deviations were not given or
data were not reported from individual arms of cross-over studies.
Awaiting assessment
No studies are currently awaiting assessment.
Ongoing studies
We identified no ongoing studies.
Risk of bias in included studies
Please also see Figure 2 and Figure 3.
Figure 2. ’Risk of bias’ graph: review authors’ judgements about each ’Risk of bias’ item presented as
percentages across all included studies.
15Chlorpromazine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 3. ’Risk of bias’ summary: review authors’ judgements about each ’Risk of bias’ item for each
included study.
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Allocation
Only four studies described the methods used to generate ran-
dom allocation. Two studies (Hine 1958; Letemendia 1967) ran-
domised by the toss of a coin, and two used tables of random num-
bers (Hamill 1975; Tetreault 1969a). Two studies (Cole 1964;
Hall 1955) described some form of allocation concealment (sealed
envelopes). For the other 53 studies, readers are given little as-
surance that bias was minimised during the allocation procedure,
yet 24 (24/53, 45%) reported that the participants allocated to
each treatment group were very similar. One study, Cooper 2000,
reported that participants were randomly assigned in blocks of six
and Weckowicz 1960 reported that participants were divided into
three matched groups. For the remaining studies it is improbable
that such equal numbers could have been obtained unless block
randomisation was used, yet 24 out of 53 studies (45%) had ex-
actly the same numbers in the chlorpromazine and placebo groups.
Blinding
Thirty-five studies had a low risk of bias for performance bias and
described the methods used to ensure blinding of participants and
personnel. Twenty studies had an unclear risk of bias. Nine studies
stated that outcome assessors were blinded and were rated a low
risk of bias, the remainder had an unclear risk of bias. Two studies
(Grygier 1958; Hall 1955) tested how successful their attempts at
blinding were. Three studies (Clark 1970b; Hamill 1975; Simon
1958) gave no indication that blinding had been attempted.
Incomplete outcome data
Twenty-nine studies were rated as low risk of bias for incomplete
outcome data and 19 studies had an unclear risk of bias. Seven
studies were rated as having a high risk of bias.
Selective reporting
Only five studies had a low risk of bias for selective reporting.
Three studies had an unclear risk of bias and 47 of the studies were
rated as high risk of bias for selective reporting.
Other potential sources of bias
Eight trials were subject to other biases as they were either partly
or fully funded by the pharmaceutical industry; in Borison 1991
two of the trialists are in prison for research fraud. Twelve studies
were of low risk of bias for other potential sources of bias and the
remainder had an unclear risk of bias.
Effects of interventions
See: Summary of findings for the main comparison
CHLORPROMAZINE versus PLACEBO for schizophrenia
We used risk ratios (RR) for dichotomous data and mean differ-
ences (MD) for continuous data, with their respective 95% con-
fidence intervals (CIs) throughout.
1. Comparison: CHLORPROMAZINE versus
PLACEBO
We categorised outcomes as short term (up to eight weeks),
medium term (nine weeks to six months) and long term (six
months to two years).
1.1 Death
We found only one small trial (n=14) that specifically reported
mortality (Baker 1959); there were no deaths in either the chlor-
promazine or placebo group (Analysis 1.1). We found no reports
of death in any study and currently over 5506 people have been
included in trials relating to this review (of which 1741 were given
chlorpromazine).
1.2 Relapse
We found short-term (n=74, 2 RCTs) and medium-term (n=809,
4 RCTs) data did not show a significant difference in rates of re-
lapse (Analysis 1.2), but with significant heterogeneity (I2=78%
and 96%, respectively). Removing the studies with results that
were causing this heterogeneity, as judged by visual inspection
(Prien 1968; Spohn 1977) eliminates this heterogeneity.We found
longer-term data (six months to two years) favoured the chlorpro-
mazine group (n=512, 3 RCTs, RR 0.65 CI 0.47 to 0.90), but
the two long-term studies lasting two to five years (Hogarty 1973;
Nishikawa 1982) showed no difference (n=394, 2 RCTs), again
with significant heterogeneity (I2 = 72% and 84%, respectively).
In this case, the larger trials (Hogarty 1973; Prien 1968) show a
better effect for chlorpromazine and it may well be that the smaller
trials are the outlying ones. However, Prien 1968 includes a high-
dose treatment arm (2000 mg/day of chlorpromazine), whichmay
explain some of the heterogeneity in the results, see the subgroup
analysis (Analysis 1.23) below.
1.3 Global state
1.3.1 No overall improvement
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We found short-term global state data (’no overall improvement’
- psychiatrist-rated ; Analysis 1.3) significantly favoured chlor-
promazine (n=728, 13 RCTs, RR 0.61 CI 0.46 to 0.82) com-
pared with placebo. Medium-term data up to six months also
favoured chlorpromazine (n=1164, 14 RCTs, RR 0.71 CI 0.58 to
0.86). There was significant heterogeneity at both short term and
medium term (I2=69% and 81%, respectively). There were no
obviously outlying trials for this outcome at short term, so none
were removed from the analysis. For medium term, removal of the
largest trial, Prien 1968, restores homogeneity, an effect that does
not appear in the subgroup analysis for high versus low dose, see
the subgroup analysis (Analysis 1.23) below, and again, it may be
the smaller trials that are outliers.
Nurse-rated global state ’no overall improvement’ scores (Analysis
1.4) were equivocal at short-term assessment in one small study
(Weckowicz 1960) (n=29, RR 0.91 CI 0.65 to 1.27). However,
scores from one research group (Clark 1970a; Clark 1972; Clark
1977) favoured chlorpromazine at medium-term assessment (n=
84, 3 RCTs, RR 0.48 CI 0.35 to 0.64). Similar data were recorded
in continuous form in only one small study (Borison 1991) and
results were equivocal (n=19, 1 RCT; Analysis 1.5).
1.3.2 Severity of illness
We found estimates by psychiatrists for the severity of illness (
Analysis 1.6) were equivocal at short-term assessments (n=44, 1
RCT) however, medium-term data showed significantly greater
improvement in the chlorpromazine group (n=694, 3 RCTs, RR
0.80CI 0.74 to 0.86) comparedwith placebo.Nurse-rated severity
of illness scores (Analysis 1.7) also favoured the chlorpromazine
group (medium term, n=66, 2 RCTs, RR 0.63 CI 0.45 to 0.90)
compared with placebo.
1.4 Leaving the study early
People allocated to chlorpromazine are more likely to remain in
the study than participants given placebo (Analysis 1.8), in both
short- (n=1065, 17 RCTs, RR 0.76 CI 0.63 to 0.92) andmedium-
term studies (n=1831, 27 RCTs, RR 0.64 CI 0.53 to 0.78). The
short-term studies showed some heterogeneity (I2 = 51%). When
we analyse the data using random-effects, the result becomes non-
significant (n=1065, 17 RCTs, RR 0.80 CI0.58 to 1.10). Remov-
ing the study with results that were causing this heterogeneity,
as judged by visual inspection (Cole 1964, which used very high
doses of chlorpromazine in one arm of the trial) eliminates this
heterogeneity.However, we did not find any significant differences
in attrition rates from the comparatively large studies (Engelhardt
1960,Hogarty 1973, n=492), whichwere conducted for up to two
years. Also, longer-term data (Hogarty 1973) did not demonstrate
a significant difference in retention rates.
1.5 Mental state
There are only a few studies with usable data relating to mental
state.
1.5.1 Improved (50% reduction in BPRS)
We found no short-term difference in mental state using a cut-off
point of at least a 50% decline in score to indicate ’improvement’
(Cooper 2000, n=106; Analysis 1.9).
1.5.2 Average endpoint score (BPRS)
What continuous data there are favour chlorpromazine at short-
(n=49, 2 RCTs, MD -4.82 CI -8.48 to -1.15) and medium-term
assessments (Tetreault 1969, n=30, MD -7.70 CI -14.77 to -0.63)
(Analysis 1.10).
1.5.3 Average change score (BPRS)
See Table 1.
1.6 Behaviour
1.6.1 Deteriorated/disturbed/un-cooperative
We found participants did not differ significantly in experienc-
ing a worsening in their behaviour (Analysis 1.11) at short-term
assessment (n=87, 2 RCTs), although data are heterogeneous (I
2=65%). Medium-term data also did not differ significantly (n=
1040, 8RCTs), but again, data are heterogeneous (I2=90%).There
are no obviously outlying studies as all confidence intervals over-
lap. Removing the possibly outlying studies, either Prien 1968 or
Hall 1955, does not restore homogeneity, nor does their removal
change the results.
1.6.2 Unchanged
Both short-term (Schiele 1961, n=40) and medium-term (n=68, 2
RCTs) dichotomous data did not reveal any significant differences
between chlorpromazine and placebo when assessing change in
participants behaviour (Analysis 1.12).
1.6.3 Rosenthal Rating Scale
Tetreault 1969 provided data from the Rosenthal Rating Scale (
Analysis 1.13) andwe found short-termdata were not significantly
different (n=30, 1 RCT) between chlorpromazine and the placebo
group. Medium-term data were also not significantly different (n=
30, 1 RCT).
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1.6.4 Parkside Behaviour Rating Scale
Baker 1959 used the Parkside Behaviour Rating Scale (Analysis
1.14) to assess behaviour and we found that those given chlorpro-
mazine had a significantly better rating in their behaviour com-
pared with the placebo group (n=14, MD 6.00 CI 1.97 to 10.03).
1.6.5 Fergus Falls Behavioural Rating Scale
Ramu 1999a used the Fergus Falls Behavioural Rating Scale (
Analysis 1.15) to assess change in behaviour of participants and
we found that behaviour was not significantly different (n=42, 1
RCT) between chlorpromazine and the placebo group.
1.7 Adverse effects
1.7.1 Extrapyramidal symptoms
There is evidence that chlorpromazine increases a person’s chances
of experiencing acute movement disorders (dystonia) (n=942, 5
RCTs, RR 3.47 CI 1.50 to 8.03), parkinsonism (n=1468, 15
RCTs, RR2.11CI 1.59 to 2.80), tremor (n=392, 7RCTs, RR 1.66
CI 1.01 to 2.73) and rigidity (n=412, 7 RCTs, RR 2.24 CI 1.42
to 3.54). Akathisia (subjective feeling of restlessness that may lead
to agitation) was dominated by one trial (Prien 1968) and did not
occur more frequently in the chlorpromazine group than placebo
(n=1164, 9 RCTs), nor did tardive dyskinesia (Clark 1977, n=
18) nor ataxia (Hankoff 1962, n=97). We found extrapyramidal
adverse effects were equivocal at both short- and medium-term
assessments from one small scale study (n=30) by Tetreault 1969.
(See Analysis 1.16; Analysis 1.17).
1.7.2 Central nervous system
Chlorpromazine is clearly sedating (n=1627, 23 RCTs, RR 2.79
CI 2.25 to 3.45). There is also evidence that chlorpromazine in-
creases a person’s chances of experiencing fits (n=695, 3 RCTs,
RR 3.11 CI 1.05 to 9.18) and weakness (n=92, 3 RCTs, RR 3.33
CI 1.02 to 10.88). Convulsions did not occur more frequently
in the chlorpromazine group than placebo (Gwynne 1962, n=52;
Analysis 1.18).
1.7.3 Blood, skin, liver and eyes
We found no significant differences in blood problems such as
agranulocytosis and leucopenia (n=394, 7 RCTs), or rashes and
itching (n=1313, 13 RCTs). Liver problems, mainly jaundice were
also not significant (n=249, 4 RCTs). Further data from early trials
suggest that chlorpromazine may well cause photosensitivity (n=
799, 6 RCTs, RR 6.04 CI 3.22 to 11.32), and eye opacities or
pigment problems (n=657, 2 RCTs, RR 3.09 CI 1.87 to 5.11)
when large dosages of chlorpromazine are used. (See Analysis
1.19).
1.7.4 Other
Chlorpromazine clearly causes a lowering of blood pressure with
accompanying dizziness (n=1488, 18 RCTs, RR 2.38 CI 1.74
to 3.25). Chlorpromazine is constipating, when compared with
placebo (n=1117, 10 RCTs, RR 2.05 CI 1.33 to 3.15). We found
data that urinary problems (n=926, 5 RCTs), and also blurred vi-
sion were not significantly different between chlorpromazine and
placebo. We found that chlorpromazine does cause dry mouth
(n=1015, 7 RCTs, RR 4.56 CI 2.35 to 8.85). Chlorpromazine
increases participants’ weight (n=165, 5 RCTs, RR 4.92 CI 2.32
to 10.43). We found significantly more participants given chlor-
promazine experienced nausea (n=1024, 5 RCTs, RR 2.07 CI
1.14 to 3.73). Salivation occurred significantly more frequently
in the chlorpromazine group (n=830, 3TCTs, RR 3.37 CI 1.07
to 10.57). We found no clear evidence that chlorpromazine pre-
cipitates the frequency of amenorrhoea, menorrhagia or lactation
problems. (See Analysis 1.20).
2. Subgroup analyses
2.1 Men versus women
Few studies reported outcomes for only men or women. The only
primary outcome for which data were available for comparison is
’Behaviour deteriorated/disturbed/uncooperative’ (Analysis 1.21).
Schiele 1961 included only men (n=40) and three studies report
the same outcome for women alone (Clark 1970b; Fleming 1959;
Somerville 1960, total n=158). Results of randomised trials were
equally significant for the subgroups.
2.2 Under 18 years of age versus 18-65 years old versus older
than 65
We could not perform this subgroup analysis as data were only
available for people between the ages of 18 and 64 years.
2.3 Acutely ill people (< one month in duration) versus
people who have been ill for longer
Limited data were available for a few primary outcomes (Analysis
1.22). We found that people who were chronically ill were more
likely to have improved for short- and medium-term global im-
provement, and disturbed behaviour compared with those whose
illnesses were acute. No difference was found for rates of relapse
between acute and chronic participants. Results of randomised
trials were equally significant for all subgroups. However, these
analyses are severely limited by the lack of studies in the acutely ill
groups and no firm conclusion can be made.
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2.4 High dose (> 501 mg/day) versus low doses (1-500
mg/day)
For the outcome of relapse between nine weeks and six months,
the high-dose arm of Prien 1968 reports statistically significantly
more favourable results for the chlorpromazine group, compared
with the low-dose group of studies (P < 0.005). However, for the
low-dose subgroup there remains significant heterogeneity that is
not explained by the exclusion of the high-dose arm of Prien 1968.
For the short- and medium-term outcome ’no global improve-
ment’, there is no clear difference between studies using high-dose
chlorpromazine to low dose. Higher dosages of chlorpromazine
did not confer an advantage in reducing behavioural disturbances,
compared with the low-dose group (Analysis 1.23).
2.5 People diagnosed according to any operational criteria
versus those who have not been diagnosed using operational
criteria
For relapse in short-term studies, the any operational criteria group
had a better outcome but the sample size is too small to enable
conclusions to bemade. Relapse in medium-term studies favoured
participants diagnosed with operational criteria (P < 0.04). Global
impression ’not improved’ revealed no differences in the short and
medium term. There were no apparent differences for severity of
illness and behaviour (Analysis 1.24).
2.6 Studies published before 1990 versus studies published
between 1990 and the present
Data were available for the outcomes of ’no overall improvement’
in the short term and medium term, and ’behaviour deteriorated/
disturbed/uncooperative’ (Analysis 1.25). Few studies were avail-
able in the 1990 to 2007 group limiting the analysis. Results of
randomised trials were equally significant for all subgroups.
3. Sensitivity analyses
3.1 Implication of randomisation
For the outcome ‘no overall improvement’ in the medium term,
there were no differences in the results for one study (Ramu 1999a)
that only implied randomisation and studies that explicitly stated
that they were randomised (Analysis 1.26).
3.2 Assumptions for lost binary data
Two studies made assumptions regarding people lost to follow-up
for the outcome ‘no overall improvement’ in the short term; no
differences were found (Analysis 1.27).
3.3 Risk of bias
None of the studies had a high risk of bias for allocation con-
cealment, or blinding of participants and outcome assessors (see
Figure 2). Those that had a high risk of bias for randomisation
were included in the sensitivity analysis above (Analysis 1.26).
3.4 Imputed values
We did not undertake a sensitivity analysis to assess the effects of
including data from trials where we used imputed values for ICC
as there were no cluster-randomised trials included in the review.
3.5 Dishonest researchers
It has come to our attention that Dr Richard Borison and Dr
Bruce Diamond have been convicted of theft, making false state-
ments and violations of state racketeering law in the USA. At this
point, it seems that the crimes were to do with criminal diver-
sion of funds, rather than falsifying study data (http://www.the-
scientist.com/yr1998/oct/notebook˙981026.html). Nevertheless,
we temporarily removed studies with either of these authors from
the analyses to see if this made a substantive difference to the find-
ings. Borison 1991 presented usable data on mental state (average
endpoint score on BPRS), the removal of this study did not result
in a substantive change in the findings. Borison 1991 is the reports
one unique outcome for global state (average endpoint score on
Clinical Global Impression (CGI)), so removal of the study results
in the deletion of the complete outcome.
D I S C U S S I O N
Summary of main results
The summary below reflects the outcomes chosen for the
Summary of findings for the main comparison, and considered
the main findings of this review that can support evidence-based
decision making.
1. Death
It may be surprising that there were no more deaths reported
amongover 5000peoplewith schizophreniawhowere randomised
to chlorpromazine or placebo. The lifetime incidence of suicide
for people suffering from schizophrenia is 10% to 13% (Caldwell
1992). Furthermore, the use of large doses of neuroleptic has been
associated with sudden death (Jusic 1994), but there are no records
of such events within this review. The fact that there are none may
reflect the fact that either trial-care is more vigilant than routine
care or that death is an under-reported outcome.
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2. Relapse
Chlorpromazine reduced the number of participants experiencing
a relapse compared with placebo during six months to two years
follow-up, but not in the short, medium or long term over two
years, although data were heterogeneous. The removal of Prien
1968 and Spohn 1977 did restore homogeneity in the short- and
medium-term studies. The Prien 1968 study was different because
of the very large dosages of chlorpromazine that were employed,
although it had two arms, one with lower doses and another with
higher doses, and these two arms were pooled in the analysis.
An 86% efficacy was found for the high-dose arm in preventing
relapse and a 68% efficacy for the low-dose arm; the confidence
intervals only minimally overlap, so there is a potential impact of
Prien 1968 on this outcome.
3. Global state
The best-quality data would need to be reported from six months
onwards, and trials only reported on this outcome at short- and
medium-term follow-ups. The efficacy of chlorpromazine for im-
proving global state is 39% for short-term data and 29% for
medium term, but the data are heterogenous. Considering that
there was very little antipsychotic treatment that preceded the ad-
vent of chlorpromazine, such an efficacy can be considered noth-
ing less than revolutionary for those with very serious mental ill-
nesses.
4. Leaving the study early
The finding that using chlorpromazine results inmore people stay-
ing in the study could be seen as heartening. Perhaps a genuine
decrease in the distressing symptoms of schizophrenia leads to
an increased concordance with medication despite the unpleasant
side effects of this drug. On the other hand, this apparent willing-
ness to comply may be due partly to sedation and hypotension.
These effects (the former being linked to emotive terms such as
the ’chemical straitjacket’) may decrease a person’s ability to make
his/her own decisions.
5. Mental state
In spite of 45 years of research on this benchmark anti-psychotic
treatment, very little can be said from trials regarding its direct ef-
fect on mental state in general or specific symptoms of schizophre-
nia.
6. Satisfaction with care
No studies reported on this outcome, so it is not possible to
make any conclusions as to participants’ satisfaction with chlor-
promazine treatment.
7. Behaviour
There are more data regarding behaviour. No difference in the oc-
currence of behaviour judged to be disturbed or deteriorated was
found in both short- andmedium-term analyses, but themedium-
term result is based on heterogeneous data (I2=90%). Other mea-
sures of behaviour ’unchanged’ and the modified Rosenthal scale
and the Fergus Falls scale did not result in any significant differ-
ences. Continuous endpoint data (Baker 1959) derived from the
Parkside Behaviour Rating Scale did favour chlorpromazine but
there were only seven participants in each group and we can have
no real confidence in this finding.
8. Adverse effects
Clinicians will not be surprised that chlorpromazine produces
acute movement disorders, parkinsonism, fits, tremor, rigidity,
weakness and sleepiness. This Cochrane review, however, is a rare
report of the best available and quantitative data on this compound
that is now over half a century old. Estimates of the incidence of
movement disorders such as tardive dyskinesia, however, are not
available from this review, as these necessitate a long follow-up pe-
riod that was only attempted in a few trials. Evidence supporting a
link between chlorpromazine and akathisia is much less convinc-
ing than that for acute movement disorders, such as oculogyric
crisis, and parkinsonism. This suggests that chlorpromazine may
be less potent a cause of this unpleasant adverse effect than other
compounds.
Taking chlorpromazine commonly causes people to become sleepy.
This is an effect that, at times, may be welcomed by clinicians, but
not necessarily by those with schizophrenia. Short-term sedation
can be advantageous for clinicians trying to manage people with
very disturbed behaviour. Sedation often helps to bring a difficult
and dangerous situation under control and gives time for antipsy-
chotic measures to be effective.
In addition, chlorpromazine has a tendency to cause other adverse
effects such as jaundice, photosensitivity, eye opacities, low blood
pressure, constipation, urinary retention, blurred vision and dry
mouth. The worrying data regarding eye opacities is all derived
from one trial (Prien 1968). This large trial, however, used up to
two grams of chlorpromazine a day and it is likely that the lower
doses more usual in current practice would result in less risk of this
adverse effect. Chlorpromazine frequently causes weight increase.
9. Cost of care
Again, no studies reported on this outcome, so it is not possible to
make any conclusions about the cost of chlorpromazine treatment.
10. Subgroup analyses
As was likely from the start, the power to detect a real difference
between studies in any one of the subgroup analyses was very low.
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Only subsets of already limited lists of trials were available. The
wide confidence intervals could be hiding true differences in effect
between the groups. The only suggestions of statistically signifi-
cant differences were for acutely ill versus chronically ill for the
outcomes of global improvement and behaviour, and for high-
dose versus low-dose studies (relapse between nine weeks and six
months). It is important to remember that this is now a non-ran-
domised comparison between studies, rather than within a study,
and that this is one ofmany statistical tests thatwere undertakenon
this dataset. Further complicating matters is the fact that the other
outcomes within this particular subgroup analysis did not clearly
support or refute this difference between high and low doses. Prien
1968 is an unusual study. Using two grams of chlorpromazine per
day would be unacceptable in most situations today, a view sup-
ported by some of the findings of this review (n=657, 2 RCTs, RR
eye opacities from two grams chlorpromazine per day, 3.09 CI 1.9
to 5.1).
Overall completeness and applicability of
evidence
Applicability
The 55 included studies in this version of this review includemany
people who would be recognisable in everyday practice. There are
those with strictly diagnosed illnesses, very likely to suffer from
schizophrenia, and people whose illness was diagnosed using less
rigorous criteria. The results of the subgroup analyses ondiagnostic
rigour (see Effects of interventions section 2.5) also support the
assertion that the results are widely applicable.
The dose of chlorpromazine in the studies included in this re-
view could be considered high (mean 574.1 mg/day SD 445) but,
again, these levels are probably common for people with persistent
schizophrenia across the globe.
Although the outcomes that have been used in this review are
accessible to both clinicians and recipients of care, generalising
to treatment in community settings, could be problematic. Most
studies were undertaken in hospital, whereas the great majority of
people with schizophrenia are in the community.
Homogeneity
Some results are difficult, or impossible, to interpret because of
heterogeneity. The test for homogeneity is based on I2 analysis, and
is often fairly weak, as the number of studies is small. However, the
results of such tests, when statistically significant, suggest caution
when adding trial data together.
Quality of the evidence
The quality of the current evidence is very low based on GRADE
(Schünemann 2008). The majority of studies did not report the
method of randomisation, and only two trials described method
of allocation concealment. Although most studies were reported
to be double blind, it was not clear in many whether or not the
assessors were blinded to treatment group of participants. Forty-
eight out of the 55 included studies were rated as high risk of bias
for selective reporting. Studies frequently presented both dichoto-
mous and continuous data in graphs, or just reported statistical
measures of probability (P values). This often made it impossible
to acquire raw data for synthesis. It was also common to use P
values as a measure of association between intervention and out-
comes instead of showing the strength of the association. Although
P values are influenced by the strength of the association, they also
depend on the sample size of the groups. It is sometimes possible
to extract raw data from P values, but their exact values are needed.
In the reviewed studies this was not possible, because they were
reported as ’P < 0.05’ or ’P > 0.05’. Frequently, continuous data
were presented without providing standard deviations or standard
errors (33/55 trials) or no data were presented at all (11/55 trials).
In this way a lot of potentially informative data were lost. In some
studies it seemed that attempts had been made to use the origi-
nal trials as vehicles for answering a host of other questions about
schizophrenia. As a consequence, data from the randomised parts
of the studies became buried beneath copious subgroup analyses.
Potential biases in the review process
1. Adding the old to the new
This work includes studies that span nearly five decades of eval-
uative studies within psychiatry. It is possible that the rigour of
these experiments has changed over time, as have the participants
and even the formulation of the drug; it was thought that in-
troduction of impurities in early formulations of chlorpromazine
led to jaundice. There is some empirical evidence that the quality
of schizophrenia trial reporting has not changed much over time
(Thornley 1998) or, if it has changed, it may even have declined
(Ahmed 1998). We have found no time-related differences in re-
porting of studies within this review and no suggestion of a change
of the effect size over time. Synthesis of the results of studies seems
justified.
2. Failing to identify old trials
We identified trials by meticulous searching, including hand-
searching old files (2002 update) that covered the drug’s develop-
ment over its first two decades. Nevertheless, for this compound
formulated so long ago, publication biases may be difficult to
avoid. We did not detect any overt asymmetry of the funnel plots.
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The strength of this review is that it presents up-to-date quantita-
tive data for a benchmark treatment for schizophrenia that is used
throughout the world.
3. Sensitivity analyses on dishonest researchers
We felt that it would be harsh to immediately delete all trial data
associated withDrs Borison andDiamond without empirical data.
That removal of their data makes no discernable difference to any
outcome is reassuring.
Agreements and disagreements with other
studies or reviews
We do not know of any other systematic reviews on this topic.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
1. For people with schizophrenia
Many people with schizophrenia and their non-professional car-
ers recognise psychotic symptoms as phenomena generated by a
damaging and pernicious illness and may see the effect of chlor-
promazine, as demonstrated within this review, as positive. Others
may consider these data as supporting well-publicised objections
to the use of drugs: drugs potent in their ability to cause unpleas-
ant adverse effects, and to potentially erode a person’s ability to
make informed decisions.
2. For clinicians
This review will confirm much that clinicians already know, but
it does provide some quantification to support clinical impres-
sion. Chlorpromazine is a sedating drug, prone to cause a variety
of movement problems and increased weight. Evidence suggests
that chlorpromazine reduces relapse and facilitates global improve-
ment.
The adverse effect of sedation can, in certain clinical situations (es-
pecially in the short term), be a useful adjunct to any antipsychotic
properties that chlorpromazine may have. For example, someone
acutely disturbed and violent, perhaps because of false beliefs, may
well benefit from a certain amount of sedation while the antipsy-
chotic effects of treatment begin to work.
Chlorpromazine is a low-cost and widely available choice for the
clinician. Despite its many adverse effects chlorpromazine is likely
to remain one of themostwidely used treatments for schizophrenia
worldwide.
3. For managers or policy makers
Chlorpromazine is widely available and inexpensive. It is under-
standable that it remains one of the essential drugs listed by the
WHO for treating people with serious mental illnesses. However,
some of chlorpromazine’s adverse effects could be expensive in
terms of human suffering and cost of treatment. It could, there-
fore, prove better to use a more costly drug if the latter was equally
potent, but had a more favourable adverse effects profile.
Implications for research
1. More trials comparing chlorpromazine with placebo?
Even though chlorpromazine has been used as an antipsychotic
drug for decades, there are still a surprisingly small number of
well-conducted randomised, placebo-controlled trials measuring
its efficacy and potential to cause adverse effects. The use of chlor-
promazine for millions of people is based on clinical experience
rather than the poorly reported trials that involve, in total, only a
few thousand participants. Clinicians and researchers are mainly
satisfied with the current levels of understanding, and, therefore
new studies evaluating chlorpromazine versus placebo will be very
rare. However the chlorpromazine story is incomplete. Questions
remain regarding the effect of this drug on mental state, long-
termmovement disorders and vision. One or more large, method-
ologically sound randomised, placebo-controlled trials could help
answer these questions. With the advent of new drugs, however,
the day for studies comparing chlorpromazine with placebo has
passed.
2. Placebo-controlled studies of other treatments
Having shown that chlorpromazine is a benchmark treatment of
psychotic symptoms, and knowing that allowing schizophrenia to
go untreated may be damaging (Birchwood 1997), the question
may well be raised as to whether any placebo-controlled studies of
new antipsychotic drugs are justified.However, themarked level of
improvement in the placebo groups in this review would seem to
indicate that short-term studies of those with schizophrenia using
a placebo group are justified and would be unlikely to be damaging
to those with psychotic illnesses. Using a placebo comparison in
the longer term would seem more problematic and difficult to
justify.
3. Future trials
So much more could have been learnt about the effects of chlor-
promazine if the studies in this review had clearly described the
method of allocation, the integrity of blinding, especially for the
more subjective outcomes, and the reasons for early withdrawal.
Concrete and simple outcomes are of interest. For example, clearly
reporting improvement, ’number of violent incidents’, ’relapse’
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(giving some description of criteria), ’hospital discharge or ad-
mission’, and ’presence of delusions or hallucinations’ would have
been helpful, and simple reporting of levels of satisfaction and
quality of life would have beenmost informative. Chlorpromazine
has been in use for decades, yet clinicians still have no trial-based
data indicating how people with schizophrenia perceive the value
of this drug in the short, medium and long term.
If rating scales are to be employed, a concerted effort should be
made to agree on which measures are the most useful. Studies
within this review reported on so many scales that, even if results
had not been poorly reported, they would have been difficult to
synthesise in a clinically meaningful way.
Further information on the standardisation of trial reporting can
be found in the CONSORT statement (Moher 2001).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Abrams 1958
Methods Allocation: ’divided at random’ - no further description.
Blinding: medications ’same size, shape and colour’.
Duration: 4 months.
Design: parallel.
Country: not reported.
Participants Diagnosis: schizophrenia.
History: in hospital 2+ years, ’treatment resistant’.
N=40.
Sex: 40 F.
Age: range 20-55 years.
Setting: hospital.
Interventions 1. Chlorpromazine: dose 200 mg/day rising to 600 mg/day. N=20.
2. Placebo. N=20.
Medication given in fixed-dose regimen.
Outcomes Leaving study early.
Unable to use -
Mental state: MSRPP (no SD).
Adverse effects (no usable data).
Cognitive functioning: Weschler Bellvue Intelligence Scale, Rorschach tests (no SD)
Notes MSRPP reported with SE of differences. SDs calculated but data implausible
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Divided, at random, into two groups” no
further details reported
Allocation concealment (selection bias) Unclear risk No information reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “The experimental group received chlor-
promazine under the name of ”Thoraxine
A“, ”The control group, received a placebo,
the same size, shape and colour as the chlor-
promazine. As a differentiation from the
chlorpromazine, the placebo was known as
“Thorazine B”
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Abrams 1958 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk “During the course of the experiment sev-
eral patients had to be eliminated fromboth
groups for various reasons so that the final
chlorpromazine group consisted of 18 pa-
tients while the final placebo group con-
sisted of 16 patients”. Reasons for leaving
the study early not reported
Selective reporting (reporting bias) High risk No SDs reported for MSRPP, Weschler
Bellvue Intelligence Scale or Rorschach
tests. No useable data for adverse effects
Other bias Unclear risk Source of funding not reported.
Baker 1959
Methods Allocation: ’order determined by random selection’.
Blinding: double, matching tablets in envelopes.
Design: cross-over - first arm data used.
Duration: 5 weeks (preceded by 1 week washout).
Country: UK.
Participants Diagnosis: psychosis (schizophrenia N=21, involutional melancholia N=2, manic de-
pressive N=1, senile psychosis N=1).
History: ’chronic’, in hospital 2+ years.
N=25*.
Sex: 25 F.
Age: range 33-79 years.
Setting: hospital.
Interventions 1. Chlorpromazine: dose mean 200 mg/day, range 150-300 mg/day. N=7.
2. Placebo (lactulose): dose 1.95 g/day to 3.9 g/day. N=7.
3. Ethylcrotonylurea: dose range 600-1200 mg/day. N=8.
Medication given in fixed-dose regimen.
Outcomes Leaving study early.
Death.
Behaviour. BPRS
Adverse effects.
Unable to use -
Mental state: BPRS (no usable data).
Physiological measures (no usable data).
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Baker 1959 (Continued)
Notes *three participants not accounted for.
Only data for those with schizophrenia and senile psychosis used (N=22)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Order determined by random selection”
no further details reported
Allocation concealment (selection bias) Unclear risk No information reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Matching tablets” were used.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “The total number of tablets for each five-
week period (378) were put in a separate
envelope, labelled ”A“, ”B“, or ”C“ and a
code was kept showing which tablets any
patient was taking during any given period
[...] It was thus possible to keep the han-
dling and the knowledge of the identity of
the tablets under the control of a person
other than the psychiatric assessor of results
until the trial was completed.”
Incomplete outcome data (attrition bias)
All outcomes
High risk “There were no deaths in this group, but
one patient (Case 120) was so uncoopera-
tive in taking tablets that it was decided to
abandon the attempt, in her case”. Three
participants are not accounted for in the
analysis
Selective reporting (reporting bias) Unclear risk Unable to use BPRS data.
Other bias Unclear risk “These three substances were supplied in
matching tablets by Messrs. Smith &
Nephew, the sponsors of the new drug”
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Ban 1975
Methods Allocation: randomly assigned - no further description.
Blinding: double, ’capsules identical in appearance, taste and smell’.
Duration: 12 weeks (preceded by 2 weeks drug-free washout).
Design: parallel.
Country: not reported.
Participants Diagnosis: chronic (50%) & acute (50%) schizophrenia (criteria not specified).
N=30.
Sex: 22 M, 8 F.
Age: mean 28 yrs, range 17-46.
Setting: hospital.
Interventions 1. Chlorpromazine: dose 200-800 mg/day (dose discretionary). N=10.
2. Placebo. N=10.
3. Thiothixine: dose 10-40 mg/day (dose discretionary). N=10
Outcomes Leaving study early.
Global impression. CGI.
Unable to use -
Adverse effects (not given per individual).
Mental state: BPRS (no mean/SD).
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomised” no further details reported.
Allocation concealment (selection bias) Unclear risk No information reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Double-blind”
“All medication was supplied in capsules
identical in appearance, taste and smell”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Double-blind”no further details reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk There were no losses to follow-up.
Selective reporting (reporting bias) High risk No means and SDs reported for BPRS.
Other bias Unclear risk Supported in part by PHS Grant from the
National Institute ofMental Health, Rock-
well, Maryland
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Ban 1975 (Continued)
Drugs supplied by Pfizer (Canada) Inc,
Montreal, Canada.
Bishop 1963
Methods Allocation: randomly assigned, stratified by age, sex, history - no further description.
Blinding: double - no further description.
Duration: 10 weeks (preceded by 60 days washout).
Design: parallel.
Country: not reported.
Participants Diagnosis: schizophrenia (criteria not specified).
History: ’chronic’.
N=30.
Sex: both (proportions not given).
Age: unknown.
Setting: hospital.
Interventions 1. Chlorpromazine: dose 800 mg/day max. (dose discretionary). N=10.
2. Placebo. N=10.
3. Benzquinamide (Quantril): dose 1200 mg/day max. (dose discretionary). N=10
Outcomes Leaving study early.
Global impression.
Unable to use -
Mental state: Lorr Scale, BPRS (no data reported).
Psychological tests: Tulane Research Battery (no data reported)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Divided at random” no further details re-
ported.
Allocation concealment (selection bias) Unclear risk No information reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Double blind” no further details reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Double blind” no further details reported.
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Bishop 1963 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No losses to follow-up in the chlorpro-
mazine or placebo groups
Selective reporting (reporting bias) Unclear risk No data reported for the BPRS, Lorr scale
or Tulane Research Battery
Other bias Unclear risk Study supported by PHS Grant MY-
3701 (Psychopharmacology Service Cen-
tre - NIMII). Benzquinamide supplied by
Charles Pfizer and Company, Inc, New
York
Borison 1991
Methods Allocation: randomly assigned - no further description.
Blinding: double - no further description.
Duration: 4 weeks (preceded by 1 week placebo washout).
Design: parallel.
Country: USA.
Participants Diagnosis: schizophrenia (DSM-III criteria).
History: acutely ill, physically healthy.
N=30.
Sex: 30 M.
Age: mean 35.6 yrs, range 22-58.
Setting: hospital.
Interventions 1. Chlorpromazine: dose 400-1600 mg/day (variable dose regimen). N=9.
2. Placebo. N=10.
3. Rimcazole: dose 20-400 mg/day (variable dose regimen). N=11
Outcomes Global impression. CGI.
Mental state. BPRS.
Unable to use -
Adverse effects: SAS (no data).
Notes Those leaving early ’analysed [in paper] using last observation carried forward’
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Subjects were assigned on a double-blind,
random basis” no further details reported
Allocation concealment (selection bias) Unclear risk No information reported.
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Borison 1991 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Double blind” no further details reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Double blind” no further details reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk “Early terminators from treatment were
analysed using last observation carried for-
ward”
Selective reporting (reporting bias) High risk Use of SAS not pre-specified in methods.
No data reported for adverse effects
Other bias High risk Borison and Diamond in prison for re-
search fraud.
Chouinard 1990
Methods Allocation: randomly assigned - no further description.
Blinding: double, identical capsules.
Duration: 4 weeks (preceded by 3-7 days washout).
Design: parallel.
Country: Canada.
Participants Diagnosis: schizophrenia (DSM-III criteria & >18 on BPRS).
History: newly admitted.
N=62.
Sex: 39 M, 23 F.
Age: mean 39.7 yrs, range 19-62.
Setting: hospital inpatients, admitted through emergency room
Interventions 1. Chlorpromazine: dose 300-1200 mg/day (variable dose regimen). N=21.
2. Placebo. N=21.
3. Remoxipride: dose 150-600 mg/day (variable dose regimen). N=20
Chloral hydrate/clonazepam for sedation as requested; procyclidine for parkinsonism as
requested
Outcomes Leaving study early.
Global improvement (> 50% reduction of BPRS score).
Adverse effects (as measured by requiring procyclidine).
Requiring sedation.
Unable to use -
Mental state: BPRS (no SD).
Global impression: CGI (no SD)
Adverse effects (no usable data).
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Chouinard 1990 (Continued)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomly assigned” no further details re-
ported.
Allocation concealment (selection bias) Unclear risk No information reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Double blind”, “The trial drugs were pro-
vided in the form of identical white opaque
gelatin capsules”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Double blind” no further details reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Patients that did not complete the four
week trial “were included in the statistical
analyses by using their endpoint scores at
time of discontinuation”
“Four chlorpromazine-treated patients
failed to complete the trial: 3 on account
of side effects (1 case of leucopenia and 2
of hypotension) and 1 on account of in-
efficacy. Seven placebo-treated patients did
not complete the clinical trial (1 case of ab-
normal liver function, 5 of inefficacy, and
1 patient for administrative reasons).” Last
observation carried forward method used
Selective reporting (reporting bias) High risk No SDs reported for BPRS and CGI. No
useable data reported for adverse effects
Other bias Unclear risk Source of funding not reported.
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Clark 1961
Methods Allocation: randomly assigned, matched by OBRS scores into ”triplets“ - no further
description.
Blinding: double, identical capsules.
Duration: 24 weeks (preceded by 8-week placebo washout).
Design: parallel.
Country: USA.
Participants Diagnosis: schizophrenia (Diagnostic Manual of APA, 1952).
History: ’chronic’, in hospital > 5 years, physically healthy.
N=60.
Sex: 60 F.
Age: mean 43 yrs, range 26-52.
Setting: hospital.
Interventions 1. Chlorpromazine: dose 200-800 mg/day. N=20.
2. Placebo (lactose): dose 6-8 capsules per day. N=20.
3. Phenobarbital: dose 120-480 mg/day. N=20
Medication given in variable dose regimen.
Outcomes Global improvement.
Adverse effects.
Unable to use -
Behaviour: OBRS (no data).
Psychological tests (no usable data).
Notes One in CPZ group withdrawn (agranulocytosis, week 12). Her other ’triplets’ also with-
drawn, therefore, N=57 except side effects (N=60)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants ”individually matched into
triplets. Random assignment of triplet
members to treatment groups“, ”drawn by
a table of random numbers“
Allocation concealment (selection bias) Unclear risk No information reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk ”Double-blind“, ”neither the patients nor
the personnel involved in the care or evalu-
ation of the subjects were informed of any
individual’s medication until the end of the
study. Medications were dispensed in indi-
vidually labeled bottles so that identifica-
tion by code was not possible“
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Clark 1961 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk ”Double-blind“, ”“neither the patients nor
the personnel involved in the care or evalu-
ation of the subjects were informed of any
individual’s medication until the end of the
study”
Incomplete outcome data (attrition bias)
All outcomes
Low risk One participant in the chlorpromazine
group was withdrawn due to agranulocy-
tosis, along with the other two participants
in her “triplet”
Selective reporting (reporting bias) High risk Nodata reported forOBRS, andnouseable
data reported for psychological tests
Other bias Unclear risk Supported, in part, by USPHS Grant M-
1600 from theNational Institute ofMental
Health, National Institutes of Health, De-
partment of Health, Education, and Wel-
fare
Medications supplied by Dr Fred Alexan-
der of Smith, Kline, and French Laborato-
ries
Clark 1967
Methods Allocation: randomised - table of random numbers.
Blindness: double - identical capsules.
Duration: 10 weeks.*
Design: parallel.
Setting: inpatients.
Country: USA.
Participants Diagnosis: schizophrenia.
History: duration ill > 5 years.
N=72.
Sex: 72 F.
Age: 25-55 years.
Setting: hospital.
Interventions 1. Chlorpromazine: dose mean 678 mg/day. N=51.
2. Placebo. N=21.
Outcomes Leaving the study early.
Unable to use -
Mental state: BPRS, PRS (no data).
Behaviour: OBRS (no data).
Cognitive function: Perdue Pegboard test, Digit Symbol Test (no data).
Physiological measures (no usable data).
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Clark 1967 (Continued)
Notes * Two identical 10-week studies are reported. Same women allocated within second -
potential for cross-over effects. Data not included
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Assigned at random” no further details re-
ported.
Allocation concealment (selection bias) Unclear risk No information reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Double-blind procedure in which neither
the investigators nor the subjects knewwho
was receiving chlorpromazine.Medications
were dispensed in identical-appearing cap-
sules from individual stock bottle labeled
only with the patient’s name.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Double-blind procedure in which neither
the investigators nor the subjects knewwho
was receiving chlorpromazine”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk “Seventy subjects meeting all physical and
selection criteria completed both cycles of
study 1 year apart. During the course of
the second cycle, 2 subjects were found
to be abnormal in regard to cholesterol
metabolism [...] and their data were deleted
from this report”
“11 subjects taking chlorpromazine were
unable to tolerate the full 800 mg over the
10-week trial”
Selective reporting (reporting bias) High risk No data reported for BPRS, PRS, OBRS,
Perdue Pegboard test, Digit Symbol Test
and physiological measures
Other bias Unclear risk Chlorpromazine and placebo were sup-
plied by Smith Kline & French Laborato-
ries, Philadelphia, Pa
Supported by Grant MH-04260 from the
US Public Health Service
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Clark 1968a
Methods Allocation: randomly assigned - no further description.
Blinding: double, identical capsules.
Duration: 14 weeks (preceded by 12 week washout).
Design: parallel.
Country: USA.
Participants Diagnosis: chronic schizophrenia (criteria not specified).
History: >2 yrs of illness.
N=72.
Sex: 72 F.
Age: mean 42 yrs, range 20-60.
Setting: hospital.
Interventions 1. Chlorpromazine: dose 1000 mg/day max. N=18.
2. Placebo. N=18.
3. Trifluperidol: dose 10 mg/day max. N=18.
4. No drug group. N=18.
Barbiturates or chloral hydrate for sedation as required.
Outcomes Leaving study early.
Global improvement.
Adverse effects.
Unable to use -
Behaviour: Oklahoma Rating Scale (no SD).
Psychological tests (no SD).
Physiological tests (no data).
Notes Groups 3 and 4 combined for purposes of review.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomly assigned” no further details re-
ported.
Allocation concealment (selection bias) Unclear risk No information reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Identically appearing capsules from each
subject’s individually labelled stock bottle
to meet the double-blind requirements of
the study”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Double-blind”no further details reported.
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Clark 1968a (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk “Sixty six patients completed the study.
Two patients were dropped from the CPZ
group because of skin rashes and a third
because of a severe behavioural reaction”,
“Three were dropped form the no drug
group [...] one patient in TRP group com-
pleted only 13 weeks before undergoing
surgery”
Selective reporting (reporting bias) High risk No SDs reported for Oklahoma Rating
Scale and psychological tests. No data re-
ported for physiological tests
Other bias High risk Supported by grants from the National In-
stitute ofMental Health, US Public Health
Service and McNeil Laboratories Inc, Fort
Washington, Pennsylvania
Clark 1968b
Methods Allocation: randomised - no further details.
Blinding: double - identical tablets.
Duration: 16 weeks.
Design: parallel.
Country: USA.
Participants Diagnosis: schizophrenia.
History: duration ill ~20 years, in hospital ~16 years.
N=69.
Sex: all women.
Age: 20-60 years, mean 45.
Setting: hospital.
Interventions 1. Chlorpromazine: dose max 1000 mg/day. N=23.
2. Placebo: dose 10 tablets. N=23.
3. Butaperazine: dose max 100 mg/day. N=23.
Barbiturates, chloral hydrate, benztropine as required.
Outcomes Leaving the study early.
Adverse effects.
Unable to use -
Global improvement (no usable data).
Behaviour: OBRS (no usable data).
Personality inventory: IMPS (modified, no usable data).
Cognitive function: Perdue Pegboard, Digit Symbol test (no usable data).
Physiological tests (no data).
Notes
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Clark 1968b (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomly assigned” no further details.
Allocation concealment (selection bias) Unclear risk No information reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind“, ”All medications were
identical in appearance“
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind” no further details reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk “Sixty seven patients completed the study.
One patient was dropped from the CPZ
group because of agranulocytosis; one was
lost form the BPZ group when she eloped.
”
Selective reporting (reporting bias) High risk No useable data was reported for global
improvement, OBRS, IMPS, Perdue Peg-
board, Digit Symbol test and physiological
tests
Other bias High risk Supported by grants fromUSPublicHeath
Service and AH Robins Company
Clark 1970a
Methods Allocation: randomly assigned ’by sex’.
Blinding: double, identical capsules.
Duration: 12 weeks (preceded by 12-week washout).
Design: parallel.
Country: USA.
Participants Diagnosis: schizophrenia (criteria not specified).
History: ’chronic’.
N=44.
Sex: 7 M, 37 F.
Age: mean 39.7 yrs, range 22-55.
Setting: hospital.
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Clark 1970a (Continued)
Interventions 1. Chlorpromazine: dose 200-1000 mg/day. N=15.
2. Molindone: dose 20-100 mg/day. N=15.
3. Placebo: dose 2-10 capsules/day. N=14.
Medication given in variable dose regimen.
Outcomes Leaving study early.
Global improvement.
Severity of illness.
Cooperativeness (those who agreed to EEG tests).
Adverse effects.
Unable to use -
Mental state: BPRS (no SD).
Behaviour: NOSIE (no SD).
Various psychological tests (no SD).
Notes Drugs to combat EPS not used.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomly assigned by sex” no further de-
tails reported.
Allocation concealment (selection bias) Unclear risk No information reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Identically appearing capsules”, “double-
blind, with medications dispensed from in-
dividual stock bottles labelled only with the
patient’s name”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Double-blind”no further details reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk “One subject was dropped form the CPZ
group because of abnormal liver function
tests; another subject on CPZ was termi-
nated 2 weeks early because of surgery”
Selective reporting (reporting bias) High risk No SDs reported for BPRS, NOSIE and
the various psychological tests
Other bias High risk Supported in part by US Public Health
Service Grant, Research Scientist Devel-
opment Award from National Institute of
Mental Health. Endo Laboratories pro-
vided the medication and partial support
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Clark 1970b
Methods Allocation: randomly assigned by block - no further description.
Blinding: not described.
Duration: 24 weeks (preceded by 12 week washout).
Design: parallel.
Country: USA.
Participants Diagnosis: schizophrenia - criteria not specified.
History: “chronic”.
N=71.
Sex: 71 F.
Age: mean 43.7 yrs, range 21-60.
Setting: hospital.
Interventions 1. Chlorpromazine: dose 150 mg/day. N=17.*
2. Chlorpromazine: dose 300 mg/day. N=18.*
3. Chlorpromazine: dose 600 mg/day. N=18.*
4. Placebo. N=18.*
Medication given in fixed dose regimen; benztropine for EPS, chloral hydrate, pheno-
barbitone or sodium amytal for sedation, as required
Outcomes Leaving study early.
Adverse effects.
Behavioural disturbance (requiring more medication on >5 occasions)
Unable to use -
Global Impression: CGI (no SD).
Mental state: BPRS, IMPS (no SD).
Behaviour: OBRS (no SD).
Notes * Withdrawals partially described (N=4) - initial group unclear. Assumed one from each
group (these amended numbers appear above)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Subjects were assigned by block randomi-
sation” no further details reported
Allocation concealment (selection bias) Unclear risk No information reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No information reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information reported.
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Clark 1970b (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk “During the course of the study one subject
was dropped because of rash and anaemia,
one because of agranulocytosis, two be-
cause of elopement from the hospital, and
two because of requisite surgery”. Study
does not report which from groups the
losses to follow-ups occurred
Selective reporting (reporting bias) High risk No SDs reported for CGI, BPRS, IMPS,
and OBRS.
Other bias Low risk Supported by USPHS grant and Research
Scientist Development Award
Clark 1971
Methods Allocation: randomly assigned, blocks of 4 - no further description.
Blinding: double, identical capsules.
Duration: 4 weeks.
Design: parallel.
Country: USA.
Participants Diagnosis: schizophrenia (minimum of 2 symptoms from list).
History: mean no. admissions CPZ group=2.4, placebo group=3.6.
N=86.
Sex: male and female (numbers unclear).
Age: mean 33 years, range 21-45.
Setting: hospital.
Interventions 1. Chlorpromazine: dose 200-1000 mg/day. N=23.
2. Placebo (lactulose). N=21.
3. Fluphenazine: dose 2-10 mg/day. N=20.
4. Thioridazine: dose 200-1000 mg/day. N=22.
Medication given in variable dose regimen; usual night-time sedation permitted
Outcomes Leaving study early.
Global impression. CGI.
Adverse effects.
Unable to use -
Mental state: BPRS (no SD).
Behaviour: NOSIE (no SD).
Psychological tests (no SD).
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Clark 1971 (Continued)
Random sequence generation (selection
bias)
Unclear risk “Patients were assigned to treatment ran-
domly in blocks of four” no further details
reported
Allocation concealment (selection bias) Unclear risk No information reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Double-blind”, “identical appearingmed-
ication was administered from a bottle la-
belled only with the patient’s name”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Double-blind”no further details reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk “Of the 75 subjects completing the study,
one placebo subject was terminated be-
cause of behavioural deterioration after
only three weeks observation and one sub-
ject taking fluphenazine was discharged
from the hospital as markedly improved af-
ter only two weeks observation. In both
instances, final measures were obtained
and their data were retained for the final
analysis. Eleven additional subjects were
started in the study but were dropped with-
out obtaining final measures for a vari-
ety of reasons: in the placebo group there
was one subject absent without permission
(AWOL), one on convalescent leave, and
one subject transferred to another hospi-
tal; in the thioridazine group there were
two AWOL subjects and one with medi-
cation intolerance; in the chlorpromazine
group there was one AWOL and two sub-
jects who refused oral medication; in the
fluphenazine group there was one admin-
istrative transfer and one AWOL.”
Selective reporting (reporting bias) High risk No SDs reported for BPRS, NOSIE and
the psychological tests.
Other bias Unclear risk Supported by Public Health Service grant
and Research Scientist Award. Medication
provided by Smith Kline&French Labora-
tories, Sandoz Inc and ER SQuibb & Sons
64Chlorpromazine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Clark 1972
Methods Allocation: randomly assigned - no further description.
Blinding: double, identical capsules.
Duration: 12 weeks (preceded by 12 weeks washout).
Design: parallel.
Country: USA.
Participants Diagnosis: schizophrenia (criteria not specified).
History: ’chronic’, 2+ yrs ill.
N=55.
Sex: 24 M, 31 F.
Age: CPZ group mean 42 yrs, placebo group mean 40 yrs, range 21-60.
Setting: hospital.
Interventions 1. Chlorpromazine: dose 1000 mg/day. N=19.
2. Placebo. N=18.
3. Loxapine: dose 10 mg/day. N=18.
Medication increasing to fixed dose; antiparkinson medication as required
Outcomes Leaving study early.
Global impression. CGI.
Global severity of illness. CGI.
Adverse effects.
Unable to use -
Mental state: BPRS (no SD).
Behaviour: NOSIE (no SD).
Weight gain (no SD).
Physical tests: EKG, urine, blood (no data reported).
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ”Allocation to treatment was random, but
provided for balancing of groups by sex and
age“ no further details reported
Allocation concealment (selection bias) Unclear risk No information reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk ”Double-blind“, identical appearing med-
ication in capsule form was administered
orally to each subject rom his individual
stock bottle labelled only with his name”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Double-blind”no further details reported.
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Clark 1972 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk “Five patients were lost from the study: 2
from the PL group because of a grand mal
seizure in one, and a cardiac arrhythmia
in the second; 2 from the CPZ group be-
cause of abnormal liver function in one and
a severe allergic reaction dermatitis with
photo-sensitivity on the other; 1 from the
LOX group because of a hip fracture”
Selective reporting (reporting bias) High risk No SDs reported for BPRS, NOSIE and
weight gain. No data reported for physical
tests
Other bias High risk Supported by a grant from USPHS and a
grant-in-aid from Lederle Laboratories
Clark 1977
Methods Allocation: randomly assigned ’by sex’ - no further description.
Blinding: double, identical capsules.
Duration: 12 weeks (preceded by 8 week wash-out).
Design: parallel.
Country: USA.
Participants Diagnosis: schizophrenia (criteria not specified).
History: ’chronic’.
N=27.
Sex: 13 M, 14 F.
Age: mean 43.2 yrs, range 23-61.
Setting: hospital.
Interventions 1. Chlorpromazine: dose 1000 mg/day. N=9.
2. Placebo. N=9.
3. Butaclamol: dose 50 mg/day. N=9.
Medication increasing to fixed dose; antiparkinson medication for EPS as required;
sodium amytal and chloral hydrate for behaviour control as required
Outcomes Leaving study early.
Global impression. CGI.
Adverse effects.
Unable to use -
Mental state: BPRS (no SD).
Global impression: CGI (no SD).
Behaviour: NOSIE (no SD).
Physical tests: EKG, urine, blood (no data).
Notes
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Clark 1977 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Allocation to treatment by sex was ran-
dom” no further details reported
Allocation concealment (selection bias) Unclear risk No information reported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Placebo tablets identical to the white buta-
clamol and to the brown CPZ preparations
were taken by all subjects during the dry-
out period and by the placebo group dur-
ing treatment”
“Each patient received his/her medication
from individual stock bottles”
“Double-blind”.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Double-blind”no further details reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk “Of the 27 subjectswho started, three failed
to complete the full 12 weeks of study: one
female subject in the butaclamol group be-
came excited and agitated during the 4th
week of treatment, exacerbated a labile hy-
pertension, and was dropped at the end of
the 4thweek as treatment failure. Twomale
subjects in the placebo group also mani-
fested clinical deterioration, one at the 8th
week and one at the 11th week of treat-
ment, and were terminated as treatment
failures. In each instance, final rating were
obtained and their datawere retained in the
analysis”. Last observation carried forward
method used
Selective reporting (reporting bias) High risk No SDs reported for BPRS, CGI and
NOSIE, and no data reported for physical
tests
Other bias High risk Supported in part by a USPHS grant and a
grant-in-aid from Ayerst Laboratories, NY
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Cohen 1968
Methods Allocation: randomised.
Blinding: “using a double-blind procedure”.
Duration: 3 months.
Design: parallel.
Country: USA.
Participants Diagnosis: schizophrenia.
History: participants had symptoms of schizophrenia for at least 1-year.
N=126.
Sex: 54 M 72 F.
Age: range 18-42.
Setting: community outpatients clinic.
Interventions 1. Chlorpromazine: dose 180 mg/day. N=42.
2. Placebo. N=42.
3. Promazine: dose 180 mg/day. N=42.
Outcomes Leaving the study early.
Unable to use -
Mean change in social aggression (no SD).
Manifest anxiety state (no SD).
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomly assigned” no further details re-
ported.
Allocation concealment (selection bias) Unclear risk No information reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Double-blind”no further details reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Double-blind”no further details reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up reported.
Selective reporting (reporting bias) High risk No SDs reported for social aggression and
manifest anxiety state
Other bias Low risk Supported by grants from the National
Institute of Mental Health, Public Health
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Cohen 1968 (Continued)
Service
Cole 1964
Methods Allocation: randomly assigned, sealed envelopes, stratified by sex and race (no further
description).
Blinding: double, oral medication ’prepared as standard No. 2 pink capsules’, IM from
’1 cc glass ampules’ with sterile saline for placebo.
Duration: 6 weeks.
Design: parallel.
Country: USA.
Participants Diagnosis: schizophrenia (presence of specific symptoms/behaviours).
History: newly admitted, recent onset illness.
N=463.
Sex: male and female (proportions not given).
Age: 16-45 yrs.
Setting: hospital.
Exclusions: childhood autism or schizophrenia, brain syndrome, learning disability, al-
coholism, epilepsy, drug abuse
Interventions 1. Chlorpromazine: dose 200-1600 mg/day or 50-400 mg/day (IM). N=112.
2. Placebo: dose 2-16 doses/day or 2-16 injections/day (IM). N=125.
3. Fluphenazine: dose 2-16 mg/day or 1-8 mg/day (IM). N=115.
4. Thioridazine: dose 200-1600 mg/day or 50-400 mg/day (IM). N=111
Medication given in discretionary dose regimen; antiparkinsonian medication for EPS
as required
Outcomes Leaving study early.
Adverse effects.
Unable to use -
Global impression: Global Rating of Severity of Mental Illness & Global Rating of
Improvements (data not reported by group).
Mental state: IMPS (data not reported by group).
Behaviour: Burdock Ward Behaviour Rating Scale (data not reported by group)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Stratified by sex with randomised assign-
ment to drug treatment within each sex
group” no further details reported
Allocation concealment (selection bias) Unclear risk No information reported.
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Cole 1964 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Double-blind” oral medication “prepared
as standard No. 2 pink capsules”, IM from
“1 cc glass ampules” with sterile saline for
placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Double-blind”no further details reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 119 out of 463 participants were lost to fol-
low-up. Reasons for loss to follow-up were
balanced across groups, apart from treat-
ment failurewhere “themajority of patients
who were dropped because of treatment
failure were on placebo”
Selective reporting (reporting bias) High risk Data was not reported by group for Global
Rating of Severity of Mental Illness &
Global Rating of Improvements, IMPS and
Burdock Ward Behaviour Rating Scale
Other bias Low risk Supported by NIMH grants.
Cooper 2000
Methods Allocation: randomly assigned in blocks of 6 - no further description.
Blinding: “double dummy technique ... used to maintain blinding”.
Duration: 8 weeks.
Design: parallel.
Country: Multi-centre (Belgium, UK., Ireland and Poland)
Participants Diagnosis: schizophrenia (DSM-III-R & > moderately ill on CGI).
History: acute exacerbation or sub chronic/chronic.
N=159.
Sex: 115 M, 44 F.
Age: mean ~39 yrs, range 18-65.
Setting: inpatients and outpatients.
Interventions 1. Chlorpromazine: dose 600 mg/day. N=53.
2. Placebo. N=53.
3. Zotepine: dose 300 mg/day. N=53.
Benzodiazepines or chloral hydrate for sleeplessness as required; anticholinergic medica-
tion for EPS as required
Outcomes Leaving study early.
Global improvement (50% reduction in BPRS).
Global impression: CGI (no improvement psychiatrist rated).
Unable to use -
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Cooper 2000 (Continued)
Adverse effects (unclear if data includes withdrawals).
Mental state: BPRS, SANS (unsure of data).
Global impression: CGI (unsure of data).
Adverse effects: AIMS, COSTART, EPMS, Simpson and Angus (no means, SD)
Notes Unclear if data for ’leaving study early’ and ’improvement’ include 1 person omitted
from ’ITT’ analysis. Author contacted, replied, and further data awaited
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “All eligible patients were allocated a study
number and randomly assigned in blocks
of six” no further details reported
Allocation concealment (selection bias) Unclear risk No information reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Double-blind”
“A double-dummy technique was used to
maintain blinding because of differences in
capsule and tablet appearances, i.e. patients
received active zotepine plus placebo chlor-
promazine or placebo zotepine plus active
chlorpromazine or double placebo.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Double-blind”no further details reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk “ITT analysis”
“A total of 89 patients completed the full
8-week study.” “Sixty-nine patients with-
drew from the study” Reasons for leaving
the study not fully described
Selective reporting (reporting bias) High risk For adverse effects it is unclear if data
includes withdrawals. We are unsure of
the data reported for BPRS, SANS, CGI,
AIMS, COSTART and EPMS. No means
and SDs were reported for Simpson and
Angus
Other bias High risk Funded by Knoll Pharmaceuticals. Data
analysis was by Knoll in conjunction with
Dr Cooper
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Dean 1958
Methods Allocation: randomised.
Blinding: double blind.
Duration: 15 weeks.
Design: parallel.
Country: USA.
Participants Diagnosis: schizophrenia.
History: chronic schizophrenia.
N=18.
Sex: female.
Age: mean 37, range 26-47.
Setting: hospital.
Interventions 1. Chlorpromazine: dose mean 2400 mg/day, 2000-3000 mg/day . N=9.
2. Placebo. N=9.
Outcomes Leaving the study early.
Adverse effects (jaundice, skin reactions).
Unable to use -
Ward evaluation (unpublished scale).
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information reported.
Allocation concealment (selection bias) Unclear risk No information reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Those patients on placebo were given
tablets which were identical in appearance
with chlorpromazine.”
“Until the patients were receiving 1000
mg of chlorpromazine a day, the hospital
pharmacist was was the only person who
knew which patients were receiving place-
bos. At the 1000 mg level the ward physi-
cian checked the master list to determine
who was on the placebos”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk There were no losses to follow-up.
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Dean 1958 (Continued)
Selective reporting (reporting bias) Low risk All expected outcomes reported.
Other bias Unclear risk Chlorpromazine supplied by Smith Kline
& French Laboratories
Source of funding not reported.
Engelhardt 1960
Methods Allocation: randomly assigned - no further description.
Blinding: double, identical capsules.
Duration: 18 months.
Design: parallel.
Country: USA.
Participants Diagnosis: schizophrenia (criteria not specified).
History: illness >1 yr.
N=173.
Sex: not reported.
Age: range 18-40 yrs.
Setting: outpatients department.
Interventions 1. Chlorpromazine: dose 50-800 mg/day (variable dose regimen). N=62.
2. Placebo. N=56.
3. Promazine: dose 50-800 mg/day (variable dose regimen). N=55
Outcomes Leaving study early.
Relapse (hospitalisation).
Notes Above data extracted from Engelhardt (JAMA 1960;173:147-9).
Other reports have greater ’N’ (of which the 173 above are assumed to be an unbiased
sub-sample) but no data is usable from these papers
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Drug assignment was random” no further
details reported.
Allocation concealment (selection bias) Unclear risk No information reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Double-blind”
“The medication was in the form of pink
capsules containing either placebo, pro-
mazine hydrochloride or chlorpromazine
hydrochloride”
“The treating psychiatrist did not know
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Engelhardt 1960 (Continued)
which agent the patient received”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Double-blind”no further details reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk “The overall drop-out rate was 36.4% (63
out of 173 patients), while for individual
agents the rateswere as follows: placebo, 33.
9%; and chlorpromazine, 40.3%”. Reasons
for loss to follow-up not reported
Selective reporting (reporting bias) Unclear risk No outcomes pre-specified in methods.
Other reports have greater ’N’ (of which
the 173 above are assumed to be an unbi-
ased sub-sample) but no data is usable from
these papers
Other bias Low risk Study supported in part by a grant from
National Institute of Mental Health, US
Public Health Service
Fink 1963
Methods Allocation: randomly assigned - no further description.
Blinding: used ”40 cc of highly flavoured liquid“.
Duration: 6 weeks, follow-up 2-3 yrs.
Design: parallel.
Country: USA.
Participants Diagnosis: schizophrenia, affective disorders, personality disorders, neuroses, organic
mental disorders*
History: voluntary inpatients, ’middle-class, well educated’.
N=311 (schizophrenia N=142).
Sex: male and female (proportions unknown).
Age: mean 31.1 yrs..
Setting: hospital.
Interventions 1. Chlorpromazine: dose 1200 mg/day. N=51.
2. Placebo. N=44.
3. Imipramine: dose 300 mg/day. N=47.
Medication increasing to fixed dose; group 1 given procyclidine to prevent EPS: dose
max. 15 mg/day
Outcomes Global improvement.
Leaving the study early (Belmont 1963, N=19)
Unable to use -
Mental state: MSRPP (no usable data).
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Fink 1963 (Continued)
Memory: Rorschach tests (no SD).
Notes *Review uses schizophrenia data only.
Another 33 participants in Klein, Honigfeld, and Feldman report (1968) but no data.
Belmont 1963 reported data on a subgroup of 19 people with schizophrenia
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ”Randomly assigned“ no further details re-
ported.
Allocation concealment (selection bias) Unclear risk No information reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk ”Double-blind“
”Each medication was dissolved in a highly
flavoured liquid vehicle and each patient
received 40ml per day from individually la-
belled bottles“
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk ”Double-blind“no further details reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk ”Of the 173 patients starting medication,
19 did not complete the study because of
psychiatric reasons [...] 5 for medical com-
plications [...] 5 patients received an active
placebo in a methodological substudy and
are not included in this analysis
Selective reporting (reporting bias) High risk No useable data reported for the MSRPP
and no SDs reported for Rorschach tests
Other bias Low risk Partly funded by National Institute of
Mental Health, USPHS
Fleming 1959
Methods Allocation: randomly assigned - no further description.
Blinding: double, identical capsules.
Duration: 6 months (preceded by ’several weeks’ washout).
Design: parallel.
Country: Ireland.
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Fleming 1959 (Continued)
Participants Diagnosis: schizophrenia (criteria not specified).
History: ’chronic’, mean duration ill 21 yrs.
N=63.
Sex: 63 F.
Age: mean 57.6 yrs.
Setting: hospital.
Interventions 1. Chlorpromazine: dose 75 mg/day increasing to 300 mg/day max. N=21.
2. Placebo. N=21.
3. Promazine: dose 75 mg/day increasing to 300 mg/day max. N=21
Outcomes Leaving study early.
Disturbed behaviour (“noisy, aggressive or disturbed incidents”).
Adverse effects.
Unable to use -
Mental state: Powick Psychiatric Rating Scale (no SD).
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Patients were sub-divided, upon a random
basis, into 3 equal groups” no further details
reported
Allocation concealment (selection bias) Unclear risk No information reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Double-blind”
“the tablets of the 3 treatments were iden-
tical in appearance, the hospital dispenser
alone knowing to which treatment any par-
ticular patient had been assigned at the out-
set”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Double-blind”no further details reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk “12 patients who failed to complete the
trial was as follows: 6 patient received ECT;
2 patients developed severe extrapyramidal
symptoms (chlorpromazine); 1 patient de-
veloped agranulocytosis (chlorpromazine);
and3patientswerewithdrawn formiscella-
neous physical considerations (promazine)
”
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Fleming 1959 (Continued)
“The loss of patients was equally dis-
tributed”
Selective reporting (reporting bias) High risk NoSDreported for PowickPsychiatricRat-
ing Scale.
Other bias Unclear risk John Wyeth & Bro. supplied the pro-
mazine, Messrs, May&Baker Ltd supplied
chlorpromazine and placebo tablets
Grygier 1958
Methods Allocation: randomly assigned - pairs matched (on age, duration of illness, intelligence,
and aptitude for OT), and ’pharmacist decided at random’ - no further description.
Blinding: not described but raters asked to guess which participants were on which
medication.
Duration: 24 weeks.
Design: parallel.
Country: UK.
Participants Diagnosis: chronic schizophrenia (criteria not specified).
History: ’chronic’, mean duration ill 19.6 yrs.
N=30.
Sex: 30 F.
Age: mean 49.8 yrs, SD 10.7 yrs.
Setting: hospital.
Interventions 1. Chlorpromazine: dose 150 mg/day. N=15.
2. Placebo. N=15.
Outcomes Global improvement.
Unable to use -
Behaviour: Albany Behavioral Rating Scale (no SD).
Leaving study early (both members of a pair removed from analysis when one left).
Adverse effects (both members of a pair removed from analysis when one developed a
serious side effect e.g. granulocytosis, jaundice)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “selected two groups, matching them as
closely as possible”, “pharmacist decided at
random” no further details reported
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Grygier 1958 (Continued)
Allocation concealment (selection bias) Low risk “The pharmacist decided at random which
group would receive chlorpromazine and
which inert tablets, and only she had this
information at any time”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No information reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “At the end of the experiment both raters
were asked to ”guess“ the composition of
the chlorpromazine group” no further de-
tails reported, implies assessors were blind
for treatment allocation
Incomplete outcome data (attrition bias)
All outcomes
High risk “if any patient had to discontinue the pro-
gram, her ”pair“ could also be omitted”
“Three pairs were lost: one due to death
from unassociated causes; two due to ma-
jor side-effects”. Both members of a pair re-
moved from analysis when one left
Selective reporting (reporting bias) High risk No SDs reported for Albany Behavioral
Rating Scale.
Other bias Unclear risk Source of funding not reported.
Gwynne 1962
Methods Allocation: randomised.
Blinding: unclear.
Duration: 4 months.
Design: parallel.
Setting: inpatients.
Country: not reported.
Participants Diagnosis: schizophrenia.
N=78.
Age: average 49 years.
Sex: M 38 F 38.
History: Hospital record diagnosis of schizophrenia for a least 5 years, history of with-
drawal for at least one year.
Exclusions: not reported.
Setting: hospital.
Interventions 1. Chlorpromazine: dose 7 days on 100 mg/day, 200 mg/day, 300 mg/day, and 400 mg/
day until maximum improvement or side-effects intervened. N=26.
2. Trifluoperazine: dose 7 days on 10 mg/day, 20 mg/day, 30 mg/day, and 40 mg/day
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Gwynne 1962 (Continued)
until maximum improvement or side-effects intervened. N=26.
3. Placebo. N=26.
Benztropine methanesulfonate (2 mg) as required.
Outcomes Adverse effects*.
Leaving the study early.
Unable to use -
Mental state: MRSPP (no means and SDs reported)
Notes *N not reported, assumed to be N randomised.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Three groups of 26patients each (13males
and 13 females) were formed by random
selection from the basic group” no further
details reported
Allocation concealment (selection bias) Unclear risk No information reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “All drugs and placebo were identical in
appearance and taste.” No further details
reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk In the placebo group, one participant left
the study early due to adverse effects and
two due to unmanageability. There were no
losses to follow-up in the chlorpromazine
group
Selective reporting (reporting bias) High risk No means and SDs reported for MSRPP.
Other bias Unclear risk Drugs provided by Smith, Kline and
French, and Merck, Sharp & Dohme
Source of funding not reported.
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Hall 1955
Methods Allocation: randomly assigned - ’code letters ... assigned at random to these batches [of
drugs]. In turn, these code letters ... assigned in serial fashion to patients on each ward,
thus insuring randomised and unknown assignment of drug and placebo’.
Blinding: double, identical capsules and blindness tested (see notes).
Duration: 66 days (preceded by 32 day washout).
Design: parallel.
Country: USA.
Participants Diagnosis: schizophrenia (criteria not specified).
History: ’chronic’, ’semi-disturbed’.
N=175.
Sex: 54 M, 121 F.
Age: range 20-59 yrs.
Setting: hospital.
Interventions 1. Chlorpromazine: dose variable up to 750 mg/day (discretionary). N=87.
2. Placebo (terra alba). N=88.
Outcomes Leaving study early.
Global improvement.
Behaviour. Modified Fergus Falls Behavior Rating Sheet.
Adverse effects.
Unable to use -
Specific symptoms (no usable data).
Liver biopsy data (non-random subset of participants).
Notes Blindness testing. Psychiatrists guessed 22/50 CPZ group correctly, and 56/61 placebo
group correctly. Psychologists guessed 31/50 CPZ group correctly, and 53/63 placebo
group correctly - side effects=main source of unblinding
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomised selection” no further details
reported.
Allocation concealment (selection bias) Low risk “The drug manufacturer supplied the ma-
terial in 10 coded batches. Half of the
batches contained drug, and half placebo
(terra alba), and code letters were assigned
at random to these batches. In turn, these
codes letters were assigned in serial fashion
to
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk ”Double-blind“
”identical-appearing placebo“
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Hall 1955 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk ”Double-blind“, ”the participating tech-
nicians, psychiatrists and psychologist
recorded their judgments as the whether
the patient received drug or placebo“, ”the
psychiatrists and psychologist were neither
completely “blind” nor completely “un-
blind”
Incomplete outcome data (attrition bias)
All outcomes
Low risk “The three patients who developed jaun-
dice were eliminated from the project”
Selective reporting (reporting bias) High risk There were no useable data for specific
symptoms and liver biopsy data was only
reported for a non-random subset of par-
ticipants
Other bias High risk Smith, Kline & French Laboratories pro-
vided chlorpromazine, partly supported
the study with a grant for statistical analysis
and provided other assistance
Hamill 1975
Methods Allocation: assigned ’using a table of random numbers’.
Blinding: unclear.
Duration: 5 days.
Design: parallel.
Country: USA.
Participants Diagnosis: schizophrenia (presence of > 2 symptoms from checklist).
History: newly admitted.
N=44.
Sex: 33% M, 67% F.
Age: range 18-55 yrs.
Setting: hospital.
Interventions 1. Chlorpromazine: dose 306-475 mg/day. N=22.
2. Placebo. N=22.
Medication given in variable dose regimen.
Outcomes Leaving study early.
Unable to use -
Mental state: BPRS (no mean, N, or SD).
Global improvement: CGI (no SD).
Behaviour: NOSIE (no mean, N, or SD).
Notes
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Hamill 1975 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Assignment of patients to the chlorpro-
mazine or the placebo group was deter-
mined using a table of random numbers”
Allocation concealment (selection bias) Unclear risk “Patients were given a number from 1 to 44
according to the randomisation and with-
out the participation of the research psy-
chiatrist”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No information reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk “Of the 44 patients evaluated, 11 were
dropped from the study during the 5 day
period. OF the 111 dropped patients, 6
were in the drug group and 5 in the placebo
group.” Reasons for leaving the study early
balanced across groups
Selective reporting (reporting bias) High risk No useable data reported for the BPRS and
NOSIE and no SDs reported for CGI
Other bias Unclear risk Source of funding not reported. Placebo
provided by Smith Kline & French Labo-
ratories, Philadelphia, Pa
Hamilton 1960
Methods Allocation: block randomisation into six groups.
Blinding: double, ’placebo tablets .... indistinguishable from the active drugs’.
Design: factorial (2 x 3).
Duration: 8 weeks.
Country: UK.
Participants Diagnosis: schizophrenia (no specified criteria).
History: ’chronic’; all liable to overactivity/aggression.
N=54.
Sex: 54 M.
Age: mean 38 yrs.
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Hamilton 1960 (Continued)
Setting: hospital.
Interventions 1. Chlorpromazine: dose 300 mg/day. N=18.
2. Placebo. N=18.
3. Thiopropazate: dose 30 mg/day. N= 18.
Medication given in fixed dose regime; factored to:
A. Occupational therapy. N=27.
B. No occupational therapy.N=27.
Outcomes Leaving study early.
Adverse effects.
Unable to use -
Mental state: Lorr (no mean, SD).
Behaviour: nurse-rated scale (no mean, SD).
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ”The patients were randomly allotted to 6
groups of 9 patients each“
”Each of these 3 groups was randomly cou-
pled with another group, and the names of
the patients in the 3 pairs of groups given
to the hospital pharmacist. He randomly
selected one pair of no further details re-
ported
Allocation concealment (selection bias) Unclear risk “Pharmacist [...] randomly selected”
groups, no further details reported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Form the point of view of the patients,
nurses and physicians, there were 27 pa-
tients receiving one kind of tablet and
27 patients receiving the other kind, but
only the pharmacist knew which of the pa-
tients were receiving active and which in-
ert tablets. All the tablets were sugar-coated
nad the placebo tablets were indistinguish-
able from the active drugs. ”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Form the point of view of the patients,
nurses and physicians, there were 27 pa-
tients receiving one kind of tablet and
27 patients receiving the other kind, but
only the pharmacist knew which of the pa-
tients were receiving active and which inert
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Hamilton 1960 (Continued)
tablets.”
“The patients were assessed on Behaviour
in the ward by the charge nurses and on
Symtoms by the physician”
Incomplete outcome data (attrition bias)
All outcomes
Low risk There were no losses to follow-up.
Selective reporting (reporting bias) High risk No means and SDs reported for mental
state and a nurse-rated behaviour scale
Other bias Unclear risk Source of funding not reported.
Hankoff 1962
Methods Allocation: randomised.
Blinding: double.
Duration: 2 weeks.
Design: parallel.
Country: USA.
Participants Diagnosis: schizophrenia and non-schizophrenia.
N=174.
Age: mean 39 years.
Sex: M 70, F 64
History: not reported.
Exclusions: not reported.
Setting: community.
Interventions 1. Chlorpromazine: dose 150 mg/day. N=25.
2. Chlordiazepoxide: dose 30 mg/day. N=27.
3. Meprobamate: dose 600 mg/day. N=27.
4. Placebo. N=72.
Doses adjusted at one week intervals as necessary.
Outcomes Global improvement.
Leaving the study early.
Adverse effects.
Unable to use -
Manifest Anxiety (no SDs reported).
Affect Adjective Checklist (no SDs reported).
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Hankoff 1962 (Continued)
Random sequence generation (selection
bias)
Unclear risk “Patients were randomly assigned to treat-
ment groups” no further details reported
Allocation concealment (selection bias) Unclear risk No information reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Double-blind”
“All the drugs and their placebos were ad-
ministered in pink No.2 capsules”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Double-blind”no further details reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk “Of 174 patients starting in the project,
134 completed the two-week drug trial.
The 40 patients who failed to complete the
study usually did not return for appoint-
ments. An occasional patient in this total
of 40 was dropped for reasons of protocol
violation”
Selective reporting (reporting bias) High risk No SDs reported for Manifest Anxiety and
Affect Adjective Checklist
Other bias Low risk Supported by a grant from the US Public
Health Service.
Hine 1958
Methods Allocation: matched on level of withdrawal symptoms and assigned at ’the toss of a coin’.
Blinding: double, ’corresponding tablets or solution’.
Duration: 20 weeks (preceded by 11 week baseline period).
Design: parallel.
Country: USA.
Participants Diagnosis: schizophrenia (criteria unspecified).
History: ’chronic’, ’more withdrawn than usual’, continuously hospitalised for > 5 yrs.
N=22.
Sex: 22 F.
Age: range 30-50 yrs.
Setting: hospital.
Interventions 1. Chlorpromazine: dose increasing to max. tolerable level or 750 mg/day. N=11.
2. Placebo. N=11.
Outcomes Leaving study early.
Adverse effects. weakness, skin rash.
Improvement. change in hospital status, such as grounds privileges
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Hine 1958 (Continued)
Unable to use -
Withdrawal: Southeast Louisiana Hospital Behavior Rating Scale (no data)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”Matched pairs“ based on withdrawal
symptoms ”and one member of this pair
was assigned to the treatment group by the
toss of a coin
Allocation concealment (selection bias) Unclear risk No information reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Double-blind”
“The results of this assignment were not
known to the judges, raters or other ward
personnel”
“corresponding placebo tablets or solution”
no further details reported
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Double-blind”
“The results of this assignment were not
known to the judges, raters or other ward
personnel”
Incomplete outcome data (attrition bias)
All outcomes
Low risk “Itwas necessary to discontinuemedication
during the third week on one patient in the
treatment group because of the develop-
ment of severe angioneurotic edema. This
patient was eliminated from the project”
Selective reporting (reporting bias) High risk No data reported for the Southeast
Louisiana Hospital Behavior Rating Scale
Other bias Unclear risk Drugs provided by Smith Kline & French
Laboratories
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Hogarty 1973
Methods Allocation: stratified by sex and randomly assigned - no further description.
Blinding: double, “identical looking tablets”.
Design: factorial (2 x 2).
Duration: 3 years (preceded by 2 months CPZ-stabilisation period)
Country: USA.
Participants Diagnosis: schizophrenia (no specified criteria).
History: recently discharged.
N=374.
Sex: 43% M, 57% F.
Age: mean 34 yrs, range 18-53.
Setting: community.
Interventions 1. Chlorpromazine: dose variable min. 100 mg/day, mean 270 mg/day. N=192.
2. Placebo. N=182.
Factored to:
A. Major role therapy. N=190.
B. Rehabilitation counseling. N=184.
Outcomes Leaving study early.
Relapse.
Unable to use -
Death (N given, but not by group).
Trouble with police (N given, but not by group).
Mental state: BPRS, Symptom Checklist, IMPS, Springfield Symptom Inventory (no
SD).
Social functioning: Major Role Adjustment Inventory, Katz Adjustment Scale, Casework
Evaluation Schedule (no SD).
Carer morbidity: Family Distress Scale (no SD).
Notes Assumption re ’leaving study early’: One report states - 27 people ’terminated’ during
month 1-10, 3 due to side effects of CPZ. No data on remaining 24 - group of allocation
unknown. However, by 2 yrs ’terminations’=31 (Table 3, ’II. Two-year relapse rates’
paper), 13 from CPZ, 18 from placebo group. This allowed calculation of group of
allocation of the original 24 at 10 months (10 + 3 already known=CPZ group, 14=
placebo group)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomly assigned” no further details re-
ported.
Allocation concealment (selection bias) Unclear risk No information reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Assigned on a double-blind basis to iden-
tical looking 100 mg or 50 mg tablets of
chlorpromazine or placebo”
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Hogarty 1973 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Double-blind”no further details reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Losses to follow-up not clearly reported.
Reasons for leaving the study early re-
ported, but not according to group
Selective reporting (reporting bias) High risk Number of deaths and number of partic-
ipants in trouble with police not reported
by group
No SDs reported for BPRS, Symptom
Checklist, IMPS, Springfield Symptom In-
ventory,MajorRoleAdjustment Inventory,
Katz Adjustment Scale, Casework Evalua-
tion Schedu
Other bias Unclear risk Supported by grants from the Psychophar-
macology Research Branch, National Insti-
tute of Mental Health (NIMH)
Chlorpromazine was supplied by Smith
Kline & French Laboratories, Philadelphia
Klein 1973
Methods Allocation: randomly assigned - no further description.
Blinding: double, used ’highly flavoured liquid placebo’, a constant 40 ml per day from
individually labelled bottles.
Duration: 6 weeks.
Design: parallel.
Country: USA.
Participants Diagnosis: schizophrenia (specified criteria).
N=88.
Sex: 51% M, 49% F.
Age: mean 26.7 yrs, range 17-61.
Setting: hospital.
Interventions 1. Chlorpromazine: dose increased by 300 mg/day/week to max. 1200 mg/day, week 4-
6. N=46.
2. Placebo. N=42.
Chlorpromazine combined with procyclidine for EPS: dose max. 15 mg/day
Outcomes Leaving study early.
Unable to use -
Mental state: MSRPP (no SD).
Notes
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Klein 1973 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomly assigned” no further details re-
ported.
Allocation concealment (selection bias) Unclear risk No information reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Double-blind”
“Medication was administered in a highly
flavoured liquid placebo, and each patient
received a constant 40 ml/day from indi-
vidually labelled bottles”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Double-blind”no further details reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk There were no losses to follow-up.
Selective reporting (reporting bias) High risk No SDs reported for MSRPP.
Other bias Unclear risk Supported in part by grants from the Pub-
lic Health Service of the National Institue
of Mental Health
Smith Kline & French Laboratories and
Wellcome and Co supplied the drugs
Kurland 1961
Methods Allocation: assigned by “predetermined random selection”.
Blinding: double, “standard unmarked capsules”, “coloured pink to mask all identifying
consistencies and colours of drugs”.
Duration: 6 weeks.
Design: parallel.
Country: USA.
Participants Diagnosis: ’predominantly schizophrenic in character’.
History: newly admitted, target symptoms of hyperactivity, anxiety, tension, overt ag-
gression.
N=277.
Sex: 1:2 ratio M:F.
Age: mean 31 yrs, range 18-61.
Setting: hospital.
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Kurland 1961 (Continued)
Interventions 1. Chlorpromazine: dose 25 mg/day IM (days 1-2) then min. 300 mg/day (no max.).
N=33.
2. ’Positive’ placebo (phenobarbital): dose 65 mg/day IM (days 1-2) then min. 97.5 mg/
day (no max.). N=37.
3. ’Negative’ placebo (saline/lactose): dose IM (days 1-2) then oral. N=37.
4. Promazine: dose 50 mg/day IM (days 1-2) then min. 300 mg/day (no max.). N=32.
5. Mepazine: dose 25 mg/day IM (days 1-2) then min. 75 mg/day (no max.). N=34.
6. Triflupromazine: dose 25 mg/day IM (days 1-2) then min. 75 mg/day (no max.). N=
36.
7. Prochlorperazine: dose 5 mg/day IM (days 1-2) then min. 30 mg/day (no max.). N=
32.
8. Perphenazine: dose 5 mg/day (days 1-2) then min. 24 mg/day (no max.). N=36
Outcomes Leaving study early.
Adverse effects.
Global improvement.
Unable to use -
Mental state: MSRPP, Psychotic Reaction Profile, Psychiatric Scale of Target Symptoms
(no SD)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “The choice of the particular drug to be
used in any case was based on a predeter-
mined random selection” no further details
reported
Allocation concealment (selection bias) Unclear risk No information reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Double-blind”
“The drugs were dispensed in standard un-
marked capsules [...] coloured pink tomask
all identifying consistencies and colours of
the drugs”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Double-blind”
“Ratings were blind, in that raters did not
know which drug the patients was receiv-
ing”
Incomplete outcome data (attrition bias)
All outcomes
High risk “Those patients whom data were incom-
plete, together with
those not receiving medication for at least
ten days, were excluded from the study”
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Kurland 1961 (Continued)
“Of the 238 patients who met all popu-
lation restrictions, 187 remained in the
project at least 10 days [...] Fifty-nine pa-
tients completed the prescribed six-week
treatment course.”
Selective reporting (reporting bias) High risk No SDs reported for theMSRPP, Psychotic
Reaction Profile and Psychiatric Scale of
Target Symptoms
Other bias Unclear risk Funded by a research grant from the Na-
tional Advisory Mental Health Council,
National Institute of Health, US Public
Health Service
Drugs provided by Smith Kline & French
Laboratories, Squibb Laboratories, Shering
Corporation and Warner-Chilcott Labora-
tories
Letemendia 1967
Methods Allocation: matched (age, length of hospitalisation & severity) then assigned by toss of
a coin.
Blinding: double, “medication dispensed in uniform amber-coloured capsules”.
Design: cross-over.
Duration: 9 months per arm of cross-over.
Country: UK.
Participants Diagnosis: schizophrenia (N=26 - criteria not specified), deluded (N=2), concurrent
learning difficulties (N=2).
History: > 5 yrs continuous hospitalisation, physically healthy.
N=28.
Sex: 28 M.
Age: < 65 years.
Setting: hospital.
Interventions 1. Chlorpromazine: dose 300 mg/day. N=14.
2. Placebo. N=14.
Outcomes Leaving study early.
Unable to use -
Mental state & behaviour (authors’ own scale - no SD).
Notes 2 people dropped out - unsure if before/after randomisation.
Risk of bias
Bias Authors’ judgement Support for judgement
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Letemendia 1967 (Continued)
Random sequence generation (selection
bias)
Low risk Groups matched according to age, length
of hospital stay and severity, “The designa-
tion of the two groups was determined by
tossing a coin”
Allocation concealment (selection bias) Unclear risk No information reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Double-blind”
“Neither patients, doctors, nor nurses knew
which patients were being given chlorpro-
mazine and which placebo. All medication
was dispensed in uniform amber-coloured
capsules. Each patient was supplied from
a separated bottle, replenished weekly ac-
cording to the design by an independent
party”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Double-blind”no further details reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk “Of the 30 patients who initially fulfilled
out conditions, one died from a cerebrovas-
cular accident during the period of prelim-
inary observations, and a second was elim-
inated because of slow phasic changes in
mental state”. Two losses to follow-up, but
unclear is before or after randomisation
Selective reporting (reporting bias) High risk No SDs reported for mental state and be-
haviour scale
Other bias Low risk Supported by a grant from the Rockefeller
foundation.
Nishikawa 1982
Methods Allocation: randomly assigned - no further description.
Blinding: double, drug appearance (colour, taste, volume) identical.
Design: cross-over, data reported for first arm only.
Duration: up to 3 years (or relapse, if sooner).
Country: Japan.
Participants Diagnosis: schizophrenia (criteria not specified).
History: remitted illness, but > 1 relapses.
N=55.
Sex: 37 M, 18 F.
Age: mean 33.3 yrs, SD 8.0.
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Nishikawa 1982 (Continued)
Setting: outpatients department.
Interventions 1. Chlorpromazine: dose 75 mg/day. N=10.
2. Placebo. N=10.
3. Diazepam: dose 15 mg/day. N=13.
4. Imipramine: dose 50 mg/day. N=12.
5. Haloperidol: dose 3 mg/day. N=10.
Medication given in fixed-dose regimen; nitrazepam 10mg/day for insomnia as required;
biperiden 3 mg/day for EPS as required
Outcomes Relapse.
Unable to use -
Symptom-free days (survival data not supported by RevMan).
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ”Randomly assigned“ no further informa-
tion reported.
Allocation concealment (selection bias) Unclear risk No information reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk ”Double-blind“
”Drug appearance, with respect to powder
colour, taste and volume, was made iden-
tical by adding a kind of stomachics
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Double-bind” no further details reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk “Then nine patients were dropped from
the study for various reasons. These reasons
included: failure to report to the hospital
for scheduled appointments (N=3); admis-
sions to other hospitals (N=2); strong re-
quests from the patient not to change the
previous drugs (N=3); and a suicide after
admission to the hospital (N=1)”. Number
of participants and reasons for leaving the
study early not reported by groups
Selective reporting (reporting bias) High risk Not all expected outcomes reported.
Other bias Unclear risk Drugs provided by SMP (Sankyo, Japan).
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Payne 1960
Methods Allocation: “double blind technique employed”.
Blinding: double blind.
Duration: 6 weeks.
Design: parallel.
Country: Canada.
Participants Diagnosis: schizophrenia.
History: chronic, hospitalised for an average of 12.7 years.
N=21.
Sex: 21 M.
Age: 23-73 (41.9 average).
Setting: hospital.
Interventions 1. Chlorpromazine: dose 25 mg/tds increasing to 100 mg/tds. N=7.
2. Placebo. N=7.
3. Vesprin: dose 25 mg/tds increasing to 100 mg/tds . N=7.
Outcomes Adverse effects.
Unable to use -
Categories of improved, much improved and unimproved (no usable data)
Notes Withdrawals not described.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “The patients were divided into three
groups of seven persons” no further details
reported
Allocation concealment (selection bias) Unclear risk No information reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Double-blind”
“All three types of tablet were exactly the
same colour, size and shape. Each patient’s
medication was supplied to the wards in
identical containers bearing the patient’s
name only. The physician and ward per-
sonnel were unaware of which patient was
receiving which tablet; the latter being
known only to the pharmacist and not di-
vulged until the completion of the investi-
gation”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Double-blind” no further information re-
ported.
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Payne 1960 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Did not report any losses to follow-up.
Selective reporting (reporting bias) High risk Results for categories of ’improved’, ’much
improved’ and ’unimproved’ not fully re-
ported
Other bias Unclear risk Drugs supplied by ER Squibb and Sons of
Canada, Limited.
Source of funding not reported.
Peet 1981
Methods Allocation: randomly assigned - no further description.
Blinding: double, used ’capsules of identical external appearance’.
Duration: 3 months.
Design: parallel.
Country: UK.
Participants Diagnosis: schizophrenia (Feighner’s criteria).
History: unclear. ’with a diagnosis of chronic schizophrenia’.
N=53.
Sex: 40 M, 13 F.
Age: mean 51.3 yrs.
Setting: hospital.
Exclusions: heart disease, asthma, liver disease, diabetes, alcoholism, drug abuse, other
regularly prescribed psychotropic drugs
Interventions 1. Chlorpromazine: dose max. 400 mg/day. N=16.
2. Placebo: dose max. 8 capsules/day. N=18.
3. Propranolol: dose max. 640 mg/day. N=19.
Medication given in discretionary dose regimen; diazepam used as required
Outcomes Leaving study early.
Relapse.
Adverse effects. tremor, drowsiness.
Unable to use -
Mental state: BPRS (no mean, N, or SD).
Behaviour: NOSIE (no mean, N, or SD).
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomly assigned” no further details re-
ported.
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Peet 1981 (Continued)
Allocation concealment (selection bias) Unclear risk No information reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Double-blind”
“Capsules of identical appearance”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Double-blind”no further details reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 6 patients left the study early from the
propanolol and chlorpromazine groups,
and 9 from the placebo group. Reasons for
loss evenly distributes across groups
Selective reporting (reporting bias) High risk No means or SDs reported for IMPS,
NOSIE and Discharge Readiness Inven-
tory
Other bias Unclear risk Source of funding not reported.
Prien 1968
Methods Allocation: randomly assigned - no further description.
Blinding: double - no further description.
Duration: 24 weeks (preceded by 8 weeks ’routine hospital medication’)
Design: parallel.
Country: USA.
Participants Diagnosis: schizophrenia (specified criteria).
History: ’chronic’.
N=838.
Sex: male and female (proportions not given).
Age: mean 41 yrs, range 19-55.
Setting: hospital.
Interventions 1.Chlorpromazine: dose 2000mg/day (“high dose”).N=208. (Permanent dose reduction
to 1500 mg permitted to control side effects).
2. Chlorpromazine: dose 300 mg/day (“low dose”). N=208.
3. Placebo. N= 212.
4. ’Routine conventional hospital treatment’. N=210.
Outcomes Leaving study early.
Behaviour deterioration.
Global improvement (own 7-point rating scale).
Global severity of illness (own 7-point rating scale).
Adverse effects.
Relapse.
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Prien 1968 (Continued)
Unable to use -
Mental state: IMPS (no mean or SD).
Behaviour: NOSIE (no mean or SD).
Social function: Discharge Readiness Inventory (no mean or SD)
Notes Blood problems reported from just one centre (N=58).
Tardive dyskinesia side-effects- extracted from a sub-study by Crane (1968)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomly assigned” no further details re-
ported.
Allocation concealment (selection bias) Unclear risk No information reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Double-blind”no further details reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk “The placebo group had the highest per-
centage of dropout (38%), followed by the
high dose group (25%), and the low dose
group (15%). Terminations due to side ef-
fects were most frequent in the high dose
group, while the placebo group had the
highest incidence of dropouts due to dete-
riorated behavior.” Losses to follow-up bal-
anced across intervention groups, with sim-
ilar reasons for missing data
Selective reporting (reporting bias) High risk No SD for IMPS, NOSIE, Discharge
Readiness Inventory.
Other bias Low risk The study appears to be free of other
sources of bias.
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Ramu 1999
Methods Allocation: randomised.
Blinding: double.
Duration: 2 months.
Design: parallel.
Country: India.
Participants Diagnosis: schizophrenia (in accordance with National Institute of Mental Health, Psy-
chopharmacological service centre, collaborative study group)
N=136.
Age: 15-45 years.
Sex: male and female.
History: significant hospitalisation during previous 12 months. Acute episode of chronic
schizophrenia.
Exclusions: stuporous and exclusively withdrawn patients.
Setting: outpatients.
Interventions 1. Chlorpromazine: dose 200 mg/day in month 1 and 300 mg/day in month 2. N=27*.
2. Placebo. N=27*.
3. Brahmadiyoga. N=27*.
4. Tagara. N=27*.
Outcomes Global impression: no global improvement.
Adverse effects.
Unable to use -
Psychotic rating scale (unclear whether a validated scale).
Spiral after effect (not a validated scale).
Notes *N randomised to each group not reported; N after losses to follow-up
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomly allocated” no further details re-
ported.
Allocation concealment (selection bias) Unclear risk No information reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Double-blind”
“The medicines and placebo were admin-
istered in the form of identical tablets”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Double-blind”no further details reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk “Out of 136 patients 108 who have com-
pleted the treatment for a period of 2
months were taken for final assessment.
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Ramu 1999 (Continued)
The remaining 28 were dropouts for rea-
sons of escape and leaving without med-
ical advice”. Number randomised to each
group not reported.Number lost from each
group not reported
Selective reporting (reporting bias) High risk Not all expected outcomes reported.
Unclear which rating scales are reported in
the results tables
Other bias Unclear risk Source of funding not reported.
Ramu 1999a
Methods Allocation: not stated.
Blinding: double.
Duration: 11 weeks.
Design: parallel.
Country: India.
Participants Diagnosis: schizophrenia (WHO glossary of mental disorders)
N=78.
Age: average ~32 (SD 7) for chlorpromazine and placebo groups.
Sex: M 30, F 35.
History: Chronic schizophrenia between 2 and 6 years.
Exclusions: not reported.
Setting: not reported.
Interventions 1. Chlorpromazine: dose 300 mg/day up to day 30 and 450 mg/day up to day 75. N=
22*.
2. Brahmyadiyoga: 12 g/day up to day 30 and 16 g/day up to day 75. N=23*.
3. Placebo. N=20*.
Outcomes No global improvement.
Behaviour: Fergus Falls rating scale**.
Adverse effects: drowsiness**.
Unable to use -
Psychiatric symptoms rating scale (not a validated scale).
Notes *N randomised to each group not reported; N after losses to follow-up.
**N not reported, assumed to be the number reported in each group after losses to
follow-up
Risk of bias
Bias Authors’ judgement Support for judgement
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Ramu 1999a (Continued)
Random sequence generation (selection
bias)
High risk No information reported.
Allocation concealment (selection bias) Unclear risk No information reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Double-blind”
“Sugar coated uniform tablets of the trial
drugs” no further details reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Double-blind”no further details reported.
Incomplete outcome data (attrition bias)
All outcomes
High risk “78 cases were taken for the study.Of them,
13 cases were dropped out for various rea-
sons” N randomised to each group not re-
ported. Reasons for losses and number of
losses to follow-up per group not reported
Selective reporting (reporting bias) High risk N not reported for psychiatric rating scale.
Total scores not reported for final assess-
ment of psychiatric rating scale
N reported for global improvement differs
from N reported in each group
Other bias Unclear risk Drugs supplied by M/s Eros Pharma, Ban-
galore.
Rappaport 1978
Methods Allocation: randomly assigned - no further description.
Blinding: single, staff ’remained blind as to whether the patient was receiving medication
or placebos’.
Duration: unclear, mean hospitalisation=43 days, follow up at 1-36 months after dis-
charge
Design: parallel.
Country: USA.
Participants Diagnosis: schizophrenia (no specified criteria).
History: ’acute’ illness.
N=127.
Sex: 127 M.
Age: range 16-40 yrs.
Setting: hospital.
Interventions 1. Chlorpromazine: dose variable 300-900 mg/day. N=53.
2. Placebo.N=74.
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Rappaport 1978 (Continued)
Outcomes Leaving study early.
Relapse (rehospitalisation).
Notes N’s at allocation unbalanced - integrity of randomisation unclear.
Unclear when outcomes recorded - assumed ’medium-term’ in all cases (to reflect mode
outcome period in review)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Assigned randomly” no further details re-
ported.
Allocation concealment (selection bias) Unclear risk No information reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “physician [...] and the nursing staff re-
mained blind as to whether the patient was
receiving medication or placebos” no fur-
ther details reported
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Ratings were made by a trained research
assistant who was unaware as to what the
patient’s medication condition was while
he was hospitalised”
Incomplete outcome data (attrition bias)
All outcomes
High risk “The 80 patients in this study represented
63%of the total sample (127) studiedwhile
in the hospital. It was noted that during the
follow-up period, there was a significantly
larger attrition of subjects from the group
assigned to placebo while in the hospital
than the group assigned to chlorpromazine
(45% vs 26%).”
Selective reporting (reporting bias) High risk Unclear when outcomes recorded. Not all
expected outcomes reported
Other bias Low risk SupportedCaliforniaDepartment ofMen-
tal Hygiene and the National Institute of
Mental Health and from theWickes Foun-
dation and Esalen Institute
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Reardon 1966
Methods Allocation: randomly assigned - no further description.
Blinding: ’neither the ward personnel nor the investigator knew which drug the patient
received’.
Duration: min. 4 weeks, max. 12 weeks.
Design: parallel.
Country: USA.
Participants Diagnosis: paranoid schizophrenia (Bleuler criteria).
History: ’acute’ illness.
N=34.
Sex: 22 M, 12 F.
Age: not stated.
Setting: hospital.
Interventions 1. Chlorpromazine: dose 300 mg/day (week 1), 600 mg/day thereafter. N=11.
2. Placebo: dose 2-4 cc/day (week 1), 5-10 cc/day thereafter. N=12.
3. Trifluoperazine: dose 20 mg/day (week 1), 40 mg/day thereafter. N=11
Medication given in fixed-dose regimen; artane: 10 mg/day given to all to reduce side
effects
Outcomes Leaving study early.
Global improvement (lack of previously observed delusions and hallucinations)
Unable to use -
Mental state: MMPI (no means or SD).
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomly assigned” no further details re-
ported.
Allocation concealment (selection bias) Unclear risk “Randomly assigned trifluorop-
erazine, chlorpromazine or placebo by the
pharmacy” no further details reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Neither the ward personnel nor the in-
vestigator knew which drug the patient re-
ceived” no further details reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Neither the ward personnel nor the in-
vestigator knew which drug the patient re-
ceived” no further details reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk “Six patients had to be excluded from the
investigation as they were given ECT. Of
these subjects two were on trifluoroper-
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Reardon 1966 (Continued)
azine, one on chlorpromazine and three
were controls”
“An additional three subjects, one from
each group, had to be removed from the
study because of transfer or home leave”
Selective reporting (reporting bias) High risk No means or SDs reported for the MMPI.
Not all expected outcomes reported
Other bias Unclear risk Smith Kline and French provided drugs.
Source of funding not reported.
Reschke 1974
Methods Allocation: randomly assigned - no further description.
Blinding: double - no further description.
Duration: approximately 25 hours.
Design: parallel.
Country: not reported.
Participants Diagnosis: schizophrenia (no specified criteria).
History: severe agitation.
N=50.
Sex: 2 M, 48 F.
Age: mean 35.9 yrs, range 19-57.
Setting: hospital.
Interventions 1. Chlorpromazine: dose 25 mg IM. N=10.
2. Placebo. N=11.
3. Haloperidol: dose 5 mg IM. N=10.
4. Haloperidol: dose 2 mg IM. N=11.
5. Haloperidol: dose 1 mg IM. N=8.
Max. of 4 injections administered at min. intervals of 30 minutes
Outcomes Leaving study early.
Global improvement (own 5-point rating scale).
Adverse effects.
Unable to use -
Mental state: BPRS and own target symptoms scale (no mean or SD)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomly assigned” no further details re-
ported.
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Reschke 1974 (Continued)
Allocation concealment (selection bias) Unclear risk No information reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Double-blind”no further details reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Double-blind”no further details reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk There were no losses to follow-up.
Selective reporting (reporting bias) High risk No means and SDs reported for BPRS.
Other bias Unclear risk Source of funding not reported.
Saretsky 1966
Methods Allocation: randomly assigned - no further description.
Blinding: double, ’two kinds of pills ... identical in size, shape, colour, and taste’.
Duration: 3 months.
Design: parallel.
Country: USA.
Participants Diagnosis: schizophrenic reaction (no criteria stated).
History: newly admitted.
N=40.
Sex: 40 M.
Age: < 55 yrs.
Setting: hospital.
Interventions 1. Chlorpromazine: dose 400 mg/day. N=20.
2. Placebo (lactose): dose 4 pills/day. N=20.
Medication given in fixed-dose regimen.
Outcomes Leaving study early.
Unable to use -
Mental state: MSRPP (mean appears erroneous).
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Saretsky 1966 (Continued)
Random sequence generation (selection
bias)
Unclear risk “Randomly assigned” no further details re-
ported.
Allocation concealment (selection bias) Unclear risk No information reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “The drugs were packaged in individual
bottles with only the patient’s name printed
on them as a means of identification.”
“Throughout the experiment, whether the
patient received the drug or a placebo was
not known to anyone connected with the
experiment.”
“The two kinds of pills were identical in
size, shape, colour, and taste.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Throughout the experiment, whether the
patient received the drug or a placebo was
not known to anyone connected with the
experiment.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk There were no losses to follow-up.
Selective reporting (reporting bias) High risk Not all expected outcomes reported.
Other bias Unclear risk Source of funding not reported.
Schiele 1961
Methods Allocation: randomly assigned - no further description.
Blinding: double - no further description.
Duration: 16 weeks.
Design: parallel.
Country: USA.
Participants Diagnosis: schizophrenia (no criteria stated).
History: all had been hospitalised for an average of 10 years.
N=80.
Sex: 80 M.
Age: 40.6 years (average).
Setting: hospital.
Interventions 1. Chlorpromazine: dose 200-1000 mg/day. N=20.
2. Placebo: N=20.
3. Thioridazine: dose 200-1000 mg/day. N=20.
4. Trifluoperazine: dose 10-50 mg/day. N=20.
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Schiele 1961 (Continued)
Outcomes Leaving the study early.
Mental state. MMPI.
Global estimate of clinical change - via ward staff.
Adverse effects.
Unable to use -
Behaviour: MBS (no SD).
Notes Withdrawals described.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomly assigned” no further details re-
ported.
Allocation concealment (selection bias) Unclear risk No information reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “During the first 16 weeks, the study was
carried out under strict double-blind con-
ditions. Each patient had his individual
bottle of medication; the capsules were
identical in appearance, and only the hos-
pital pharmacist had the code for determin-
ing which patient was receiving each kind
of medication”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Double-blind”no further details reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk “Only 2 patients were dropped [...] because
their psychiatric condition became and re-
mained worse.”
“During the thirteenth week. a third pa-
tient who was in the trifluoperazine group
eloped from the hospital.” Only 43 partic-
ipants took the MMPI three times
Selective reporting (reporting bias) High risk No SD reported for the MBS.
Other bias Unclear risk Source of funding not reported.
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Serafetinides 1972
Methods Allocation: randomly assigned - no further description.
Blinding: double, used ’identically appearing capsules’.
Duration: 12 weeks (preceded by 12 week dry-out period).
Design: parallel.
Country: USA.
Participants Diagnosis: schizophrenia (criteria not specified).
History: > 2 yrs ill.
N=57*.
Sex: 25 M, 32 F.
Age: range 21-61 yrs.
Setting: hospital.
Interventions 1. Chlorpromazine: dose max. 1000 mg/day. N=14.
2. Placebo: dose max. 10 capsules/day. N=13.
3. Haloperidol: dose max. 15 mg/day. N=14.
4. Clopenthixol: dose max. 250 mg/day. N=15.
Medication given in variable dose regimen’ medication for EPS or insomnia as required
Outcomes Leaving study early.
Global improvement. CGI.
Adverse effects.
Liver function.
Unable to use -
Global improvement: CGI (discrepancy with group totals).
Mental state: BPRS, Venables-O’Conner scale (no SD).
Behaviour: NOSIE, OBRS (no SD).
Psychological function: test battery (no data).
Notes *One participant not accounted for.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomly assigned” no further details re-
ported.
Allocation concealment (selection bias) Unclear risk No information reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “All medications were prepared in identi-
cally appearing capsules” no further details
reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information reported.
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Serafetinides 1972 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk “Four of the 57 subjects, three onCPZ, and
one on PL,failed to complete the 12 weeks
of study. The PL subject and one CPZ sub-
jectwere terminated because of behavioural
deterioration after 4 and 8 weeks respec-
tively. The other two CPZ subjects devel-
oped intestinal obstruction secondary to
massive fecal impactions and were termi-
nated in the 7th week of study.”
Selective reporting (reporting bias) High risk NoSDswere reported for theCGI,NOSIE
and the OBPRS.
No data was reported for the psychological
function tests.
Other bias Low risk Supported in part by a US Public Health
Service Grant.
Shepherd 1956
Methods Allocation: randomly assigned - no further description.
Blinding: unclear,medication identical and ’nobody but ... doctor and ... dispenser [knew
who was] receiving drugs [or] placebo’.
Design: cross-over (Latin square, slightly modified) - data extracted for first arm only.
Duration: 6 weeks (each individual arm).
Country: UK.
Participants Diagnosis: schizophrenia (apathetic and deteriorated).
History: duration of hospitalisation, mean 15.8 yrs, range 7-29.
N=24.
Sex: 24 F.
Age: mean 40 yrs, range 27-52.
Setting: hospital.
Interventions 1. Chlorpromazine: dose 300 mg/day. N=8.
2. Placebo. N=8. [see notes].
3. Reserpine: dose 15 mg (reduced to) 10 mg/day. N=8. [see notes]
Medication given in fixed-dose regimen.
Outcomes Improvement.
Leaving study early.
Unable to use -
Adverse effects (not reported for individual arm of cross-over)
Notes Before first cross-over reserpine group inadvertently given 0.75 mg/day (not 15 mg/day)
. This group therefore regarded as placebo group by trialists and reviewers (hence N for
placebo=16)
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Shepherd 1956 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The 24 patients were divided into three
groups of eight (A,B, and C) by random
selection“ no further details reported
Allocation concealment (selection bias) Unclear risk No information reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Two kinds of inert substances were em-
ployed, one indistinguishable from reser-
pine, the other from chlorpromazine. No-
body but the ward doctor allocating the
drugs and the dispenser knew which pa-
tients were receiving drugs and which pa-
tients were on placebo”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Weekly clinical assessments were carried
out by one of us (DCW) who was unaware
of the nature of individual prescriptions”
Incomplete outcome data (attrition bias)
All outcomes
Low risk There were no losses to follow-up.
Selective reporting (reporting bias) High risk Adverse effects were not reported for each
individual arm.
Other bias Unclear risk Messrs Ciba supplied serpasil and dummy
tablets, Messrs May and Baker supplied
dummy tablets
Simon 1958
Methods Allocation: by list of random numbers.
Blinding: unclear.
Duration: 30 days.
Design: parallel.
Country: USA.
Participants Diagnosis: schizophrenia (78), schizoaffective (2).
History: treatment naive, duration treated ~33 days.
N=80
Sex: not reported.
Age: mean ~31 years.
IQ: mean ~ 103.
Setting: hospital.
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Simon 1958 (Continued)
Interventions 1. Chlorpromazine: dose mean 400 mg/day, range 200-1200 mg/day. N=20.
2. Reserpine: dose mean mg/day, range 2-mg/day. N=20.
3. Clinical judgement: any treatment - could include chlorpromazine. N=20.
4. Hospital routine: admission but no specific treatment, no drugs. N=20
Outcomes Leaving the study early.
Unable to use -
Personality profile: MMPI (no means, no SD).
Social functioning: Scale of Occupational Adjustment (no data reported)
Notes Withdrawals described.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Assigned to one of 4 treatment groups on
a random basis [...] the staff was kept igno-
rant of the order within the random list”
Allocation concealment (selection bias) Unclear risk No information reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No information reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk There were no losses to follow-up.
Selective reporting (reporting bias) High risk Means and SDs were not reported for the
MMPI.
No data was reported for the Scale of Oc-
cupational Adjustment
Other bias Unclear risk Source of funding not reported.
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Smith 1961
Methods Allocation: divided into 3 matched groups on the basis of age, illness duration and
symptom.
Blinding: double.
Duration: 14 weeks.
Design: parallel.
Country: not reported.
Participants Diagnosis: schizophrenia.
History: chronic.
N=41.
Sex: male and female.
Age: 42.21 years (average).
Setting: research unit.
Interventions 1. Chlorpromazine: dose 150-600 mg/day. N=13.
2. Placebo. N=15.
3. Chlordiazepoxide: dose 150-700 mg/day. N=13.
Outcomes Behaviour rating scale.
Unable to use-
Leaving the study early (no usable data).
Notes Withdrawals described but unclear.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The 45 patients were divided into three
matched groups on the basis of age, illness
duration and predominant symptomatol-
ogy” no further details reported
Allocation concealment (selection bias) Unclear risk No information reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Themedication used during the studywas
prepared in identical capsules”
“Neither the patients nor the attending
physicians knew what medication was be-
ing given. An identifying codewas available
but not broken until the end of the study.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Neither the patients nor the attending
physicians knew what medication was be-
ing given.” no further details reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Two participants lost to follow-up in the
chlorpromazine group and two in the clor-
diazepoxide group, reasons for leaving the
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Smith 1961 (Continued)
study early not reported. Unclear whether
there were any losses in the placebo group
Selective reporting (reporting bias) Low risk All expected outcomes reported.
Other bias Unclear risk Source of funding not reported.
Somerville 1960
Methods Allocation:matched on symptoms, age, anddurationof illness, then allocated ’by random
choice’ - no further description.
Blinding: ’the twoplaceboswere identical in appearancewith the respective active tablets’.
Duration: 6 weeks.
Design: parallel.
Country: Australia.
Participants Diagnosis: schizophrenia or ’paraphrenic psychoses’ (N=56); manic depression (N=4).
History: duration of illness, mean 9.5 yrs, range 0.4-29.
N=60.
Sex: 60 F.
Age: mean 41 yrs, range 24-58.
Setting: hospital.
Interventions 1. Chlorpromazine: dose 200-800 mg/day. N=15.
2. Placebo. N=30.
3. Thioridazine: dose 200-800 mg/day. N=15.
Outcomes Leaving study early.
Clinical improvement (own 5-point rating scale).
Behaviour. Fergus Falls Rating Scale.
Adverse effects.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Random choice” matched on symptoms,
age, and duration of illness, no further de-
tails reported
Allocation concealment (selection bias) Unclear risk “A doctor who had no duties connected
with the ward concerned allotted each of
the groups to a particular therapy” no fur-
ther details reported
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Somerville 1960 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “The twoplaceboswere identical in appear-
ance with the respective active tablets.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk There were no losses to follow-up.
Selective reporting (reporting bias) Low risk All expected outcomes reported.
Other bias Unclear risk Sandoz Australia Proprietary Limited and
May & Baker (Australia) Proprietary Lim-
ited supplied drugs
Source of funding not reported.
Spohn 1977
Methods Allocation: randomly assigned - no further description.
Blinding: double, used ’chlorpromazine facsimile” placebo.
Duration: “at least six weeks” (preceded by abrupt medication withdrawal & 6 week
washout)
Design: parallel.
Country: USA.
Participants Diagnosis: chronic schizophrenia (’official hospital diagnosis’).
N=40.
Sex: 28 M, 12 F.
Age: range 18-55 yrs.
Setting: hospital.
Interventions 1. Chlorpromazine: dose discretionary min. 200 mg/day. N=20.
2. Placebo. N=20.
Antiparkinsonian medication for EPS as required; chloral hydrate for insomnia as re-
quired
Outcomes Relapse.
Unable to use -
Global severity of illness: Global Severity Scale (no means or SD).
Global improvement: Global Improvement Scale (no means or SD).
Behaviour: Ward Behavior Rating Scale (no means or SD).
Notes
Risk of bias
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Spohn 1977 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Random assignment” no further details
reported.
Allocation concealment (selection bias) Unclear risk No information reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “During the drug treatment period, pa-
tients, project personnel, and hospital per-
sonnel were ”blind“ to the patients’ drug
status” no further details reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “During the drug treatment period, pa-
tients, project personnel, and hospital per-
sonnel were ”blind“ to the patients’ drug
status” no further details reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Losses to follow-up not reported.
Selective reporting (reporting bias) High risk Means and SDs were not reported for the
Global Severity Scale, Global improvement
Scale and theWard Behaviour Rating Scale
Other bias Unclear risk Supported by a Public Health Service re-
search grant and a research scientist award
from the National Institute of Mental
Health and by the Ittleson Family Founda-
tion
Chlorpromazine supplied by Smith Kline
and French Laboratories
Tetreault 1969
Methods Allocation: randomly assigned - according to a ’random number table’.
Blinding: double, identical capsules.
Duration: 12 weeks (preceded by 19-day wash-out).
Design: parallel.
Country: Canada.
Participants Diagnosis: schizophrenia (no specified criteria).
History: ’chronic’, mean duration of hospitalisation 16.3 yrs.
N=45.
Sex:45 F.
Age: mean 50.5 yrs.
Setting: hospital.
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Tetreault 1969 (Continued)
Interventions 1. Chlorpromazine: dose 300 mg increasing to 600 mg/day. N=15.
2. Placebo: dose 3 capsules increasing to 6 capsules/day. N=15.
3. TPS-23 (Mesoridazine): dose 150 mg increasing to 300 mg/day. N=15
Chlorpromazine (50 mg im), chloral hydrate (650 mg), ethchlorvynol (500 mg), pro-
cyclidine (5 mg IM) as required ’in case of emergency’
Outcomes Leaving study early.
Mental state. BPRS.
Behaviour. Modified Rosenthal Rating Scale.
Extrapyramidal adverse effects.
Adverse effects.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients received one of the tested drugs
according to a random number table”
Allocation concealment (selection bias) Unclear risk No information reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “TPS-23 (50mg, chlorpromazine (100mg)
and placebo presented in identical white
capsules; they were distributed on the ward
in containers on which only the patient’s
name appeared. The double-blind tech-
nique was followed throughout the experi-
ment”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Double-blind”no further details reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk There were no losses to follow-up.
Selective reporting (reporting bias) Low risk All expected outcomes reported.
Other bias High risk Partly supported by a grant-in-aid from
Sandoz (Canada) Ltd. who supplied the
drugs
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Vaughan 1955
Methods Allocation: randomly assigned - no further description.
Blinding: ’the hospital pharmacist alone knowing which patients were receiving CPZ
and which the placebo’.
Duration: not specified.
Design: parallel.
Country: UK.
Participants Diagnosis: not specified; all participants had motor restlessness, psychomotor agitation,
and excitement, were ’chronic and intractable’, and had a poor prognosis.
History: mean duration of hospitalisation 9.6 yrs.
N=48.
Sex: 48 F.
Age: mean 43 yrs.
Setting: hospital.
Interventions 1. Chlorpromazine: dose variable 75-450 mg/day. N=24.
2. Placebo. N=24.
Outcomes Global improvement.
Notes Reviewers assume short-term outcome - in keeping with other studies of that period
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “By random selection” no further details
reported.
Allocation concealment (selection bias) Unclear risk No information reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “The hospital pharmacist alone knowing
which patients were receiving chlorpro-
mazine and which the placebo” no further
details reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “The hospital pharmacist alone knowing
which patients were receiving chlorpro-
mazine and which the placebo” no further
details reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Losses to follow-up not reported.
Selective reporting (reporting bias) High risk Not all expected outcomes reported.
Other bias Unclear risk Messrs May & Baker supplied the placebo
tablets.
Source of funding not reported.
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Walsh 1959
Methods Allocation: randomly assigned - ’allocation of a preparation to a group was purely arbi-
trary’ - matched on age, hospitalisation, adjustment, psychotic behaviour, and activity/
withdrawal.
Blinding: unclear, no. & size of placebo tablets altered when active preparations altered.
Duration: 8 weeks.
Design: parallel.
Country: not reported
Participants Diagnosis: schizophrenia (no specified criteria).
History: ’chronic’, mean duration of hospitalisation 13 yrs, range 1-28.
N=66.
Sex: 66 F.
Age: mean 40 yrs, range 27-50.
Setting: hospital.
Interventions 1. Chlorpromazine: dose 75 mg/day increasing to 300 mg/day. N=22.
2. Placebo. N=22.
3. Triflupromazine: dose 75 mg/day increasing to 300 mg/day. N=22
Outcomes Clinical improvement (4-point rating scale).
Adverse effects.
Unable to use -
Mental state: Rowell ’Psychoticism’ Rating Scale (no SD).
Behaviour: Venables Activity-Withdrawal Rating Scale (no SD)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ”Allocation of a preparation to a group
was purely arbitrary“, participantsmatched
on age, hospitalisation, adjustment, psy-
chotic behaviour, and activity/withdrawal.
No further details reported
Allocation concealment (selection bias) Unclear risk No information reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk As this involved periodic changes in the
number and/or size of the tablets, the num-
ber and/or size of the tablets given to the
placebo group was altered simultaneously.
Neither the doctor nor the ward staff were
aware of the nature of the preparation be-
ing given to a particular patient. A sepa-
rate bottle was assigned to each patient and
in this supplies of the specific preparation
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Walsh 1959 (Continued)
were issued at weekly intervals”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Neither the doctor nor the ward staff were
aware of the nature of the preparation be-
ing given to a particular patient” no further
details reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk There were no losses to follow-up.
Selective reporting (reporting bias) High risk NoSDswere reported forRowell ’Psychoti-
cism’ Rating Scale and the Venables Activ-
ity-Withdrawal Rating Scale
Other bias Unclear risk ERSquibb and Sons Ltd, London provided
drugs.
Source of funding not reported.
Weckowicz 1960
Methods Allocation: not stated.
Blinding: double blind.
Duration: 8 weeks.
Design: parallel.
Country: Canada.
Participants Diagnosis: schizophrenia (criteria not reported).
N=48
Age: average was 48 to 51 in each group.
Sex: F 48.
History: Disturbed chronic schizophrenic patients.
Exclusions: not reported.
Setting: hospital.
Interventions 1. Chlorpromazine: dose 50 mg/day for 2 days, 100 mg/day for 3 days and 150 mg/day
for the remaining 28 days. N=16.
2. Placebo. N=16.
3. RO5-0690. dose 50mg/day for 2 days, 100 mg/day for 3 days and 150 mg/day for
the remaining 28 days. N=16
Outcomes Global impression: no global improvement (rated by nurse).
Adverse effects.
Unable to use -
Weyburn Assessment Scale (no SDs reported).
Notes
Risk of bias
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Weckowicz 1960 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk “On the basis of rating they were divided
into three matched groups” no further de-
tails reported
Allocation concealment (selection bias) Unclear risk No information reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Double-blind”
“The patients in the three groups received
respectively from bottles marked ”A“, ”B“
and ”C“ 50mg tablets which looked exactly
the same”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Double-blind”no further details reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk For the outcome global impression “the
number [of participants] is less than 16 in
the groups, because some patients refused
to take their medication”
Selective reporting (reporting bias) High risk N and SD not reported for the Weyburn
assessment scale.
Other bias Low risk Funded by the Rockefeller Foundation and
the Federal Fund.
Xiong 1994
Methods Allocation: randomly divided.
Blinding: double.
Duration: 9 weeks.
Design: parallel.
Country: China.
Participants Diagnosis: chronic schizophrenia (DSM III-R).
History: not reported.
N=48*.
Sex: all male.
Age: range 27-46, mean 35 years.
Setting: hospital.
Interventions 1. Chlorpromazine: dose mean 295 mg/day. N=12.
2. Placebo. N=12.
3. Chlorpromazine: dose mean 143.5 mg/day + Phenytoin ~ 155 mg/day. N=12.
4. Phenytoin: dose mean 327 mg/day. N=12.
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Xiong 1994 (Continued)
Outcomes Leaving the study early.
Unable to use -
Mental state: BPRS, SANS (no data for placebo arm).
Adverse effects (no data for the placebo arm).
Notes *Only data from groups 1 and 2 used.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomly divided.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double blind.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double blind.
Incomplete outcome data (attrition bias)
All outcomes
High risk Drop outs are unaccounted for in the final
analysis.
Selective reporting (reporting bias) Low risk All measured outcomes were reported.
Other bias Low risk None obvious.
General Abbreviations
CPZ - Chlorpromazine
ECT - electroconvulsive therapy
EPS - extrapyramidal symptoms
HCL - hydrochloride
ITT - Intention-to-treat
IM - intra muscular injection
max - maximum
min - minimum
SD - standard deviation
SE - standard error
tds - three times daily
yrs - years
Rating scales
Behaviour -
OBRS - Oklahoma Behaviour Rating Scale
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PBRS - Parkside Behaviour Rating Scale
RRS - Rosenthal Rating Scale
Global impression -
CGI - Clinical Global Impression
Mental state -
BPRS - Brief Psychiatric Rating Scale
IMPS - Inpatient Multidimensional Psychiatric Rating Scale
MMPI - Minnesota Multiphasic Personality Inventory
MSRPP -Multidimensional Scale for Rating Psychiatric Patient
NOSIE - Nurses Observation Scale for Inpatient Evaluation
PRS - Psychiatric Rating Scale
Adverse effects -
SAS - Simpson-Angus Scale
TESS - Treatment Emergent Symptoms Scale
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abse 1960 Study 1
Allocation: randomised.
Participants: people with schizophrenia.
Interventions: reserpine versus powdered opium versus placebo
Study 2
Allocation: randomised.
Participants: people with schizophrenia.
Interventions: chlorpromazine versus powdered opium versus placebo
Results of two studies are added and placebo groups are reported as one
Acker 1965 Allocation: unclear, not described.
Participants: people with schizophrenia.
Interventions: chlorpromazine or thioridazine versus placebo.
Outcomes: not reported for individual drugs.
Affleck 1966 Allocation: ’balanced order’ - unclear if randomised, cross-over.
Participants: any patient with anxiety as a major symptom - unclear if schizophrenia.
Interventions: chlorpromazine + high expectations of effect versus chlorpromazine + low expec-
tations of effect versus placebo + high expectations of effect versus placebo + low expectations of
effect.
Outcomes: no usable data before the first cross-over.
Agarwal 1985 Allocation: randomised.
Participants: people with schizophrenia.
Interventions; modified ECT versus simulated ECT, used chlorpromazine in the early stages of the
study
Akimoto 1966 Allocation: unclear, “double-blind placebo method”.
Participants: people with schizophrenia.
Interventions: chlorpromazine, placebo, levomepromazine, prochlorperazine.
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Outcomes: behaviour,mental state - no outcomes for the chlorpromazine versus placebo comparison
Alpert 1966 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: chlorpromazine versus placebo.
Outcomes: no data presented by group of allocation, report focused on use of taped recordings to
measure outcomes
Alpert 1978 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: chlorpromazine versus L-dopa, no placebo.
Alson 1964 Allocation: not randomised, hospitalised patients switched from chlorpromazine to placebo
Aman 1985 Allocation: randomised.
Participants: severely and profoundly retarded adolescents and adults
Amin 1977 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: chlorpromazine versus benzquinamide versus benzquinamide and group therapy, no
placebo group
Ananth 1972 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: nicotinic acid, nicotinamide and placebo.
Andrews 1976 Allocation: randomised.
Participants: people with schizophrenia, stabilised on chlorpromazine.
Interventions: continuing chlorpromazine versus chlorpromazine withdrawal
Ashcroft 1961 Allocation: not randomised.
Participants: people with schizophrenia.
Interventions: chlorpromazine, tetrabenazine and placebo.
Ayers 1984 Allocation: not randomised, case series.
Azima 1954 Allocation: not randomised, case series.
Bagadia 1981 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: chlorpromazine and simulated ECT versus placebo and ECT
Ban 1977 Allocation: unclear, ’double-blind study’.
Participants: people with chronic schizophrenia.
Interventions: chlorpromazine and placebo versus chlorpromazine and megavitamins
Beech 1990 Allocation: unclear, ’double-blind, cross-over study’.
Participants: healthy volunteers.
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Benaim 1960 Allocation: not described.
Participants: people with schizophrenia.
Interventions: insulin versus insulin with chlorpromazine versus insulin with chlorpromazine and
phenytoin
Bennett 1956 Allocation: alternate allocation.
Participants: people with schizophrenia and other diagnoses.
Interventions: chlorpromazine versus reserpine.
Blumberg 1964 Allocation: ’random assignment’.
Participants: people with non chronic mental disorder, majority with schizophrenia.
Interventions: chlorpromazine with procyclidine, imipramine and placebo.
Outcomes: blood pressure data were not supported with SD’s.
Blumberg 1969 Allocation: randomised.
Participants: voluntary co-operative psychiatric patients on an open ward, not schizophrenia
Boullin 1975 Allocation: not randomised, case control study.
Bowes 1956 Allocation: quasi-randomised.
Participants: people with schizophrenia.
Interventions: frenkel versus placebo, not chlorpromazine.
Bressler 1971 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: chlorpromazine versus thiothixene.
Brizer 1985 Allocation: randomised.
Participants: people with treatment-resistant schizophrenia.
Interventions: placebo versus methadone, chlorpromazine equivalents calculated
Burnett 1975 Allocation: randomised, cross-over design.
Participants: people with schizophrenia.
Interventions: chlorpromazine versus thiothixene, placebo used for washout only
Cabrera Gomez 1994 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: recombinant alpha-interferon versus placebo, chlorpromazine used as needed but
not randomised
Caffey 1963 Allocation: randomised.
Participants: people with chronic schizophrenia.
Interventions: chlorpromazine or thioridazine (maintenance dose) versus chlorpromazine or thior-
idazine (3/7 of dose) versus placebo, withdrawal study.
Outcomes: data not reported for individual drug.
Caffey 1975 Allocation: not randomised, non-systematic review of other studies (confirmed by Russian transla-
tor)
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Campbell 1972 Allocation: non-randomised double-blind, cross-over trial.
Cardone 1969 Allocation: unclear, ’one group was given ...’.
Participants: people with chronic schizophrenia.
Interventions: chlorpromazine versus placebo versus nothing.
Outcomes: psychological tests of body image, no clinical data
Carrillo 1971 Allocation: randomised.
Participants: ’emotionally unstable character disorder’, not schizophrenia
Casey 1960 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: chlorpromazine versus promazine versus phenobarbital versus placebo.
Outcomes: numbers allocated to each group not reported.
US veterans association contacted for archived data - none available
Casey 1961 Allocation: randomised.
Participants: people with chronic schizophrenia.
Interventions: d-amphetamine versus isocarboxazid versus imipramine versus trifluoperazine versus
placebo, chlorpromazine given to everyone
Chacon 1972 Allocation: ’randomly selected’.
Participants: people with schizophrenia.
Interventions: chlorpromazine, fluphenazine decanoate and placebo for ’washout’
Childers 1961 Allocation: not randomised - ’assigned sequentially as they were admitted’.
Participants: people with schizophrenia.
Interventions: chlorpromazine versus trifluoperazine versus placebo versus nothing
Chouinard 1977 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: chlorpromazine and penfluridol -placebo used for washout period
Chouinard-G 1983 Allocation: ’randomly assigned’.
Participants: people with schizophrenia.
Interventions: chlorpromazine, fluspirilene and placebo.
Outcomes: data not related to placebo.
Claghorn 1983 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: chlorpromazine versus clozapine, placebo used for washout period only
Clark 1970c Allocation: unclear.
Participants: unclear.
Interventions: chlorpromazine versus placebo versus a ’thioxanthene and a butyrophenone’.
Outcomes: no data reported.
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Clark 1970d Allocation: randomised.
Participants: people with schizophrenia.
Interventions: chlorpromazine versus placebo.
Outcomes: body weight, serum cholesterol - no usable data (study 5 in cited report.)
Clark 1975 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: chlorpromazine versus placebo.
Outcomes: numbers allocated to each group not reported.
Cobb 1956 Allocation: not randomised.
Cole 1967 Allocation: ’randomly assigned to one of the three drug treatments’
Participants: people with schizophrenia.
Interventions: chlorpromazine, fluphenazine and acetophenazine
Coons 1962 Allocation: ’randomly assigned’.
Participants: “long term mental hospital patients”.
Interventions: chlorpromazine, trifluoperazine and placebo.
Outcomes: no SD’s used.
Cowden 1956 Allocation: participants assigned on basis of behavioural rating scale and average hospitalisation of
different groups - not random
Crane 1970 Allocation: randomised.
Participants: people with chronic mental illness and tardive dyskinesia.
Interventions: trifluoperazine and placebo.
Crane 1971 Allocation: not randomised, review.
Crow 1986 Allocation: randomised.
Participants: people with non-affective psychosis.
Interventions: continuing drug (chlorpromazine or fluphenazine or haloperidol or pimozide or
trifluoperazine) versus placebo (drug withdrawal).
Results not broken down by individual drug, and withdrawal study
Curry 1972 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: chlorpromazine versus fluphenazine decanoate; placebo used for blinding purposes
only (’double-dummy’)
Cutler 1957 Allocation: ’divided into three groups’
Participants: people with schizophrenia.
Interventions: reserpine and placebo.
Dally 1966 Allocation: not described.
Participants: people with anorexia nervosa.
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Danion 1992 Allocation: randomised.
Participants: healthy volunteers.
Daston 1958 Allocation: not randomised, ’stylus maze performance test’.
Daston 1959 Allocation: unclear, ’double blind, cross-over trial’.
Participants: people with schizophrenia.
Interventions: chlorpromazine versus promazine versus phenobarbital versus placebo.
Outcomes: psychological tests, no clinical outcomes, no dropout data
Davies 1973 Allocation: unclear, ’patients were divided into groups’ - likely non-random.
Participants: people with schizophrenia.
Interventions: chlorpromazine versus placebo.
Outcomes: no data presented.
Dean 1967 Allocation: randomised.
Participants: 50 people with prophyria variegata, not schizophrenia
Den Boer 2000 Allocation: randomly assigned.
Participants: people with schizophrenia.
Interventions: ritanserin and placebo.
Denber 1955 Allocation: “selected at random”.
Participants: people with schizophrenia.
Interventions: mescaline sulphate and chlorpromazine hydrochloride
Denber 1956 Allocation: not randomised, case study.
Denber 1957 Allocation: quasi-random, ’assigned in rotation’ during consecutive admissions
Desager 1988 Allocation: double blind Latin-square design.
Participants: healthy volunteers, not people with schizophrenia
Douglas 1969 Allocation: ’double blind’.
Participants: 64 people with functional psychiatric disability.
Interventions: chlorpromazine versus mesoridazine, not placebo
Downing 1963 Allocation: ’randomly assigned’.
Participants: people with schizophrenia.
Interventions: chlorpromazine, fluphenazine and thioridazine.
Outcomes: no SD’s used.
Dube 1981 Allocation: ’randomly administered’.
Participants: people with schizophrenia.
Interventions: lithium, chlorpromazine and placebo washout.
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Eitan 1991 Allocation: ’were assigned’ - no further description.
Participants: people with schizophrenia.
Interventions: chlorpromazine versus thioridazine versus trifluoperazine versus placebo.
Outcomes: cognitive function not reported for individual arms of cross-over
Ekdawi 1966 Allocation: randomised.
Participants: people with chronic schizophrenia.
Interventions: methixene hydrochloride versus orphenadrine versus procyclidine, all on antipsy-
chotics including chlorpromazine
Elkes 1954 Allocation: unclear if randomised - ’double blind, cross-over trial’.
Participants: chronically over-active psychotic people.
Interventions: chlorpromazine versus placebo.
Outcomes: first arm of cross-over not reported.
Feldman 1956 Allocation: ’a staff psychiatrist (not involved in the project) who cross-matched the patients into
two similar groups’ - not randomised
Fink 1958 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: chlorpromazine versus insulin coma therapy, no placebo group
Fink 1965 Allocation: “randomly assigned”.
Participants: “classified as affective disorder”.
Interventions: chlorpromazine with procyclidine, imipramine and placebo.
Outcomes: no usable data.
Fleischhacker 1995 Allocation: not randomised.
Participants: not described.
Interventions: seroquel, chlorpromazine and placebo.
Outcomes: no usable data.
Fleming 1958 Allocation: randomised, cross-over design.
Participants: people with schizophrenia and manic-depressive illness.
Interventions: chlorpromazine versus B.W.203 versus placebo.
Outcomes: data not reported for individual arms of cross-over
Foote 1958 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: chlorpromazine-reserpine combination versus placebo
Forrest 1967 Allocation: randomised.
Participants: healthy volunteers.
Freed 1956 Allocation: not randomised.
Participants: “primary behaviour disorders, psychoneurotic, schizophrenic, reactive behaviour dis-
orders”.
Interventions: chlorpromazine.
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Freedman 1965 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: chlorpromazine, promazine and placebo.
Outcomes: no usable data.
Freeman 1956 Allocation: ’divided into two groups matched primarily on the basis of their rating scores and, sec-
ondarily, on the basis of age, duration of hospitalisation, and years since lobotomy’ - not randomised
Freeman 1973 Allocation: “randomly assigned”.
Participants: people with schizophrenia.
Interventions: mesoridazine, chlorpromazine and placebo.
Outcomes: chlorpromazine data not evaluated against placebo.
Friedhoff 1960 Allocation: ’“divided into two sub-groups by alternation of patients”
Fromm 1956 Allocation: ’Dr Forsberg matched the patients and decided whether they were to receive chlorpro-
mazine or placebo’ - not randomised
Gaitz 1955 Allocation: “assigned randomly to 3 groups”.
Participants: “actively psychotic having a schizophrenic reaction”.
Interventions: group A was an artificial hibernation group, group B received chlorpromazine and
group C receiving their usual treatment without chlorpromazine
Galbrecht 1968 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: chlorpromazine versus fluphenazine versus thioridazine, no placebo
Galdi 1988 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: chlorpromazine versus fluphenazine versus perphenazine, no placebo
Gallant 1963 Allocation: randomised - “divided at random” - no further details.
Participants: people with chronic schizophrenia.
Interventions: chlorpromazine versus methysergide (UML-491) versus placebo.
Outcomes: no usable data as number in each group unspecified
Gallant 1967 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: chlorpromazine + placebo versus chlorpromazine + BL-KR140
Gardner 1955 Allocation: no evidence of randomisation.
Gardos 1968 Allocation: divided into two groups- ’withdrawn’ and ’agitated’.
Participants: “psychotic”.
Interventions: trifluoperazine, chlorpromazine, (placebo used for ’wash out’)
Gardos 1976 Allocation: not randomised, review article of other trials performing withdrawal studies
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Garfield 1962 Allocation: random assignment.
Participants: “adjustment reactionof childhood (n=6), psychoneurotic disorder (n=5), schizophrenic
reaction childhood type (n=5), personality trait disturbance (n=2), chronic brain disturbance with
psychosis (n=1).
Interventions: chlorpromazine versus placebo.
Outcomes: no usable data.
Garmezy 1969 Allocation: ”randomly assigned“.
Participants: people with schizophrenia.
Interventions: chlorpromazine and placebo.
Outcomes: no usable data (no SD).
Gauthier 1967 Allocation: random numbers table used.
Participants: not described from french translation.
Interventions: trifluperidol versus trifluoperazine.
Gendron 1973 Allocation: ”randomly assigned“.
Participants: people with schizophrenia.
Interventions: chlorpromazine and Al-1021
Gibbs 1956 Allocation: ’assigned by an unbiased, alternatingmethod’ and ’assigned to one of the three treatment
groups on an alternating basis as they entered the study’ - not randomised.
Participants: heterogeneous diagnoses, ”27 were diagnosed psychoneurotic and the remaining 12
psychotic“
Gilgash 1957 Allocation: unclear, ’two groups .... matched on the basis of admission diagnosis, age, sex and IQ’.
Participants: patients with catatonic schizophrenia.
Interventions: chlorpromazine versus placebo.
Outcomes: cognitive function; no clinical measures.
Goldberg 1968 Allocation: ”random assignment“.
Participants: people with schizophrenia, based on two separate hospital studies.
Interventions: Acetophenazine, chlorpromazine, thioridazine fluphenazine and placebo.
Outcomes: data based on prediction equations and are unusable
Goldberg 1970 Allocation: ”allocated at random to a group“.
Participants: people with schizophrenia.
Interventions: oxypertine and chlorpromazine with 3-week washout with placebo
Goldberg 1972 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: chlorpromazine versus acetophenazine versus placebo.
Outcomes: no usable data - unclear how many allocated to each group
Goldman 1955 Allocation: not randomised, review.
Good 1958 Allocation: randomised.
Participants: people with schizophrenia stabilised on chlorpromazine.
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Interventions: continued chlorpromazine versus placebo, withdrawal study
Goodwin-Austin 1971 Allocation: randomised.
Participants: people with dementia and movement disorders, not schizophrenia
Goyne 1958 Allocation: not described.
Participants: people with schizophrenia.
Interventions: vesperin versus chlorpromazine.
Graupner 1972 Allocation: randomised.
Participants: healthy volunteers.
Green 1996 Allocation: balanced Latin-square randomisation.
Participants: healthy volunteers.
Green 1998 Allocation: not described.
Participants: healthy volunteers.
Greenberg 1966 Allocation: unclear if randomised.
Participants: people with schizophrenia.
Interventions: chlorpromazine versus withdrawal of chlorpromazine to placebo
Griffiths 1979 Allocation: ’double blind’.
Participants: people with a history of sedative drug abuse, not people with schizophrenia
Guy 1978 Allocation: not randomised, review.
Hammond 1978 Allocation: A-B-A design, not randomised.
Hamner 1996 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: chlorpromazine and ICI 204 636.
Hankoff 1960 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: chlorpromazine versus promazine versus placebo.
Outcomes: chlorpromazine and promazine data combined - no usable outcomes
Hanlon 1958 Allocation: not described- cross over study.
Participants: people with psychosis.
Hanlon 1960 Allocation: not randomised, survey.
Harper 1976 Allocation: unclear, ’double-blind, cross-over’.
Participants: people with schizophrenia.
Interventions: chlorpromazine versus fluphenazine decanoate.
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Hartley 1978 Allocation: ’Latin square counterbalanced design’
Participants: healthy volunteers, not people with schizophrenia
Hartley 1987 Allocation: randomised.
Participants: ’normals’.
Interventions: chlorpromazine versus placebo.
Outcomes: physiological tests.
Hartley 1989 Allocation: implied randomisation.
Participants: healthy volunteers.
Hartley 1991 Allocation: ’double blind’.
Participants: healthy volunteers, not people with schizophrenia
Hartmann 1973 Allocation: ”balanced cross-over design“.
Participants: healthy volunteers.
Haskell 1974 Allocation: randomised.
Participants: anxious and depressed people, not schizophrenia
Heilizer 1959 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: chlorpromazine versus placebo.
Outcomes: no usable data - unclear how many people allocated to each group
Hekimian 1967 Allocation: ’assigned in rotation’ - quasi-randomised.
Herrera 1988 Allocation: not randomised.
Participants: people with schizophrenia.
Interventions: haloperidol with benztropine versus chlorpromazine with benztropine (placebo used
for ’wash out’)
Herrmann 1991a Allocation: randomised, cross-over design.
Participants: healthy men.
Interventions: chlorpromazine versus savoxepine versus placebo
Herrmann 1991b Allocation: randomised, cross-over design.
Participants: healthy men.
Interventions: chlorpromazine versus imipramine versus placebo
Herz 1991 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: maintenance phenothiazines, including chlorpromazine versus intermittent drug
treatment
Hoffer 1975 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: niacin versus placebo.
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Hogarty 1976 Allocation: not randomised, discontinuation study.
Hollis 1968 Allocation: not randomised, case report.
Hollister 1955 Allocation: no evidence of randomisation (five studies).
Participants: people with chronic schizophrenia.
Interventions: chlorpromazine versus placebo.
Holt 1984 Allocation: ’matched’, no further description - likely not randomised.
Participants: ’male psychiatric inpatients’.
Interventions: chlorpromazine versus haloperidol versus fluphenazine decanoate versus no drug
therapy.
Outcomes: platelet levels.
Hong 1996a Allocation: randomised , four parallel groups.
Participants: people with schizophrenia.
Interventions: ICI 204, 636, chlorpromazine.
Outcomes: no data provided for chlorpromazine and placebo.
Hong 1996b Allocation: not described.
Participants: people with schizophrenia.
Interventions: ICI 204, 636 and placebo.
Hopkin 1954 Allocation: not randomised, case series.
Participants: people in need of analgesia.
Hrushka 1966 Allocation: ”random basis“.
Participants: people with psychosis.
Interventions: chlorpromazine combined with placebo.
Huang 1967 Allocation: A-B design, not randomised.
Hughes 1967 Allocation: not randomised, before and after design.
Hurst 1960 Allocation: ’assigned to 3 groups ... alternately, in order of their admission to hospital’ - quasi-
random. double-blind, cross-over design.
Participants: people with schizophrenia.
Interventions: chlorpromazine versus pecazine versus placebo.
Outcome: no usable data.
Hurst 1996 Allocation: not randomised, review .
Hussar 1969 Allocation: not described.
Participants: people with schizophrenia and psychiatric patients without schizophrenia.
Interventions: chlorpromazine and no treatment.
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IRCT138811022935N3 2010 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: Chlorpromazine plus placebo versus chlorpromazine plus omega-3
Itil 1968 Allocation: ’random order’, cross-over design.
Participants: ’normals’, people with psychoneurotic disorders and those with schizophrenia.
Interventions: chlorpromazine versus imipramine versus chlordiazepoxide versus placebo.
Outcomes: physiological tests; not reported for first arm of cross-over
Itil 1971 Allocation: not randomised, review.
Jia 2004 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: chlorpromazine plus TCM drugs versus chlorpromazine plus placebo
Johnstone 1978 Allocation: randomly allocated.
Participants: people with schizophrenia.
Interventions: alpha-flupenthixol, 3-flupenthixol and placebo. chlorpromazine added to the active
drugs
Jones 1969 Allocation: not randomised, A-B design.
Jones 1971 Allocation: unclear.
Participants: people with schizophrenia.
Interventions: chlorpromazine versus trifluoperazine; placebo for ’washout’ only
Joseph 1979 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: alpha-flupenthixol, beta-flupenthixol and placebo
Joshi 1980 Allocation: randomised.
Participants: people with acute schizophrenia.
Interventions: each of four groups received chlorpromazine (different doses) with either placebo or
adjunctive B vitamins
Kabes 1982 Allocation: ’randomly distributed’.
Participants: people with schizophrenia.
Interventions: chlorpromazine, haloperidol, clorothepine and placebo.
Outcomes: no data provided for chlorpromazine.
Kammerer 1968 Allocation: unclear.
Participants: people mainly with affective disorders.
Interventions: possibly Pertofran (Geigy) but not chlorpromazine versus placebo
Kaplan 1974 Allocation: A-B-A design, not randomised.
Keskiner 1970 Allocation: not randomised, placed into groups according to pre-study medication
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Kim 1960 Allocation: likely not randomised, ’divided into two matching groups’.
Participants: people with treatment-refractory, chronic schizophrenia.
Interventions: chlorpromazine + placebo versus chlorpromazine + prednisolone
Kimbell 1971 Allocation: not randomised, allocated by ’doctor’s choice’.
King 1959 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: prochlorperazine, chlorpromazine and placebo.
Outcomes: no usable data.
King 1994 Allocation: randomised, cross-over design.
Participants: healthy volunteers.
Interventions: chlorpromazine versus remoxipride (immediate release) versus remoxipride (con-
trolled release) versus lorazepam versus placebo
Klein 1974 Allocation: randomised.
Participants: ”some form of psychotic disturbance“.
Interventions: imipramine or chlorpromazine, self administered with or without instruction versus
imipramine or chlorpromazine, nurse administered with or without instruction
Kopell 1968 Allocation: cross-over design, no mention of randomisation.
Participants: people with schizophrenia and other psychotic disorders.
Interventions: chlorpromazine versus methamphetamine versus placebo.
Outcomes: signal detection, no clinically meaningful outcomes
Kordas 1968 Allocation: not randomised, ’allocated to three groups’, and ’double-blind controlled trial’ - no
further information.
Participants: people with chronic schizophrenia.
Interventions: clopenthixol versus chlorpromazine versus placebo.
Outcomes: no usable data (individual participant data, or means and SD)
Kornetsky 1957 Allocation: unclear, ’Latin square’, cross-over design.
Participants: normal volunteers.
Interventions: chlorpromazine versus secobarbital versus meperidine hydrochloride versus lysergic
acid diethylamide, placebo used between arms of cross-over
Kornetsky 1958 Allocation: unclear.
Participants: normal volunteers.
Interventions: chlorpromazine versus secobarbital, placebo for ’washout’ only
Kornetsky 1959 Allocation: unclear, ’modified Latin square’, cross-over design.
Participants: people with schizophrenia.
Interventions: chlorpromazine versus secobarbital versus placebo.
Outcomes: various psychological tests, results not reported for individual arms of cross-over
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Korol 1965 Allocation: randomised.
Participants: people with schizophrenia, stabilised on chlorpromazine.
Interventions: continuing chlorpromazine versus chlorpromazine withdrawal
Kovitz 1955 Allocation: no evidence of randomisation, cross-over design.
Participants: people with chronic schizophrenia, and other psychoses.
Interventions: chlorpromazine versus reserpine versus placebo
Kramer 1975 Allocation: randomised.
Participants: people with acute schizophrenia.
Interventions: chlorpromazine versus metiapine versus placebo.
Outcomes: various relevant outcomes, but study rejected because placebo group was withdrawn
after the first 13 were randomised - no data for chlorpromazine at this point in the study
Kugler 1980 Allocation: unclear, double-blind, Latin-square design.
Participants: healthy volunteers.
Interventions: chlorpromazine versus amylobarbitone versus placebo
Kupfer 1971 Allocation: not randomised, A-B cross-over design.
Kurland 1981 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: chlorpromazine or haloperidol supplemented with either viloxazine or placebo.
Outcomes: no usable data.
Lampe 1969 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: clomacran versus placebo.
Latz 1965 Allocation: no evidence of randomisation, Latin-square cross-over design.
Participants: people with schizophrenia.
Interventions: chlorpromazine versus secobarbital versus placebo.
Outcomes: tests of cognitive function; no usable data (no N or SD, and results not reported for
individual arms of cross-over)
Laurian 1981 Allocation: randomised.
Participants: healthy volunteers, not people with schizophrenia
Leff 1971 Allocation: randomised (to drug group vs placebo), but allocation to different drugs not randomised
(based on pre-study medication).
Interventions: trifluoperazine or chlorpromazine versus placebo.
Outcomes: not broken down by drug group.
Leszek 1991 Allocation: not described.
Participants: people with schizophrenia.
Interventions: interferon and placebo, chlorpromazine used to control symptoms
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Levin 1959 Allocation: not randomised, ’assigned to groups in sequence’, and ’not possible to assign subjects
in a purely random fashion’.
Participants: people with schizophrenia.
Interventions: chlorpromazine versus phenobarbital versus promethazine versus placebo
Levine 1997 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: chlorpromazine, perphenazine and placebo.
Outcomes: no usable data (no SD)
Levita 1961 Allocation: ’randomly assigned’.
Participants: people with schizophrenia.
Interventions: chlorpromazine, promazine and placebo.
Outcomes: no usable data (no SD) .
Lewis 1973 Allocation: unclear, ’double-blind cross-over trial.
Participants: children and adolescents with ’a psychiatric syndrome of sufficient severity to warrant
the use of a major tranquillising drug’.
Interventions: haloperidol versus chlorpromazine versus placebo.
Outcomes: no usable data; information from each arm not separated
Li 2006 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: chlorpromazine versus ziprasidone.
Liberman 1973 Allocation: not randomised, A-B cross-over design.
Little 1958 Allocation: randomised, cross-over design.
Participants: people with chronic mental illness.
Interventions: chlorpromazine versus amylobarbitone versus placebo.
Outcomes: results not reported for individual arms of cross-over
Loranger 1968 Allocation: randomised.
Participants: people with schizophrenia (n=30), psychoneurotic reaction (n=13), manic-depressive
reaction (n=11), sociopathic personality disturbance (n=3), other psychoses (n=3).
Interventions: chlorpromazine versus neurosterone versus placebo.
Outcomes: this abstract reports P values only; no means or SD.
Author contacted for further data, but none available.
Lorr 1961 Allocation: ’randomly assigned’, to one of five treatment groups (no further description).
Participants: ’16% of patients were psychotic, 57% psychoneurotic, 27% psychophysiologic’
Lyberi 1956 Allocation: not randomised.
Participants: not schizophrenia.
Maculans 1964 Allocation: randomised, cross-over design.
Participants: people with chronic schizophrenia.
Interventions: chlorpromazine versus chlorprothixene versus diazepam (placebo used for washout
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period between arms of cross-over)
Mahal 1976 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: tagara, brahmyadi yoga, chlorpromazine and placebo.
Outcomes: no usable data (no SD).
Majewski 1968 Allocation: no evidence of randomisation (translation by Polish speaker)
Marjerrison 1969 Allocation: randomised, cross-over design.
Participants: people newly admitted with acute schizophrenia.
Interventions: chlorpromazine versus haloperidol versus chlorprothixene versus placebo.
Placebo only compared with haloperidol and chlorprothixene.
Marrazzi 1972 Allocation: unclear if randomised, A-B-C design.
Participants: people with schizophrenia.
Interventions: chlorpromazine versus placebo with LSD challenge
Mason-Browne 1957 Allocation: no evidence of randomisation.
Participants: ’chronic patients’; no indication of diagnosis.
Interventions: chlorpromazine versus perphenazine versus placebo
Mathur 1981 Allocation: randomised.
Participants: people with chronic schizophrenia stabilized on chlorpromazine.
Interventions: continuing chlorpromazine versus placebo (withdrawal study)
Mattila 1994 Allocation: Latin-square cross-over.
Participants: healthy volunteers, not people with schizophrenia
McClelland 1990 Allocation: randomised, cross-over design.
Participants: healthy volunteers.
Interventions: chlorpromazine versus haloperidol versus sulpiride versus placebo
Melnyk 1966 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: thioridazine, chlorpromazine and placebo.
Outcomes: no usable data (no SD).
Merry 1957 Allocation: unclear.
Participants: people with chronic neurotic tension (no schizophrenia or psychoses).
Interventions: chlorpromazine versus placebo.
Michaux 1966 Allocation: randomised.
Participants: 181 people with schizophrenia.
Interventions: chlorpromazine and placebo versus chlorpromazine and chlordiazepoxide versus
chlorpromazine and imipramine
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Millar 1963 Allocation: ”divided into random groups“.
Participants: people with schizophrenia.
Interventions: fluphenazine and placebo.
Milne 1960 Allocation: quasi-randomised, ’divided arbitrarily into four groups’.
Participants: people with chronic schizophrenia.
Interventions: chlorpromazine versus prochlorperazine versus methotrimeprazine versus placebo.
Outcomes: improvement, behaviour; no usable data (no mean, N or SD)
Milstein 1994 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: Iloperidone versus chlorpromazine versus placebo
Outcomes: EEG - no clinical outcomes.
Milton 1978 Allocation: randomised.
Participants: people with delusions.
Interventions: confrontation versus belief modification, also on chlorpromazine or clozapine but
not randomised to these drugs
Mitchell 1956 Allocation: quasi-randomised (used surnames beginning A-L for first group).
Participants: people with schizophrenia.
Interventions: chlorpromazine versus placebo.
Outcomes: no usable data (no means, N, or SD).
Mitchell 1960 Allocation: assigned by matching variables.
Participants: ”psychiatric patients“
Interventions: chlorpromazine.
Monteleone 1999 Allocation: randomised.
Participants: people with schizophrenia and healthy particpants.
Interventions: D-fenfluramine and placebo.
Morgenstern 1960 Allocation: not described.
Participants: ”acutely disturbed patients“.
Interventions: triflupromazine, chlorpromazine, placebo with ECT being administered concur-
rently with the drug interventions
Morton 1968 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: continued maintenance therapy (chlorpromazine or trifluoperazine) versus placebo
(withdrawal study)
Moss 1958 Allocation: not randomised - appears to be A-B-A design.
Participants: people with schizophrenia.
Interventions: chlorpromazine versus placebo.
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Neal 1969 Allocation: randomised.
Participants: people with chronic schizophrenia.
Interventions: chlorpromazine versus oxypertine; placebo given during first 4 weeks of trial (for
washout)
Newbold 1956 Allocation: not described.
Participants: ”patients undergoing thorazine treatment - 3 with a form of schizophrenia“
Interventions: chlorpromazine and placebo.
Outcomes: no usable data.
Okuma 1979 Allocation: randomised.
Participants: 63 people with mania, not schizophrenia.
Orzack 1969 Allocation: ’randomly determined treatment”’.
Participants: people with schizophrenia and normal volunteers.
Interventions: chlorpromazine, and placebo used ’at two appropriate intervals’.
Outcomes: no usable data.
Osmakova 1972 Allocation: not randomised, review article (translated by native Russian speaker)
Pai 2001 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: risperidone and placebo.
Paredes 1966 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: chlorpromazine and placebo.
Outcomes: no usable data (no SD).
Park 1981 Allocation: randomised.
Participants: people with acute schizophrenia.
Interventions: chlorpromazine + triiodothyronine versus chlorpromazine + placebo
Pasamanick 1967 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: home (drugs) versus home (placebo) versus hospital treatment; data not split by drug
(chlorpromazine or trifluoperazine or thioridazine)
Patterson 1981 Allocation: unclear, Latin-square design.
Participants: healthy male volunteers, not schizophrenia.
Peet 1980 Allocation: randomised, cross-over design.
Participants: people with schizophrenia.
Interventions: chlorpromazine versus chlorpromazine + propranolol
Pennington 1957 Allocation: not randomised, case series.
Pietzcker 1978 Allocation: not randomised, review.
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Pigache 1973 Allocation: randomised, cross-over design.
Participants: people with schizophrenia, maintained on chlorpromazine.
Interventions: chlorpromazine versus placebo; withdrawal study
Pigache 1993 Allocation: randomised, cross-over design.
Participants: people with schizophrenia.
Interventions: chlorpromazine (300-600mg/day) versus chlorpromazine (600-1200mg/day) versus
chlorpromazine (900-1800 mg/day); no placebo period or placebo group (identical placebo tablets
used for maintaining double-blind procedure)
Platz 1967 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: chlorpromazine versus carphenazine versus trifluoperazine; placebo given during first
3 weeks of trial (for washout)
Pleasure 1956 Allocation: not randomised, alternately allocated.
Pollack 1956 Allocation: not randomised, case series.
Pollard 1959 Allocation: not described.
Participants: people with schizophrenia.
Interventions: chlorpromazine with meprobamate and placebo.
Outcomes no usable data.
Quigley 1996 Allocation: unclear if randomised, Latin-square design.
Participants: healthy volunteers, not schizophrenia.
Quinn 1960 Allocation: no evidence of randomisation - “the pharmacist ... allocated the treatment to the three
groups”.
Participants: people with schizophrenia.
Interventions: chlorpromazine versus placebo versus methotrimeprazine
Raaska 2000 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: ciprofloxacin and placebo.
Ragland 1968 Allocation: randomised.
Participants: people with chronic schizophrenia.
Interventions: chlorpromazine versus placebo.
Outcomes: no usable data (no individual patient outcomes, or means reported for continuous
outcomes)
Raja 2000 Allocation: non-randomised study.
Rappaport 1967 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: chlorpromazine versus perphenazine versus sodium pentobarbital versus placebo.
Outcomes: auditory attention tasks, no clinical data.
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Rappaport 1968 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: chlorpromazine versus perphenazine versus dextroamphetamine versus
methylphenidate versus placebo.
Outcomes: auditory attention tests, no clinical data.
Rathod 1958 Allocation: randomised, cross-over design.
Participants: ’disturbed psychotic patients’.
Interventions: chlorpromazine versus placebo.
Outcomes: results not reported for individual arms of cross-over
Raymond 1957 Allocation: randomised, cross-over design.
Participants: a ’heterogeneous group of psychoneurotic disorders’ all with a ’tension component’ -
no mention of schizophrenia or psychosis
Remr 1970 Allocation: no evidence of randomisation, ’single-blind, placebo-controlled, cross-over design’.
Participants: people with schizophrenia.
Interventions: chlorpromazine versus placebo.
Outcomes: various psychomotor tasks; results not reported for individual arms of cross-over
Rifkin 1978 Allocation: ’randomised unequally’.
Participants: ’patients receiving a maintenance dose of antipsychotic medication’.
Interventions: procyclidine and placebo.
Rinaldi 1956 Allocation: ’double blind crosover’.
Participants: people with schizophrenia.
Interventions: chlorpromazine versus placebo versus azacyclonol versus reserpine.
Outcomes: no data reported for the chlorpromazine versus placebo comparison
Rivera-Calimlim 1973 Allocation: not randomised, case series.
Rojo-Sierra 1971 Allocation: not randomised, review.
Rosen 1972 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: chlorpromazine versus placebo versus promazine.
Outcomes: no usable data.
Rosenheck 2000 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: clozapine and haloperidol.
Rosner 1955 Allocation: quasi-randomised; ’placed on one of the drugs or a placebo in strict order of admission’.
Participants: people with various psychotic, neurotic or character disorders.
Interventions: chlorpromazine versus reserpine versus phenobarbital versus placebo
Rudy 1957 Allocation: not randomised, A-B design.
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Rudy 1958 Allocation: ’double blind cross-over’.
Participants: people with chronic psychotic illnesses.
Interventions: trifluoperazine versus placebo, not chlorpromazine
Sainz 1955 Allocation: not described.
Participants: people with schizophrenia, alcoholism, birth trauma, anxiety reactions, obsessive com-
pulsive reactions
Saletu 1972 Allocation: randomised.
Participants: healthy volunteers.
Salisbury 1957 Allocation: unclear, Latin-square design.
Participants: people with chronic schizophrenia.
Interventions: chlorpromazine versus ’control’ (placebo) versus ritalin (at two dose levels).
Outcomes: behaviour and mental state outcomes not reported for individual arms of cross-over
Schiele 1959 Allocation: divided into 2 matched groups of 19, not randomised
Schmidt 1957 Allocation: no evidence of randomisation.
Participants: people with chronic schizophrenia.
Interventions: combination of chlorpromazine + reserpine versus placebo
Schooler 1976 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: chlorpromazine versus placebo.
Outcomes: preliminary report of larger study.
Seager 1955 Allocation: no evidence of randomisation, cross-over design.
Participants: people with schizophrenia (thirteen), depression (six), or dementia (twenty-nine).
Interventions: chlorpromazine versus inert control.
Serafetinides 1973 Allocation: not randomised, review.
Shaskan 1975 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: chlorpromazine + imipramine versus placebo + thiothixine
Shawver 1959 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: continuing chlorpromazine versus reserpine versus placebo; a withdrawal study
Shopsin 1978 Allocation: unclear, ’double-blind controlled comparison’.
Participants: people with schizophrenia.
Interventions: chlorpromazine versus clozapine versus placebo.
Outcomes: no usable data reported.
NB: some evidence in this report suggests that this trial is the same as Shopsin 1979.
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Shopsin 1979 Allocation: randomised.
Participants: patients with schizophrenia.
Interventions: chlorpromazine versus clozapine versus placebo. However, ’all of the placebo-treated
patients were prematurely terminated from study because of continued aggravation of psychopathol-
ogy ... and it was mutually agreed that this study group be dissolved’.
Outcomes: no comparison with placebo group possible, data from chlorpromazine group was never
compared with placebo group at the point where allocation to placebo was terminated
Silver 2000 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: fluvoxamine and placebo.
Simopoulos 1971 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: dilantin versus placebo, no chlorpromazine group
Simpson 1974 Allocation: no evidence of randomisation; double-blind cross-over trial.
Participants: people with schizophrenia.
Interventions: chlorpromazine (generic) versus chlorpromazine (Thorazine branded); placebo ad-
ministered during washout period
Simpson 1980 Allocation: no evidence of randomisation; ’double-blind split cross-over trial’.
Participants: people with schizophrenia.
Interventions: chlorpromazine + trihexyphenidyl hydrochloride versus chlorpromazine + placebo
Singh 1974 Allocation: no evidence of randomisation, cross-over design.
Participants: people with schizophrenia.
Interventions: chlorpromazine versus haloperidol versus benzotropine versus placebo, results not
reported for placebo arms of cross-over (placebo used for baseline and washout periods)
Singh 1990 Allocation: randomised.
Participants: people with schizophrenia, meeting criteria for supersensitivity psychosis.
Interventions: neuroleptic medication versus placebo (withdrawal of usual medication) - neurolep-
tic drugs (haloperidol, fluphenazine, chlorpromazine, thioridazine, thiothixene or loxapine) not
analysed separately
Small 1987 Allocation: no evidence of randomisation.
Participants: people with treatment resistant schizophrenia.
Interventions: chlorpromazine + benzotropine versus clozapine + placebo; placebo used in washout
periods and as double-dummy to maintain blinding.
Outcomes: EEG - no clinical outcomes.
Smith 1958 Allocation: no evidence of randomisation, cross-over design.
Participants: people with chronic schizophrenia.
Interventions: chlorpromazine versus triflupromazine versus placebo.
Outcomes: results not reported for individual arms of cross-over
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Smith 1960 Allocation: no evidence of randomisation, matched groups.
Participants: people with chronic schizophrenia or manic-depression.
Interventions: chlorpromazine versus chlordiazepoxide versus placebo
Smith 1967 Allocation: randomisation implied but not mentioned.
Participants: people with schizophrenia.
Interventions: chlorpromazine versus chlorpromazine and ECT, no placebo
Sommerness 1957 Allocation: no evidence of randomisation.
Participants: people with schizophrenia, manic-depression, and various other psychoses.
Interventions: chlorpromazine versus placebo.
Outcomes: no usable data reported (no means, N or SD).
South-East 1961 Allocation: ’allocation to groups A and B’.
Participants: people with schizophrenia.
Interventions: chlorpromazine, prochlorperazine and placebo.
Outcomes: no usable data (no SD).
Soyka 1968 Allocation: not described.
Participants: people with psychosis, depression and neurosis
Spiegel 1967 Allocation: randomised.
Participants: people with chronic schizophrenia.
Interventions: chlorpromazine versus trifluoperazine versus carphenazine, placebo for ’washout’
only
Spohn 1974 Allocation: randomised, cross-over.
Participants: healthy volunteers.
Sugerman 1964 Allocation: no evidence of randomisation, cross-over design.
Participants: people with schizophrenia.
Interventions: chlorpromazine versus placebo versus perphenazine versus deanol.
Outcomes: EEG; no data for clinical outcomes; no data given per arm of cross-over
Sun 2006 Allocation: randomised.
Participants: people with chronic schizophrenia.
Interventions: Chlopromazine plus placebo versus chlorpromazine plus venlafaxine
Syvalahti 1997 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: citalopram or placebo given as an adjuvant to neuroleptic medication
Talbot 1964 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: chlorpromazine versus trifluoperazine versus chlorpromazine + trifluoperazine;
placebo used to maintain double-blind conditions
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Tang 2005 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: chlorpromazine plus placebo versus chlorpromazine plus herb mixture
Tang 2005a Allocation: randomised.
Participants: people with schizophrenia.
Interventions: chlorpromazine plus placebo versus chlorpromazine plus Chinese medicine
Tang 2006 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: chlorpromazine plus placebo versus chlorpromazine plus TCM herbs
Tassis 1959 Allocation: not described.
Participants: people with schizophrenia.
Interventions: insulin, ECT and chlorpromazine.
Teja 1975 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: chlorpromazine versus trifluoperazine versus thiothixine versus haloperidol versus
placebo.
Outcomes: no usable data.
Tenenblatt 1956 Allocation: no evidence of randomisation.
Terminska 1989 Allocation: unclear.
Participants: people with paranoid schizophrenia.
Interventions: chlorpromazine versus perazine versus fluphenazine versus trifluoperazine versus
haloperidol; no placebo group (confirmed by Polish speaker)
Tetreault 1969a Allocation: randomised.
Participants: people with schizophrenia.
Intervention: fluphenazine in enanthate, fluphenazine bichlorhydrate and placebo
Thorpe 1956 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: chlorpromazine versus pacatal versus no treatment versus placebo.
Outcomes: no usable data.
Tourlentes 1958 Allocation: “randomly assigned”.
Participants: people with schizophrenia.
Interventions: chlorpromazine versus placebo.
Outcomes: no usable data.
Troshinsky 1962 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: placebo versus ’active medication’ (phenothiazine); phenothiazines were chlorpro-
mazine, trifluoperazine, triflupromazine, thioridazine
Outcomes: results not reported for individual drugs - withdrawal study
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Turner 1956 Allocation: not described.
Participants: “people neurosis, psychosis and epilepsy”.
Interventions: chlorpromazine.
Turner 1966 Allocation: random order Latin-square design.
Participants: healthy volunteers, not people with schizophrenia
Urquhart 1959 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: stage 1: placebo versus acetyl promazine versus promazine hydrochloride, cross-over
design; stage 2: chlorpromazine versus reserpine, cross-over design; no arm comparing chlorpro-
mazine versus placebo
van Praag 1975 Allocation: randomised.
Participants: people with acute psychotic disorders.
Interventions: chlorpromazine versus oxypertine, placebo used to maintain blinding during dose
changes
Vestre 1961 Allocation: not described.
Participants: people with schizophrenia.
Interventions: chlorpromazine and placebo.
Outcomes: no usable data.
Vinar 1973 Allocation: randomised, a ’continuous controlled trial’.
Participants: people with functional psychoses.
Interventions: chlorpromazine versus ’control’.
Outcomes: no usable data, multivariate analysis of Brief Psychiatric Rating Scale and 1-year out-
comes of total group, no comparisons between chlorpromazine and control
Vinar 1976 Allocation: not randomised.
Volavka 1983 Allocation: randomised, cross-over design.
Participants: people with schizophrenia.
Interventions: (Des-tyr)-gamma-endorphin versus placebo.
Warner 1996 Allocation: unclear.
Participants: people with schizophrenia and other diagnoses.
Interventions: unspecified neuroleptic medications versus unmedicated controls
Weir 1968 Allocation: randomised.
Participants: disturbed, ’mentally subnormal’ people, not people with schizophrenia
Welbel 1980 Allocation: unclear.
Participants: people with schizophrenia.
Interventions: chlorpromazine versus clozapine versus levopromazine versus triflupromazine versus
pimozide versus sulpiride, no placebo group (confirmed by Polish-speaker)
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Whitehead 1958 Allocation: randomised.
Participants: people with chronic psychoses.
Interventions:chlorpromazine versus placebo, unclear how many people assigned to each group
Wilcott 1962 Allocation: not described.
Participants: emotionally disturbed children.
Wilson 1961 Allocation: unclear, ’Latin square’, cross-over design.
Participants: people with paranoid schizophrenia.
Interventions: chlorpromazine versus prochlorperazine versus trifluoperazine versus placebo
Winkelman 1957 Allocation: not described- case report series.
Winter 1956 Allocation: randomised.
Participants: people with a ’variety of diagnostic categories’, and ’acutely disturbed’.
Interventions: chlorpromazine versus placebo.
Outcomes: chlorpromazine and placebo groups not reported separately
Wode-Helgodt 1977 Allocation: randomised.
Participants: those with psychoses, and ’schizophrenic symptomology’.
Interventions: chlorpromazine 200 mg/day versus chlorpromazine 400 mg/day versus chlorpro-
mazine 600 mg/day, placebo used for washout only
Wold 1959 Allocation: not described.
Participants: people with schizophrenia.
Interventions: chlorpromazine and placebo.
Outcomes: no usable data.
Wolpert 1969 Allocation: ’assigned at random’.
Participants: people with schizophrenia.
Interventions: chlorpromazine, triiodothyronine and placebo.
Outcomes: no usable data.
Wyatt 1997 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: milieu therapy versus psychotherapy versus ECT versus antipsychotic medications
(including chlorpromazine amongst others) versus antipsychotic medication + psychotherapy
Outcomes: not possible to separate chlorpromazine data from totals
Wykes 1994 Allocation: randomised.
Participants: people with schizophrenia and cognitive difficulties.
Interventions: cognitive remediation versus treatment as usual
Yan 2004 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: chlorpromazine plus placebo versus chlorpromazine plus ferrous sulphate
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Yang 2005 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: psychological rehabilitation therapy versus general rehabilitation
Yorkston 1977 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: propranolol versus placebo, all on antipsychotics, doses expressed as chlorpromazine
equivalents
Yuan-guang 1994 Allocation: randomised.
Participants: 41 people with schizophrenia.
Interventions: three different doses of chlorpromazine, no placebo
Zeller 1956 Allocation: possibly randomised, ’selected at random’.
Participants: mainly people with schizophrenia.
Interventions: continuing chlorpromazine or reserpine versus placebo, withdrawal study
, 1995 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: cross-over trial, chlorpromazine plus lithium versus chlorpromazine plus placebo
, 2008 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: chlorpromazine plus placebo versus chlorpromazine plus aripiprazole
CPZ - chlorpromazine
ECT - electroconvulsive therapy
EEG - electroencephalogram
SD - standard deviation
TCM - traditional Chinese medicine
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D A T A A N D A N A L Y S E S
Comparison 1. CHLORPROMAZINE versus PLACEBO
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 1 14 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Relapse 7 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 short term (0-8 weeks) 2 74 Risk Ratio (M-H, Random, 95% CI) 0.24 [0.01, 5.49]
2.2 medium term (9 weeks - 6
months)
4 809 Risk Ratio (M-H, Random, 95% CI) 0.61 [0.21, 1.72]
2.3 long term (6 months - 2
years)
3 512 Risk Ratio (M-H, Random, 95% CI) 0.65 [0.47, 0.90]
2.4 2 - 5 years 2 394 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.51, 1.09]
3 Global state: 1a. No
overall improvement
(psychiatrist-rated)
27 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 short term (0-8 weeks) 13 728 Risk Ratio (M-H, Random, 95% CI) 0.61 [0.46, 0.82]
3.2 medium term (9 weeks - 6
months)
14 1164 Risk Ratio (M-H, Random, 95% CI) 0.71 [0.58, 0.86]
4 Global state: 1b. No overall
improvement (nurse-rated)
4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 short term (0-8 weeks) 1 29 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.65, 1.27]
4.2 medium term (9 weeks-6
months)
3 84 Risk Ratio (M-H, Fixed, 95% CI) 0.48 [0.35, 0.66]
5 Global state: 2. Average endpoint
score - short term (CGI, high
score=worse)
1 19 Mean Difference (IV, Fixed, 95% CI) 0.10 [-0.35, 0.55]
6 Global state: 3a. Severity
of illness, severely ill or
worse (CGI 5+ points,
psychiatrist-rated)
4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 short term (0-8 weeks) 1 44 Risk Ratio (M-H, Fixed, 95% CI) 0.46 [0.16, 1.30]
6.2 medium term (9 weeks - 6
months)
3 694 Risk Ratio (M-H, Fixed, 95% CI) 0.80 [0.74, 0.86]
7 Global state: 3b. Severity of
illness, severely ill or worse -
medium term (CGI 5+ points,
nurse-rated)
2 66 Risk Ratio (M-H, Fixed, 95% CI) 0.63 [0.45, 0.90]
8 Leaving the study early 45 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
8.1 short term (0-8 weeks) 17 1065 Risk Ratio (M-H, Fixed, 95% CI) 0.76 [0.63, 0.92]
8.2 medium term (9 weeks - 6
months)
27 1831 Risk Ratio (M-H, Fixed, 95% CI) 0.64 [0.53, 0.78]
8.3 long term (>6 months - 2
years)
2 492 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.71, 1.59]
8.4 >2 - 5 years 1 374 Risk Ratio (M-H, Fixed, 95% CI) 0.68 [0.35, 1.36]
9 Mental state: 1. Improved - short
term (BPRS, 50% change)
1 106 Risk Ratio (M-H, Fixed, 95% CI) 1.25 [0.36, 4.40]
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10 Mental state: 2. Average
endpoint scores (BPRS, high
score=worse)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
10.1 short term (0-8 weeks) 2 49 Mean Difference (IV, Fixed, 95% CI) -4.82 [-8.48, -1.15]
10.2 medium term (9 weeks -
6 months)
1 30 Mean Difference (IV, Fixed, 95% CI) -7.70 [-14.77, -0.63]
11 Behaviour: 1. Deteriorated/
disturbed/un-cooperative
10 Risk Ratio (M-H, Random, 95% CI) Subtotals only
11.1 short term - (0-8 weeks) 2 87 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.34, 1.35]
11.2 medium term (9 weeks -
6 months)
8 1040 Risk Ratio (M-H, Random, 95% CI) 0.49 [0.24, 1.00]
12 Behaviour: 2. Unchanged 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
12.1 short term (0-8 weeks) 1 40 Risk Ratio (M-H, Fixed, 95% CI) 0.63 [0.25, 1.58]
12.2 medium term (9 weeks -
6 months)
2 68 Risk Ratio (M-H, Fixed, 95% CI) 1.15 [0.64, 2.07]
13 Behaviour: 3. Average endpoint
scores (RRS, high score=worse)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
13.1 short term (0-8 weeks) 1 30 Mean Difference (IV, Fixed, 95% CI) -2.90 [-6.74, 0.94]
13.2 medium term (9 weeks -
6 months)
1 30 Mean Difference (IV, Fixed, 95% CI) -4.60 [-9.47, 0.27]
14 Behaviour: 4. Average endpoint
score - short term (PBRS, high
score=good)
1 14 Mean Difference (IV, Fixed, 95% CI) 6.0 [1.97, 10.03]
15 Behaviour: 5. Average endpoint
scores - medium term (Fergus
Falls Behavioural rating scale)
1 42 Mean Difference (IV, Fixed, 95% CI) -2.36 [-6.11, 1.39]
16 Adverse effects: 1. Movement
disorders
25 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
16.1 acute movement
disorders (dystonia)
5 942 Risk Ratio (M-H, Fixed, 95% CI) 3.47 [1.50, 8.03]
16.2 parkinsonism (includes
EPS)
15 1468 Risk Ratio (M-H, Fixed, 95% CI) 2.11 [1.59, 2.80]
16.3 tremor 7 392 Risk Ratio (M-H, Fixed, 95% CI) 1.66 [1.01, 2.73]
16.4 rigidity 7 412 Risk Ratio (M-H, Fixed, 95% CI) 2.24 [1.42, 3.54]
16.5 akathisia 9 1164 Risk Ratio (M-H, Fixed, 95% CI) 0.78 [0.54, 1.11]
16.6 chronic movement
disorders (tardive dyskinesia)
1 18 Risk Ratio (M-H, Fixed, 95% CI) 1.5 [0.32, 6.94]
16.7 ataxia 1 97 Risk Ratio (M-H, Fixed, 95% CI) 8.64 [0.94, 79.31]
17 Adverse effects: 2. Movement
disorders: Average endpoint
scores (Extrapyramidal Bilan,
high score=worse)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
17.1 short term (0-8 weeks) 1 30 Mean Difference (IV, Fixed, 95% CI) -1.40 [-3.22, 0.42]
17.2 medium term (9 weeks -
6 months)
1 30 Mean Difference (IV, Fixed, 95% CI) -1.80 [-4.19, 0.59]
18 Adverse effects: 1. Central
nervous system
25 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
18.1 sleepiness 23 1627 Risk Ratio (M-H, Fixed, 95% CI) 2.79 [2.25, 3.45]
18.2 fits / loss of consciousness 3 695 Risk Ratio (M-H, Fixed, 95% CI) 3.11 [1.05, 9.18]
18.3 weakness 3 92 Risk Ratio (M-H, Fixed, 95% CI) 3.33 [1.02, 10.88]
18.4 convulsions 1 52 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 7.82]
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19 Adverse effects: 3. Blood, skin,
liver, eyes
20 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
19.1 blood problems
(agranulocytosis, leukopenia)
7 394 Risk Ratio (M-H, Fixed, 95% CI) 2.08 [0.74, 5.83]
19.2 rashes/itching/skin
disorders
13 1313 Risk Ratio (M-H, Fixed, 95% CI) 1.45 [0.92, 2.29]
19.3 liver problems 4 249 Risk Ratio (M-H, Fixed, 95% CI) 4.31 [0.98, 18.95]
19.4 photosensitivity 6 799 Risk Ratio (M-H, Fixed, 95% CI) 6.04 [3.22, 11.32]
19.5 eye opacity / eye pigment
problems
2 657 Risk Ratio (M-H, Fixed, 95% CI) 3.09 [1.87, 5.11]
20 Adverse effects: 4. Other 21 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
20.1 blood pressure - low +/-
dizziness/syncope
18 1488 Risk Ratio (M-H, Fixed, 95% CI) 2.38 [1.74, 3.25]
20.2 constipation 10 1117 Risk Ratio (M-H, Fixed, 95% CI) 2.05 [1.33, 3.15]
20.3 urinary problems 5 926 Risk Ratio (M-H, Fixed, 95% CI) 1.73 [0.70, 4.30]
20.4 blurred vision 7 962 Risk Ratio (M-H, Fixed, 95% CI) 1.16 [0.51, 2.65]
20.5 dry mouth 7 1015 Risk Ratio (M-H, Fixed, 95% CI) 4.56 [2.35, 8.85]
20.6 weight increase 5 165 Risk Ratio (M-H, Fixed, 95% CI) 4.92 [2.32, 10.43]
20.7 weight decrease 5 165 Risk Ratio (M-H, Fixed, 95% CI) 0.38 [0.22, 0.66]
20.8 nausea/vomiting 5 1024 Risk Ratio (M-H, Fixed, 95% CI) 2.07 [1.14, 3.73]
20.9 salivation 3 830 Risk Ratio (M-H, Fixed, 95% CI) 3.37 [1.07, 10.57]
20.10 menorrhagia / abnormal
menstruation
2 46 Risk Ratio (M-H, Fixed, 95% CI) 1.39 [0.62, 3.13]
20.11 amenorrhea 1 161 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.17, 3.99]
20.12 lactation 2 192 Risk Ratio (M-H, Fixed, 95% CI) 1.48 [0.57, 3.81]
21 SUBGROUP ANALYSIS: 1.
MEN vs WOMEN: Behaviour:
Deteriorated/disturbed/un-
cooperative
4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
21.1 only men 1 40 Risk Ratio (M-H, Fixed, 95% CI) 0.04 [0.00, 0.63]
21.2 only women 3 158 Risk Ratio (M-H, Fixed, 95% CI) 0.46 [0.29, 0.73]
22 SUBGROUP ANALYSIS: 2.
ACUTE vs CHRONIC
31 Risk Ratio (M-H, Random, 95% CI) Subtotals only
22.1 acute - Relapse (9 wks -
6 months)
1 127 Risk Ratio (M-H, Random, 95% CI) 1.21 [0.94, 1.55]
22.2 chronic - Relapse (9 wks
- 6 months)
3 682 Risk Ratio (M-H, Random, 95% CI) 0.46 [0.18, 1.15]
22.3 acute - Global state 1. No
overall improvement (0-8 wks)
2 149 Risk Ratio (M-H, Random, 95% CI) 0.68 [0.44, 1.05]
22.4 chronic - Global state 1.
No overall improvement (0-8
wks)
9 459 Risk Ratio (M-H, Random, 95% CI) 0.57 [0.39, 0.84]
22.5 acute - Global state 2.
No overall improvement (9
wks-6 months)
1 23 Risk Ratio (M-H, Random, 95% CI) 0.18 [0.03, 1.28]
22.6 chronic - Global state
2. No overall improvement (9
wks-6 months)
12 1121 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.64, 0.86]
22.7 acute - Behaviour
deteriorated/disturbed/unco-
operative
1 42 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.60, 1.29]
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22.8 chronic - Behaviour
deteriorated/disturbed/unco-
operative
9 1085 Risk Ratio (M-H, Random, 95% CI) 0.49 [0.26, 0.92]
23 SUBGROUP ANALYSIS: 3.
HIGH vs LOW DOSE
22 Risk Ratio (M-H, Random, 95% CI) Subtotals only
23.1 high - Relapse (9 wks-6
Months)
1 420 Risk Ratio (M-H, Random, 95% CI) 0.14 [0.08, 0.26]
23.2 low - Relapse (9 wks-6
Months)
3 474 Risk Ratio (M-H, Random, 95% CI) 0.51 [0.26, 0.98]
23.3 high - Global state 1. No
overall improvement (0-8 wks)
2 201 Risk Ratio (M-H, Random, 95% CI) 0.48 [0.18, 1.25]
23.4 low - Global state 1. No
overall improvement (0-8 wks)
9 425 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.52, 1.01]
23.5 high - Global state 1. No
overall improvement (9 wks-6
months)
6 576 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.51, 0.94]
23.6 low - Global state 1. No
overall improvement (9 wks-6
months)
3 493 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.60, 1.16]
23.7 high - Behaviour 1.
Deteriorated/disturbed/unco-
operative
2 447 Risk Ratio (M-H, Random, 95% CI) 0.50 [0.04, 6.21]
23.8 low - Behaviour 1.
Deteriorated/disturbed/unco-
operative
2 462 Risk Ratio (M-H, Random, 95% CI) 0.39 [0.27, 0.56]
24 SUBGROUP ANALYSIS: 4.
DIAGNOSTIC CRITERIA
vs NO DIAGNOSTIC
CRITERIA
36 Risk Ratio (M-H, Random, 95% CI) Subtotals only
24.1 diagnostic criteria -
Relapse (0-8 wks)
1 34 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.26, 2.19]
24.2 no diagnostic criteria -
Relapse (0-8 wks)
1 40 Risk Ratio (M-H, Random, 95% CI) 0.05 [0.00, 0.76]
24.3 diagnostic criteria -
Relapse (9 wks-6 months)
2 662 Risk Ratio (M-H, Random, 95% CI) 0.34 [0.13, 0.90]
24.4 no diagnostic criteria -
Relapse (9 wks-6 months)
2 147 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.66, 1.60]
24.5 diagnostic criteria -
Global state 1. No overall
improvement (0-8 wks)
3 192 Risk Ratio (M-H, Random, 95% CI) 0.63 [0.40, 0.99]
24.6 no diagnostic criteria
- Global state 1. No overall
improvement (0-8 wks)
11 565 Risk Ratio (M-H, Random, 95% CI) 0.64 [0.46, 0.90]
24.7 diagnostic criteria -
Global state 1. No overall
improvement (9 wks-6 months)
3 689 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.57, 1.05]
24.8 no diagnostic criteria
- Global state 1. No overall
improvement (9 wks-6 months)
11 475 Risk Ratio (M-H, Random, 95% CI) 0.71 [0.59, 0.85]
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24.9 diagnostic criteria -
Global state 3. Severity of
illness (9 wks-6 months)
1 628 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.75, 0.88]
24.10 no diagnostic criteria
- Global state 3. Severity of
illness (9 wks-6 months)
2 66 Risk Ratio (M-H, Random, 95% CI) 0.58 [0.36, 0.95]
24.11 diagnostic criteria -
Behaviour 1. deteriorated/
disturbed/unco-operative
2 670 Risk Ratio (M-H, Random, 95% CI) 0.48 [0.14, 1.72]
24.12 no diagnostic criteria
- Behaviour 1. deteriorated/
disturbed/unco-operative
8 457 Risk Ratio (M-H, Random, 95% CI) 0.56 [0.33, 0.97]
25 SUBGROUP ANALYSIS:
5. STUDIES PRE-1990 vs
STUDIES 1990-2007
32 Risk Ratio (M-H, Random, 95% CI) Subtotals only
25.1 Pre-1990 - Global state
1. No overall improvement (0-
8 wks)
11 555 Risk Ratio (M-H, Random, 95% CI) 0.64 [0.46, 0.91]
25.2 1990 to 2002 -
Global state 1. No overall
improvement (0-8 wks)
3 202 Risk Ratio (M-H, Random, 95% CI) 0.61 [0.40, 0.94]
25.3 Pre-1990 - Global state
1. No overall improvement (9
wks-6 months)
13 1121 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.67, 0.88]
25.4 1990 to 2002 -
Global state 1. No overall
improvement (9 wks-6 months)
1 43 Risk Ratio (M-H, Random, 95% CI) 0.48 [0.30, 0.79]
25.5 Pre-1990 - Behaviour 1.
deteriorated/disturbed/unco-
operative
9 1085 Risk Ratio (M-H, Random, 95% CI) 0.49 [0.26, 0.92]
25.6 1990 to 2002 -
Behaviour 1. deteriorated/
disturbed/unco-operative
1 42 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.60, 1.29]
26 SENSITIVITY ANALYSIS: 1.
RANDOMISATION
14 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
26.1 not stated - Global state:
1. No overall improvement (9
weeks - 6 months)
1 43 Risk Ratio (M-H, Fixed, 95% CI) 0.48 [0.30, 0.79]
26.2 stated - Global state: 1.
No overall improvement (9
weeks - 6 months)
13 1121 Risk Ratio (M-H, Fixed, 95% CI) 0.80 [0.75, 0.85]
27 SENSITIVITY ANALYSIS: 2.
ASSUMPTIONS FOR LOST
BINARY DATA
14 Risk Ratio (M-H, Random, 95% CI) Subtotals only
27.1 LOCF - Global state: 1.
No overall improvement (0-8
weeks)
2 86 Risk Ratio (M-H, Random, 95% CI) 0.46 [0.17, 1.29]
27.2 not LOCF - Global state:
1. No overall improvement (0-
8 weeks)
12 671 Risk Ratio (M-H, Random, 95% CI) 0.66 [0.49, 0.88]
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Analysis 1.1. Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 1 Death.
Review: Chlorpromazine versus placebo for schizophrenia
Comparison: 1 CHLORPROMAZINE versus PLACEBO
Outcome: 1 Death
Study or subgroup Chlorpromazine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Baker 1959 0/7 0/7 Not estimable
Total (95% CI) 7 7 Not estimable
Total events: 0 (Chlorpromazine), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 1.2. Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 2 Relapse.
Review: Chlorpromazine versus placebo for schizophrenia
Comparison: 1 CHLORPROMAZINE versus PLACEBO
Outcome: 2 Relapse
Study or subgroup Chlorpromazine Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 short term (0-8 weeks)
Peet 1981 4/16 6/18 58.0 % 0.75 [ 0.26, 2.19 ]
Spohn 1977 0/20 10/20 42.0 % 0.05 [ 0.00, 0.76 ]
Subtotal (95% CI) 36 38 100.0 % 0.24 [ 0.01, 5.49 ]
Total events: 4 (Chlorpromazine), 16 (Placebo)
Heterogeneity: Tau2 = 4.14; Chi2 = 4.61, df = 1 (P = 0.03); I2 =78%
Test for overall effect: Z = 0.90 (P = 0.37)
2 medium term (9 weeks - 6 months)
Nishikawa 1982 6/10 8/10 25.1 % 0.75 [ 0.41, 1.36 ]
Peet 1981 4/16 7/18 21.6 % 0.64 [ 0.23, 1.80 ]
Prien 1968 39/416 85/212 26.5 % 0.23 [ 0.17, 0.33 ]
Rappaport 1978 38/53 44/74 26.8 % 1.21 [ 0.94, 1.55 ]
Subtotal (95% CI) 495 314 100.0 % 0.61 [ 0.21, 1.72 ]
Total events: 87 (Chlorpromazine), 144 (Placebo)
Heterogeneity: Tau2 = 1.04; Chi2 = 68.53, df = 3 (P<0.00001); I2 =96%
Test for overall effect: Z = 0.94 (P = 0.35)
3 long term (6 months - 2 years)
Engelhardt 1960 28/62 35/56 30.6 % 0.72 [ 0.51, 1.02 ]
Hogarty 1973 70/192 131/182 39.1 % 0.51 [ 0.41, 0.62 ]
Nishikawa 1982 8/10 10/10 30.3 % 0.81 [ 0.57, 1.14 ]
Subtotal (95% CI) 264 248 100.0 % 0.65 [ 0.47, 0.90 ]
Total events: 106 (Chlorpromazine), 176 (Placebo)
Heterogeneity: Tau2 = 0.06; Chi2 = 7.13, df = 2 (P = 0.03); I2 =72%
Test for overall effect: Z = 2.62 (P = 0.0089)
4 2 - 5 years
Hogarty 1973 99/192 149/182 54.1 % 0.63 [ 0.54, 0.73 ]
Nishikawa 1982 9/10 10/10 45.9 % 0.90 [ 0.69, 1.18 ]
Subtotal (95% CI) 202 192 100.0 % 0.74 [ 0.51, 1.09 ]
Total events: 108 (Chlorpromazine), 159 (Placebo)
Heterogeneity: Tau2 = 0.06; Chi2 = 6.12, df = 1 (P = 0.01); I2 =84%
Test for overall effect: Z = 1.53 (P = 0.13)
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Analysis 1.3. Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 3 Global state: 1a. No
overall improvement (psychiatrist-rated).
Review: Chlorpromazine versus placebo for schizophrenia
Comparison: 1 CHLORPROMAZINE versus PLACEBO
Outcome: 3 Global state: 1a. No overall improvement (psychiatrist-rated)
Study or subgroup Chlorpromazine Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 short term (0-8 weeks)
Baker 1959 7/7 6/7 10.5 % 1.15 [ 0.79, 1.68 ]
Chouinard 1990 (1) 9/21 13/21 8.3 % 0.69 [ 0.38, 1.26 ]
Clark 1971 (2) 3/23 11/21 4.4 % 0.25 [ 0.08, 0.77 ]
Cooper 2000 26/53 35/53 11.0 % 0.74 [ 0.53, 1.04 ]
Fink 1963 10/51 30/44 8.4 % 0.29 [ 0.16, 0.52 ]
Hankoff 1962 12/16 65/68 11.4 % 0.78 [ 0.59, 1.05 ]
Kurland 1961 9/33 30/74 8.1 % 0.67 [ 0.36, 1.25 ]
Ramu 1999 6/27 18/27 6.9 % 0.33 [ 0.16, 0.71 ]
Reschke 1974 7/10 4/11 5.9 % 1.93 [ 0.80, 4.64 ]
Shepherd 1956 3/8 10/16 5.3 % 0.60 [ 0.23, 1.59 ]
Somerville 1960 7/15 23/30 8.5 % 0.61 [ 0.34, 1.08 ]
Vaughan 1955 8/24 19/24 8.3 % 0.42 [ 0.23, 0.77 ]
Walsh 1959 2/22 8/22 3.1 % 0.25 [ 0.06, 1.05 ]
Subtotal (95% CI) 310 418 100.0 % 0.61 [ 0.46, 0.82 ]
Total events: 109 (Chlorpromazine), 272 (Placebo)
Heterogeneity: Tau2 = 0.17; Chi2 = 38.79, df = 12 (P = 0.00011); I2 =69%
Test for overall effect: Z = 3.33 (P = 0.00087)
2 medium term (9 weeks - 6 months)
Ban 1975 6/10 8/10 5.9 % 0.75 [ 0.41, 1.36 ]
Bishop 1963 2/10 10/10 2.6 % 0.24 [ 0.08, 0.71 ]
Clark 1961 13/19 19/19 9.4 % 0.69 [ 0.51, 0.95 ]
Clark 1968a 10/18 30/36 7.7 % 0.67 [ 0.43, 1.03 ]
Clark 1970a 8/15 9/14 5.7 % 0.83 [ 0.45, 1.53 ]
Clark 1972 10/19 14/18 7.0 % 0.68 [ 0.41, 1.11 ]
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(. . . Continued)
Study or subgroup Chlorpromazine Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Clark 1977 3/9 9/9 3.7 % 0.37 [ 0.16, 0.87 ]
Grygier 1958 13/15 13/15 9.9 % 1.00 [ 0.76, 1.32 ]
Hall 1955 56/87 72/88 11.1 % 0.79 [ 0.65, 0.95 ]
Hine 1958 6/11 11/11 6.5 % 0.57 [ 0.33, 0.96 ]
Prien 1968 (3) 380/416 205/212 12.2 % 0.94 [ 0.91, 0.98 ]
Ramu 1999a 10/23 18/20 7.1 % 0.48 [ 0.30, 0.79 ]
Reardon 1966 1/11 6/12 1.0 % 0.18 [ 0.03, 1.28 ]
Serafetinides 1972 12/14 13/13 10.3 % 0.86 [ 0.67, 1.11 ]
Subtotal (95% CI) 677 487 100.0 % 0.71 [ 0.58, 0.86 ]
Total events: 530 (Chlorpromazine), 437 (Placebo)
Heterogeneity: Tau2 = 0.08; Chi2 = 68.82, df = 13 (P<0.00001); I2 =81%
Test for overall effect: Z = 3.44 (P = 0.00059)
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Analysis 1.4. Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 4 Global state: 1b. No
overall improvement (nurse-rated).
Review: Chlorpromazine versus placebo for schizophrenia
Comparison: 1 CHLORPROMAZINE versus PLACEBO
Outcome: 4 Global state: 1b. No overall improvement (nurse-rated)
Study or subgroup Chlorpromazine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 short term (0-8 weeks)
Weckowicz 1960 11/14 13/15 100.0 % 0.91 [ 0.65, 1.27 ]
Subtotal (95% CI) 14 15 100.0 % 0.91 [ 0.65, 1.27 ]
Total events: 11 (Chlorpromazine), 13 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
2 medium term (9 weeks-6 months)
Clark 1970a 7/15 14/14 34.5 % 0.48 [ 0.29, 0.82 ]
Clark 1972 9/19 18/18 43.7 % 0.49 [ 0.31, 0.78 ]
Clark 1977 4/9 9/9 21.9 % 0.47 [ 0.24, 0.95 ]
Subtotal (95% CI) 43 41 100.0 % 0.48 [ 0.35, 0.66 ]
Total events: 20 (Chlorpromazine), 41 (Placebo)
Heterogeneity: Chi2 = 0.00, df = 2 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 4.54 (P < 0.00001)
Test for subgroup differences: Chi2 = 7.13, df = 1 (P = 0.01), I2 =86%
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Analysis 1.5. Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 5 Global state: 2. Average
endpoint score - short term (CGI, high score=worse).
Review: Chlorpromazine versus placebo for schizophrenia
Comparison: 1 CHLORPROMAZINE versus PLACEBO
Outcome: 5 Global state: 2. Average endpoint score - short term (CGI, high score=worse)
Study or subgroup Chlorpromazine Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Borison 1991 9 4.4 (0.5) 10 4.3 (0.5) 100.0 % 0.10 [ -0.35, 0.55 ]
Total (95% CI) 9 10 100.0 % 0.10 [ -0.35, 0.55 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.44 (P = 0.66)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 6 Global state: 3a. Severity
of illness, severely ill or worse (CGI 5+ points, psychiatrist-rated).
Review: Chlorpromazine versus placebo for schizophrenia
Comparison: 1 CHLORPROMAZINE versus PLACEBO
Outcome: 6 Global state: 3a. Severity of illness, severely ill or worse (CGI 5+ points, psychiatrist-rated)
Study or subgroup Chlorpromazine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 short term (0-8 weeks)
Clark 1971 4/23 8/21 100.0 % 0.46 [ 0.16, 1.30 ]
Subtotal (95% CI) 23 21 100.0 % 0.46 [ 0.16, 1.30 ]
Total events: 4 (Chlorpromazine), 8 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.47 (P = 0.14)
2 medium term (9 weeks - 6 months)
Clark 1970a 3/15 6/14 2.3 % 0.47 [ 0.14, 1.52 ]
Clark 1972 9/19 14/18 5.4 % 0.61 [ 0.36, 1.04 ]
Prien 1968 298/416 186/212 92.3 % 0.82 [ 0.75, 0.88 ]
Subtotal (95% CI) 450 244 100.0 % 0.80 [ 0.74, 0.86 ]
Total events: 310 (Chlorpromazine), 206 (Placebo)
Heterogeneity: Chi2 = 2.12, df = 2 (P = 0.35); I2 =6%
Test for overall effect: Z = 5.52 (P < 0.00001)
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Analysis 1.7. Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 7 Global state: 3b. Severity
of illness, severely ill or worse - medium term (CGI 5+ points, nurse-rated).
Review: Chlorpromazine versus placebo for schizophrenia
Comparison: 1 CHLORPROMAZINE versus PLACEBO
Outcome: 7 Global state: 3b. Severity of illness, severely ill or worse - medium term (CGI 5+ points, nurse-rated)
Study or subgroup Chlorpromazine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Clark 1970a 8/15 14/14 52.9 % 0.55 [ 0.34, 0.88 ]
Clark 1972 10/19 13/18 47.1 % 0.73 [ 0.44, 1.22 ]
Total (95% CI) 34 32 100.0 % 0.63 [ 0.45, 0.90 ]
Total events: 18 (Chlorpromazine), 27 (Placebo)
Heterogeneity: Chi2 = 0.64, df = 1 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 2.57 (P = 0.010)
Test for subgroup differences: Not applicable
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Analysis 1.8. Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 8 Leaving the study early.
Review: Chlorpromazine versus placebo for schizophrenia
Comparison: 1 CHLORPROMAZINE versus PLACEBO
Outcome: 8 Leaving the study early
Study or subgroup Chlorpromazine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 short term (0-8 weeks)
Baker 1959 0/7 0/7 Not estimable
Chouinard 1990 4/21 7/21 5.3 % 0.57 [ 0.20, 1.66 ]
Clark 1971 3/23 4/21 3.2 % 0.68 [ 0.17, 2.71 ]
Cole 1964 10/112 37/125 26.5 % 0.30 [ 0.16, 0.58 ]
Cooper 2000 25/53 25/53 18.9 % 1.00 [ 0.67, 1.50 ]
Fink 1963 0/12 0/7 Not estimable
Hamill 1975 6/22 5/22 3.8 % 1.20 [ 0.43, 3.36 ]
Hamilton 1960 0/18 0/18 Not estimable
Hankoff 1962 8/25 23/95 7.3 % 1.32 [ 0.67, 2.59 ]
Klein 1973 0/46 0/42 Not estimable
Kurland 1961 24/33 63/74 29.4 % 0.85 [ 0.68, 1.07 ]
Peet 1981 6/16 8/18 5.7 % 0.84 [ 0.37, 1.91 ]
Reschke 1974 0/10 0/11 Not estimable
Shepherd 1956 0/8 0/16 Not estimable
Simon 1958 0/20 0/20 Not estimable
Somerville 1960 0/15 0/30 Not estimable
Walsh 1959 0/22 0/22 Not estimable
Subtotal (95% CI) 463 602 100.0 % 0.76 [ 0.63, 0.92 ]
Total events: 86 (Chlorpromazine), 172 (Placebo)
Heterogeneity: Chi2 = 14.19, df = 7 (P = 0.05); I2 =51%
Test for overall effect: Z = 2.76 (P = 0.0059)
2 medium term (9 weeks - 6 months)
Abrams 1958 2/20 4/20 2.2 % 0.50 [ 0.10, 2.43 ]
Ban 1975 0/10 0/10 Not estimable
Bishop 1963 0/10 0/10 Not estimable
Clark 1967 11/51 0/21 0.4 % 9.73 [ 0.60, 157.98 ]
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(. . . Continued)
Study or subgroup Chlorpromazine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Clark 1968a 3/18 3/36 1.1 % 2.00 [ 0.45, 8.94 ]
Clark 1968b 1/23 0/23 0.3 % 3.00 [ 0.13, 70.02 ]
Clark 1970a 2/15 1/14 0.6 % 1.87 [ 0.19, 18.38 ]
Clark 1970b 5/53 1/18 0.8 % 1.70 [ 0.21, 13.58 ]
Clark 1972 2/19 2/18 1.1 % 0.95 [ 0.15, 6.03 ]
Clark 1977 0/9 2/9 1.4 % 0.20 [ 0.01, 3.66 ]
Cohen 1968 0/42 0/42 Not estimable
Dean 1958 0/9 0/9 Not estimable
Fleming 1959 4/21 4/21 2.2 % 1.00 [ 0.29, 3.48 ]
Gwynne 1962 0/26 3/26 1.9 % 0.14 [ 0.01, 2.63 ]
Hall 1955 3/87 0/88 0.3 % 7.08 [ 0.37, 135.06 ]
Hine 1958 1/11 0/11 0.3 % 3.00 [ 0.14, 66.53 ]
Letemendia 1967 0/14 0/14 Not estimable
Peet 1981 6/16 9/18 4.6 % 0.75 [ 0.34, 1.64 ]
Prien 1968 83/416 81/212 58.2 % 0.52 [ 0.40, 0.68 ]
Rappaport 1978 14/53 33/74 14.9 % 0.59 [ 0.35, 0.99 ]
Reardon 1966 2/11 4/12 2.1 % 0.55 [ 0.12, 2.41 ]
Saretsky 1966 0/20 0/20 Not estimable
Schiele 1961 0/20 1/20 0.8 % 0.33 [ 0.01, 7.72 ]
Serafetinides 1972 3/14 1/13 0.6 % 2.79 [ 0.33, 23.52 ]
Smith 1961 2/15 0/15 0.3 % 5.00 [ 0.26, 96.13 ]
Tetreault 1969 0/15 0/15 Not estimable
Xiong 1994 0/12 11/12 6.2 % 0.04 [ 0.00, 0.66 ]
Subtotal (95% CI) 1030 801 100.0 % 0.64 [ 0.53, 0.78 ]
Total events: 144 (Chlorpromazine), 160 (Placebo)
Heterogeneity: Chi2 = 24.66, df = 19 (P = 0.17); I2 =23%
Test for overall effect: Z = 4.46 (P < 0.00001)
3 long term (>6 months - 2 years)
Engelhardt 1960 25/62 19/56 58.1 % 1.19 [ 0.74, 1.91 ]
Hogarty 1973 13/192 14/182 41.9 % 0.88 [ 0.43, 1.82 ]
Subtotal (95% CI) 254 238 100.0 % 1.06 [ 0.71, 1.59 ]
Total events: 38 (Chlorpromazine), 33 (Placebo)
Heterogeneity: Chi2 = 0.47, df = 1 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 0.28 (P = 0.78)
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Study or subgroup Chlorpromazine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
4 >2 - 5 years
Hogarty 1973 13/192 18/182 100.0 % 0.68 [ 0.35, 1.36 ]
Subtotal (95% CI) 192 182 100.0 % 0.68 [ 0.35, 1.36 ]
Total events: 13 (Chlorpromazine), 18 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.09 (P = 0.28)
0.005 0.1 1 10 200
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Analysis 1.9. Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 9 Mental state: 1. Improved
- short term (BPRS, 50% change).
Review: Chlorpromazine versus placebo for schizophrenia
Comparison: 1 CHLORPROMAZINE versus PLACEBO
Outcome: 9 Mental state: 1. Improved - short term (BPRS, 50% change)
Study or subgroup Chlorpromazine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Cooper 2000 5/53 4/53 100.0 % 1.25 [ 0.36, 4.40 ]
Total (95% CI) 53 53 100.0 % 1.25 [ 0.36, 4.40 ]
Total events: 5 (Chlorpromazine), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.73)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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Analysis 1.10. Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 10 Mental state: 2. Average
endpoint scores (BPRS, high score=worse).
Review: Chlorpromazine versus placebo for schizophrenia
Comparison: 1 CHLORPROMAZINE versus PLACEBO
Outcome: 10 Mental state: 2. Average endpoint scores (BPRS, high score=worse)
Study or subgroup Chlorpromazine Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 short term (0-8 weeks)
Tetreault 1969 15 42.5 (7.64) 15 48.2 (7.64) 44.9 % -5.70 [ -11.17, -0.23 ]
Borison 1991 9 46.4 (4.5) 10 50.5 (6.4) 55.1 % -4.10 [ -9.04, 0.84 ]
Subtotal (95% CI) 24 25 100.0 % -4.82 [ -8.48, -1.15 ]
Heterogeneity: Chi2 = 0.18, df = 1 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 2.58 (P = 0.010)
2 medium term (9 weeks - 6 months)
Tetreault 1969 15 41.2 (9.88) 15 48.9 (9.88) 100.0 % -7.70 [ -14.77, -0.63 ]
Subtotal (95% CI) 15 15 100.0 % -7.70 [ -14.77, -0.63 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.13 (P = 0.033)
Test for subgroup differences: Chi2 = 0.50, df = 1 (P = 0.48), I2 =0.0%
-20 -10 0 10 20
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Analysis 1.11. Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 11 Behaviour: 1.
Deteriorated/ disturbed/un-cooperative.
Review: Chlorpromazine versus placebo for schizophrenia
Comparison: 1 CHLORPROMAZINE versus PLACEBO
Outcome: 11 Behaviour: 1. Deteriorated/ disturbed/un-cooperative
Study or subgroup Chlorpromazine Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 short term - (0-8 weeks)
Chouinard 1990 14/21 16/21 60.2 % 0.88 [ 0.60, 1.29 ]
Somerville 1960 5/15 22/30 39.8 % 0.45 [ 0.22, 0.96 ]
Subtotal (95% CI) 36 51 100.0 % 0.67 [ 0.34, 1.35 ]
Total events: 19 (Chlorpromazine), 38 (Placebo)
Heterogeneity: Tau2 = 0.17; Chi2 = 2.83, df = 1 (P = 0.09); I2 =65%
Test for overall effect: Z = 1.12 (P = 0.26)
2 medium term (9 weeks - 6 months)
Clark 1970a 2/15 5/14 9.8 % 0.37 [ 0.09, 1.62 ]
Clark 1970b 10/53 6/18 13.6 % 0.57 [ 0.24, 1.34 ]
Fleming 1959 5/21 13/21 13.7 % 0.38 [ 0.17, 0.89 ]
Hall 1955 65/87 70/88 16.8 % 0.94 [ 0.80, 1.10 ]
Prien 1968 37/416 70/212 16.2 % 0.27 [ 0.19, 0.39 ]
Schiele 1961 0/20 12/20 4.8 % 0.04 [ 0.00, 0.63 ]
Serafetinides 1972 6/14 3/13 11.7 % 1.86 [ 0.58, 5.94 ]
Smith 1961 4/13 10/15 13.4 % 0.46 [ 0.19, 1.12 ]
Subtotal (95% CI) 639 401 100.0 % 0.49 [ 0.24, 1.00 ]
Total events: 129 (Chlorpromazine), 189 (Placebo)
Heterogeneity: Tau2 = 0.78; Chi2 = 70.98, df = 7 (P<0.00001); I2 =90%
Test for overall effect: Z = 1.97 (P = 0.049)
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Analysis 1.12. Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 12 Behaviour: 2.
Unchanged.
Review: Chlorpromazine versus placebo for schizophrenia
Comparison: 1 CHLORPROMAZINE versus PLACEBO
Outcome: 12 Behaviour: 2. Unchanged
Study or subgroup Chlorpromazine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 short term (0-8 weeks)
Schiele 1961 5/20 8/20 100.0 % 0.63 [ 0.25, 1.58 ]
Subtotal (95% CI) 20 20 100.0 % 0.63 [ 0.25, 1.58 ]
Total events: 5 (Chlorpromazine), 8 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.99 (P = 0.32)
2 medium term (9 weeks - 6 months)
Schiele 1961 6/20 8/20 63.3 % 0.75 [ 0.32, 1.77 ]
Smith 1961 8/13 5/15 36.7 % 1.85 [ 0.80, 4.25 ]
Subtotal (95% CI) 33 35 100.0 % 1.15 [ 0.64, 2.07 ]
Total events: 14 (Chlorpromazine), 13 (Placebo)
Heterogeneity: Chi2 = 2.19, df = 1 (P = 0.14); I2 =54%
Test for overall effect: Z = 0.48 (P = 0.63)
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Analysis 1.13. Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 13 Behaviour: 3. Average
endpoint scores (RRS, high score=worse).
Review: Chlorpromazine versus placebo for schizophrenia
Comparison: 1 CHLORPROMAZINE versus PLACEBO
Outcome: 13 Behaviour: 3. Average endpoint scores (RRS, high score=worse)
Study or subgroup Chlorpromazine Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 short term (0-8 weeks)
Tetreault 1969 15 14.5 (5.36) 15 17.4 (5.36) 100.0 % -2.90 [ -6.74, 0.94 ]
Subtotal (95% CI) 15 15 100.0 % -2.90 [ -6.74, 0.94 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.48 (P = 0.14)
2 medium term (9 weeks - 6 months)
Tetreault 1969 15 16.8 (6.8) 15 21.4 (6.8) 100.0 % -4.60 [ -9.47, 0.27 ]
Subtotal (95% CI) 15 15 100.0 % -4.60 [ -9.47, 0.27 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.85 (P = 0.064)
Test for subgroup differences: Chi2 = 0.29, df = 1 (P = 0.59), I2 =0.0%
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Analysis 1.14. Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 14 Behaviour: 4. Average
endpoint score - short term (PBRS, high score=good).
Review: Chlorpromazine versus placebo for schizophrenia
Comparison: 1 CHLORPROMAZINE versus PLACEBO
Outcome: 14 Behaviour: 4. Average endpoint score - short term (PBRS, high score=good)
Study or subgroup Chlorpromazine Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Baker 1959 7 22.6 (3.2) 7 16.6 (4.4) 100.0 % 6.00 [ 1.97, 10.03 ]
Total (95% CI) 7 7 100.0 % 6.00 [ 1.97, 10.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.92 (P = 0.0035)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
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Analysis 1.15. Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 15 Behaviour: 5. Average
endpoint scores - medium term (Fergus Falls Behavioural rating scale).
Review: Chlorpromazine versus placebo for schizophrenia
Comparison: 1 CHLORPROMAZINE versus PLACEBO
Outcome: 15 Behaviour: 5. Average endpoint scores - medium term (Fergus Falls Behavioural rating scale)
Study or subgroup Chlorpromazine Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Ramu 1999a (1) 22 22.59 (7.56) 20 24.95 (4.63) 100.0 % -2.36 [ -6.11, 1.39 ]
Total (95% CI) 22 20 100.0 % -2.36 [ -6.11, 1.39 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.23 (P = 0.22)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours CPZ Favours placebo
(1) N not reported, assumed to be the number reported in each group after losses to follow-up.
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Analysis 1.16. Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 16 Adverse effects: 1.
Movement disorders.
Review: Chlorpromazine versus placebo for schizophrenia
Comparison: 1 CHLORPROMAZINE versus PLACEBO
Outcome: 16 Adverse effects: 1. Movement disorders
Study or subgroup Chlorpromazine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 acute movement disorders (dystonia)
Clark 1977 1/9 0/9 6.8 % 3.00 [ 0.14, 65.16 ]
Cole 1964 4/88 0/74 7.4 % 7.58 [ 0.42, 138.60 ]
Kurland 1961 0/33 0/74 Not estimable
Prien 1968 21/416 4/212 71.8 % 2.68 [ 0.93, 7.69 ]
Serafetinides 1972 6/14 1/13 14.1 % 5.57 [ 0.77, 40.26 ]
Subtotal (95% CI) 560 382 100.0 % 3.47 [ 1.50, 8.03 ]
Total events: 32 (Chlorpromazine), 5 (Placebo)
Heterogeneity: Chi2 = 0.74, df = 3 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 2.90 (P = 0.0037)
2 parkinsonism (includes EPS)
Baker 1959 1/7 0/7 0.9 % 3.00 [ 0.14, 63.15 ]
Chouinard 1990 20/21 11/21 19.4 % 1.82 [ 1.20, 2.76 ]
Clark 1961 4/20 0/20 0.9 % 9.00 [ 0.52, 156.91 ]
Clark 1970b 9/53 1/18 2.6 % 3.06 [ 0.42, 22.49 ]
Fleming 1959 2/21 0/21 0.9 % 5.00 [ 0.25, 98.27 ]
Gwynne 1962 (1) 7/26 3/26 5.3 % 2.33 [ 0.68, 8.05 ]
Hall 1955 34/87 0/88 0.9 % 69.78 [ 4.35, 1120.62 ]
Hamilton 1960 1/18 0/18 0.9 % 3.00 [ 0.13, 69.09 ]
Hankoff 1962 2/25 0/72 0.5 % 14.04 [ 0.70, 282.87 ]
Kurland 1961 0/33 0/74 Not estimable
Prien 1968 50/416 28/212 65.5 % 0.91 [ 0.59, 1.40 ]
Ramu 1999 2/27 0/27 0.9 % 5.00 [ 0.25, 99.51 ]
Reschke 1974 1/10 0/11 0.8 % 3.27 [ 0.15, 72.23 ]
Somerville 1960 1/15 0/30 0.6 % 5.81 [ 0.25, 134.73 ]
Walsh 1959 0/22 0/22 Not estimable
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Study or subgroup Chlorpromazine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Subtotal (95% CI) 801 667 100.0 % 2.11 [ 1.59, 2.80 ]
Total events: 134 (Chlorpromazine), 43 (Placebo)
Heterogeneity: Chi2 = 25.08, df = 12 (P = 0.01); I2 =52%
Test for overall effect: Z = 5.19 (P < 0.00001)
3 tremor
Clark 1968b 3/23 0/23 2.8 % 7.00 [ 0.38, 128.33 ]
Clark 1970a 0/15 0/14 Not estimable
Clark 1971 6/23 2/21 11.6 % 2.74 [ 0.62, 12.12 ]
Clark 1972 4/19 2/18 11.4 % 1.89 [ 0.39, 9.11 ]
Cole 1964 5/88 4/74 24.1 % 1.05 [ 0.29, 3.77 ]
Peet 1981 11/16 8/18 41.8 % 1.55 [ 0.84, 2.86 ]
Schiele 1961 0/20 1/20 8.3 % 0.33 [ 0.01, 7.72 ]
Subtotal (95% CI) 204 188 100.0 % 1.66 [ 1.01, 2.73 ]
Total events: 29 (Chlorpromazine), 17 (Placebo)
Heterogeneity: Chi2 = 2.94, df = 5 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 1.98 (P = 0.048)
4 rigidity
Clark 1968a 7/18 6/36 18.6 % 2.33 [ 0.92, 5.93 ]
Clark 1968b 2/23 0/23 2.3 % 5.00 [ 0.25, 98.75 ]
Clark 1970a 0/15 0/14 Not estimable
Clark 1971 10/23 3/21 14.6 % 3.04 [ 0.97, 9.58 ]
Clark 1972 5/19 2/18 9.5 % 2.37 [ 0.52, 10.70 ]
Cole 1964 22/88 10/74 50.4 % 1.85 [ 0.94, 3.65 ]
Schiele 1961 2/20 1/20 4.6 % 2.00 [ 0.20, 20.33 ]
Subtotal (95% CI) 206 206 100.0 % 2.24 [ 1.42, 3.54 ]
Total events: 48 (Chlorpromazine), 22 (Placebo)
Heterogeneity: Chi2 = 0.88, df = 5 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 3.46 (P = 0.00053)
5 akathisia
Clark 1968b 1/23 0/23 0.9 % 3.00 [ 0.13, 70.02 ]
Clark 1970a 0/15 0/14 Not estimable
Clark 1970b 4/53 2/18 5.3 % 0.68 [ 0.14, 3.40 ]
Clark 1971 6/23 2/21 3.7 % 2.74 [ 0.62, 12.12 ]
Clark 1972 2/19 2/18 3.6 % 0.95 [ 0.15, 6.03 ]
Cole 1964 5/88 3/74 5.8 % 1.40 [ 0.35, 5.67 ]
Kurland 1961 0/33 0/74 Not estimable
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Study or subgroup Chlorpromazine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Prien 1968 38/416 34/212 79.8 % 0.57 [ 0.37, 0.88 ]
Schiele 1961 2/20 0/20 0.9 % 5.00 [ 0.26, 98.00 ]
Subtotal (95% CI) 690 474 100.0 % 0.78 [ 0.54, 1.11 ]
Total events: 58 (Chlorpromazine), 43 (Placebo)
Heterogeneity: Chi2 = 7.71, df = 6 (P = 0.26); I2 =22%
Test for overall effect: Z = 1.37 (P = 0.17)
6 chronic movement disorders (tardive dyskinesia)
Clark 1977 3/9 2/9 100.0 % 1.50 [ 0.32, 6.94 ]
Subtotal (95% CI) 9 9 100.0 % 1.50 [ 0.32, 6.94 ]
Total events: 3 (Chlorpromazine), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.52 (P = 0.60)
7 ataxia
Hankoff 1962 3/25 1/72 100.0 % 8.64 [ 0.94, 79.31 ]
Subtotal (95% CI) 25 72 100.0 % 8.64 [ 0.94, 79.31 ]
Total events: 3 (Chlorpromazine), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.91 (P = 0.057)
0.002 0.1 1 10 500
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(1) N not reported, assumed to be N randomised.
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Analysis 1.17. Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 17 Adverse effects: 2.
Movement disorders: Average endpoint scores (Extrapyramidal Bilan, high score=worse).
Review: Chlorpromazine versus placebo for schizophrenia
Comparison: 1 CHLORPROMAZINE versus PLACEBO
Outcome: 17 Adverse effects: 2. Movement disorders: Average endpoint scores (Extrapyramidal Bilan, high score=worse)
Study or subgroup Chlorpromazine Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 short term (0-8 weeks)
Tetreault 1969 15 7.1 (2.55) 15 8.5 (2.55) 100.0 % -1.40 [ -3.22, 0.42 ]
Subtotal (95% CI) 15 15 100.0 % -1.40 [ -3.22, 0.42 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.50 (P = 0.13)
2 medium term (9 weeks - 6 months)
Tetreault 1969 15 6.1 (3.34) 15 7.9 (3.34) 100.0 % -1.80 [ -4.19, 0.59 ]
Subtotal (95% CI) 15 15 100.0 % -1.80 [ -4.19, 0.59 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.48 (P = 0.14)
Test for subgroup differences: Chi2 = 0.07, df = 1 (P = 0.79), I2 =0.0%
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Analysis 1.18. Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 18 Adverse effects: 1.
Central nervous system.
Review: Chlorpromazine versus placebo for schizophrenia
Comparison: 1 CHLORPROMAZINE versus PLACEBO
Outcome: 18 Adverse effects: 1. Central nervous system
Study or subgroup Chlorpromazine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 sleepiness
Baker 1959 1/7 0/7 0.5 % 3.00 [ 0.14, 63.15 ]
Clark 1961 4/20 6/20 6.4 % 0.67 [ 0.22, 2.01 ]
Clark 1968a 7/18 3/36 2.1 % 4.67 [ 1.37, 15.94 ]
Clark 1968b 9/23 3/23 3.2 % 3.00 [ 0.93, 9.68 ]
Clark 1970a 8/15 1/14 1.1 % 7.47 [ 1.07, 52.33 ]
Clark 1970b 15/53 1/18 1.6 % 5.09 [ 0.72, 35.89 ]
Clark 1971 17/23 6/21 6.7 % 2.59 [ 1.26, 5.31 ]
Clark 1972 9/19 3/18 3.3 % 2.84 [ 0.91, 8.86 ]
Clark 1977 3/9 0/9 0.5 % 7.00 [ 0.41, 118.69 ]
Cole 1964 47/88 7/74 8.1 % 5.65 [ 2.72, 11.73 ]
Gwynne 1962 (1) 12/26 1/26 1.1 % 12.00 [ 1.68, 85.72 ]
Hamilton 1960 0/18 0/18 Not estimable
Hankoff 1962 10/25 9/72 4.9 % 3.20 [ 1.47, 6.96 ]
Payne 1960 2/7 0/7 0.5 % 5.00 [ 0.28, 88.53 ]
Peet 1981 11/16 9/18 9.0 % 1.38 [ 0.78, 2.43 ]
Prien 1968 110/416 30/212 42.2 % 1.87 [ 1.29, 2.70 ]
Ramu 1999a 3/22 0/20 0.6 % 6.39 [ 0.35, 116.57 ]
Reschke 1974 6/10 0/11 0.5 % 14.18 [ 0.90, 223.54 ]
Schiele 1961 4/20 3/20 3.2 % 1.33 [ 0.34, 5.21 ]
Serafetinides 1972 11/14 3/13 3.3 % 3.40 [ 1.22, 9.53 ]
Somerville 1960 5/15 0/30 0.4 % 21.31 [ 1.26, 361.69 ]
Walsh 1959 2/22 0/22 0.5 % 5.00 [ 0.25, 98.52 ]
Weckowicz 1960 2/16 0/16 0.5 % 5.00 [ 0.26, 96.59 ]
Subtotal (95% CI) 902 725 100.0 % 2.79 [ 2.25, 3.45 ]
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Study or subgroup Chlorpromazine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 298 (Chlorpromazine), 85 (Placebo)
Heterogeneity: Chi2 = 30.61, df = 21 (P = 0.08); I2 =31%
Test for overall effect: Z = 9.45 (P < 0.00001)
2 fits / loss of consciousness
Clark 1972 2/19 3/18 65.0 % 0.63 [ 0.12, 3.35 ]
Prien 1968 14/416 0/212 14.0 % 14.81 [ 0.89, 247.12 ]
Tetreault 1969 3/15 1/15 21.1 % 3.00 [ 0.35, 25.68 ]
Subtotal (95% CI) 450 245 100.0 % 3.11 [ 1.05, 9.18 ]
Total events: 19 (Chlorpromazine), 4 (Placebo)
Heterogeneity: Chi2 = 4.69, df = 2 (P = 0.10); I2 =57%
Test for overall effect: Z = 2.05 (P = 0.040)
3 weakness
Hine 1958 1/11 0/11 16.7 % 3.00 [ 0.14, 66.53 ]
Schiele 1961 1/20 0/20 16.7 % 3.00 [ 0.13, 69.52 ]
Tetreault 1969 7/15 2/15 66.7 % 3.50 [ 0.86, 14.18 ]
Subtotal (95% CI) 46 46 100.0 % 3.33 [ 1.02, 10.88 ]
Total events: 9 (Chlorpromazine), 2 (Placebo)
Heterogeneity: Chi2 = 0.01, df = 2 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 1.99 (P = 0.046)
4 convulsions
Gwynne 1962 (2) 0/26 1/26 100.0 % 0.33 [ 0.01, 7.82 ]
Subtotal (95% CI) 26 26 100.0 % 0.33 [ 0.01, 7.82 ]
Total events: 0 (Chlorpromazine), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
0.002 0.1 1 10 500
Favours CPZ Favours placebo
(1) N not reported, assumed to be N randomised.
(2) N not reported, assumed to be N randomised.
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Analysis 1.19. Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 19 Adverse effects: 3.
Blood, skin, liver, eyes.
Review: Chlorpromazine versus placebo for schizophrenia
Comparison: 1 CHLORPROMAZINE versus PLACEBO
Outcome: 19 Adverse effects: 3. Blood, skin, liver, eyes
Study or subgroup Chlorpromazine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 blood problems (agranulocytosis, leukopenia)
Clark 1961 1/20 0/20 10.0 % 3.00 [ 0.13, 69.52 ]
Clark 1968b 1/23 0/23 10.0 % 3.00 [ 0.13, 70.02 ]
Clark 1970b 4/53 1/18 29.7 % 1.36 [ 0.16, 11.38 ]
Fleming 1959 1/21 0/21 10.0 % 3.00 [ 0.13, 69.70 ]
Kurland 1961 1/33 0/74 6.2 % 6.62 [ 0.28, 158.32 ]
Prien 1968 1/42 0/16 14.3 % 1.19 [ 0.05, 27.70 ]
Tetreault 1969 1/15 1/15 19.9 % 1.00 [ 0.07, 14.55 ]
Subtotal (95% CI) 207 187 100.0 % 2.08 [ 0.74, 5.83 ]
Total events: 10 (Chlorpromazine), 2 (Placebo)
Heterogeneity: Chi2 = 1.23, df = 6 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 1.39 (P = 0.16)
2 rashes/itching/skin disorders
Clark 1961 2/20 0/20 1.8 % 5.00 [ 0.26, 98.00 ]
Clark 1968a 4/18 3/36 7.1 % 2.67 [ 0.67, 10.66 ]
Clark 1968b 1/23 0/23 1.8 % 3.00 [ 0.13, 70.02 ]
Clark 1970b 5/53 1/18 5.3 % 1.70 [ 0.21, 13.58 ]
Clark 1971 4/23 2/21 7.5 % 1.83 [ 0.37, 8.96 ]
Clark 1972 4/19 2/18 7.3 % 1.89 [ 0.39, 9.11 ]
Cole 1964 3/88 2/74 7.8 % 1.26 [ 0.22, 7.35 ]
Dean 1958 0/9 0/9 Not estimable
Hine 1958 1/11 0/11 1.8 % 3.00 [ 0.14, 66.53 ]
Kurland 1961 2/33 1/74 2.2 % 4.48 [ 0.42, 47.74 ]
Prien 1968 17/416 11/212 52.0 % 0.79 [ 0.38, 1.65 ]
Schiele 1961 1/20 1/20 3.6 % 1.00 [ 0.07, 14.90 ]
Walsh 1959 1/22 0/22 1.8 % 3.00 [ 0.13, 69.87 ]
Subtotal (95% CI) 755 558 100.0 % 1.45 [ 0.92, 2.29 ]
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Study or subgroup Chlorpromazine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 45 (Chlorpromazine), 23 (Placebo)
Heterogeneity: Chi2 = 5.83, df = 11 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 1.59 (P = 0.11)
3 liver problems
Clark 1970a 2/15 0/14 25.2 % 4.69 [ 0.24, 89.88 ]
Dean 1958 0/9 0/9 Not estimable
Hall 1955 3/87 0/88 24.2 % 7.08 [ 0.37, 135.06 ]
Serafetinides 1972 3/14 1/13 50.6 % 2.79 [ 0.33, 23.52 ]
Subtotal (95% CI) 125 124 100.0 % 4.31 [ 0.98, 18.95 ]
Total events: 8 (Chlorpromazine), 1 (Placebo)
Heterogeneity: Chi2 = 0.27, df = 2 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 1.93 (P = 0.053)
4 photosensitivity
Clark 1971 7/23 2/21 18.5 % 3.20 [ 0.75, 13.70 ]
Clark 1972 8/19 2/18 18.1 % 3.79 [ 0.93, 15.51 ]
Clark 1977 1/9 0/9 4.4 % 3.00 [ 0.14, 65.16 ]
Prien 1968 50/416 4/212 46.8 % 6.37 [ 2.33, 17.40 ]
Serafetinides 1972 5/14 1/13 9.2 % 4.64 [ 0.62, 34.65 ]
Somerville 1960 10/15 0/30 3.0 % 40.69 [ 2.54, 650.71 ]
Subtotal (95% CI) 496 303 100.0 % 6.04 [ 3.22, 11.32 ]
Total events: 81 (Chlorpromazine), 9 (Placebo)
Heterogeneity: Chi2 = 3.25, df = 5 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 5.61 (P < 0.00001)
5 eye opacity / eye pigment problems
Clark 1970a 0/15 0/14 Not estimable
Prien 1968 97/416 16/212 100.0 % 3.09 [ 1.87, 5.11 ]
Subtotal (95% CI) 431 226 100.0 % 3.09 [ 1.87, 5.11 ]
Total events: 97 (Chlorpromazine), 16 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 4.40 (P = 0.000011)
0.001 0.01 0.1 1 10 100 1000
Favours CPZ Favours placebo
177Chlorpromazine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.20. Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 20 Adverse effects: 4.
Other.
Review: Chlorpromazine versus placebo for schizophrenia
Comparison: 1 CHLORPROMAZINE versus PLACEBO
Outcome: 20 Adverse effects: 4. Other
Study or subgroup Chlorpromazine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 blood pressure - low +/- dizziness/syncope
Baker 1959 3/7 0/7 1.0 % 7.00 [ 0.43, 114.70 ]
Clark 1961 3/20 0/20 1.0 % 7.00 [ 0.38, 127.32 ]
Clark 1968a 2/18 4/36 5.3 % 1.00 [ 0.20, 4.95 ]
Clark 1968b 2/23 0/23 1.0 % 5.00 [ 0.25, 98.75 ]
Clark 1970a 2/15 0/14 1.0 % 4.69 [ 0.24, 89.88 ]
Clark 1970b 5/53 1/18 3.0 % 1.70 [ 0.21, 13.58 ]
Clark 1971 10/23 2/21 4.2 % 4.57 [ 1.13, 18.48 ]
Clark 1972 5/19 2/18 4.1 % 2.37 [ 0.52, 10.70 ]
Cole 1964 21/88 4/74 8.7 % 4.41 [ 1.59, 12.29 ]
Gwynne 1962 (1) 1/26 0/26 1.0 % 3.00 [ 0.13, 70.42 ]
Kurland 1961 2/33 1/74 1.2 % 4.48 [ 0.42, 47.74 ]
Prien 1968 52/416 15/212 39.6 % 1.77 [ 1.02, 3.06 ]
Ramu 1999a 1/22 0/20 1.0 % 2.74 [ 0.12, 63.63 ]
Reschke 1974 1/10 0/11 1.0 % 3.27 [ 0.15, 72.23 ]
Schiele 1961 1/20 0/20 1.0 % 3.00 [ 0.13, 69.52 ]
Serafetinides 1972 8/14 1/13 2.1 % 7.43 [ 1.07, 51.54 ]
Tetreault 1969 7/15 2/15 4.0 % 3.50 [ 0.86, 14.18 ]
Walsh 1959 10/22 10/22 19.9 % 1.00 [ 0.52, 1.91 ]
Subtotal (95% CI) 844 644 100.0 % 2.38 [ 1.74, 3.25 ]
Total events: 136 (Chlorpromazine), 42 (Placebo)
Heterogeneity: Chi2 = 14.99, df = 17 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 5.44 (P < 0.00001)
2 constipation
Clark 1968a 1/18 3/36 6.9 % 0.67 [ 0.07, 5.96 ]
Clark 1968b 2/23 0/23 1.7 % 5.00 [ 0.25, 98.75 ]
Clark 1970b 5/53 1/18 5.2 % 1.70 [ 0.21, 13.58 ]
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Study or subgroup Chlorpromazine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Clark 1971 4/23 2/21 7.2 % 1.83 [ 0.37, 8.96 ]
Clark 1972 3/19 2/18 7.1 % 1.42 [ 0.27, 7.54 ]
Clark 1977 0/9 1/9 5.2 % 0.33 [ 0.02, 7.24 ]
Cole 1964 29/88 9/74 33.8 % 2.71 [ 1.37, 5.35 ]
Prien 1968 19/416 6/212 27.5 % 1.61 [ 0.65, 3.98 ]
Serafetinides 1972 5/14 1/13 3.6 % 4.64 [ 0.62, 34.65 ]
Tetreault 1969 1/15 0/15 1.7 % 3.00 [ 0.13, 68.26 ]
Subtotal (95% CI) 678 439 100.0 % 2.05 [ 1.33, 3.15 ]
Total events: 69 (Chlorpromazine), 25 (Placebo)
Heterogeneity: Chi2 = 4.53, df = 9 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 3.28 (P = 0.0010)
3 urinary problems
Clark 1971 4/23 2/21 28.5 % 1.83 [ 0.37, 8.96 ]
Cole 1964 4/88 1/74 14.8 % 3.36 [ 0.38, 29.44 ]
Gwynne 1962 (2) 0/26 0/26 Not estimable
Prien 1968 7/416 2/212 36.2 % 1.78 [ 0.37, 8.51 ]
Schiele 1961 0/20 1/20 20.5 % 0.33 [ 0.01, 7.72 ]
Subtotal (95% CI) 573 353 100.0 % 1.73 [ 0.70, 4.30 ]
Total events: 15 (Chlorpromazine), 6 (Placebo)
Heterogeneity: Chi2 = 1.42, df = 3 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 1.19 (P = 0.24)
4 blurred vision
Clark 1968a 0/18 3/36 24.6 % 0.28 [ 0.02, 5.11 ]
Clark 1971 5/23 2/21 21.6 % 2.28 [ 0.49, 10.54 ]
Clark 1972 3/19 2/18 21.2 % 1.42 [ 0.27, 7.54 ]
Gwynne 1962 (3) 1/26 0/26 5.2 % 3.00 [ 0.13, 70.42 ]
Kurland 1961 0/33 0/74 Not estimable
Prien 1968 2/416 2/212 27.4 % 0.51 [ 0.07, 3.59 ]
Schiele 1961 0/20 0/20 Not estimable
Subtotal (95% CI) 555 407 100.0 % 1.16 [ 0.51, 2.65 ]
Total events: 11 (Chlorpromazine), 9 (Placebo)
Heterogeneity: Chi2 = 2.76, df = 4 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.35 (P = 0.73)
5 dry mouth
Clark 1971 6/23 2/21 19.6 % 2.74 [ 0.62, 12.12 ]
Clark 1977 1/9 0/9 4.7 % 3.00 [ 0.14, 65.16 ]
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Study or subgroup Chlorpromazine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Cole 1964 22/88 4/74 40.7 % 4.63 [ 1.67, 12.82 ]
Hankoff 1962 1/25 0/72 2.5 % 8.42 [ 0.35, 200.36 ]
Prien 1968 23/416 2/212 24.8 % 5.86 [ 1.39, 24.62 ]
Reschke 1974 1/10 0/11 4.5 % 3.27 [ 0.15, 72.23 ]
Somerville 1960 1/15 0/30 3.2 % 5.81 [ 0.25, 134.73 ]
Subtotal (95% CI) 586 429 100.0 % 4.56 [ 2.35, 8.85 ]
Total events: 55 (Chlorpromazine), 8 (Placebo)
Heterogeneity: Chi2 = 0.85, df = 6 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 4.48 (P < 0.00001)
6 weight increase
Clark 1968a 6/18 4/36 39.4 % 3.00 [ 0.97, 9.30 ]
Clark 1970a 4/15 0/14 7.6 % 8.44 [ 0.50, 143.77 ]
Clark 1972 10/19 2/18 30.3 % 4.74 [ 1.20, 18.73 ]
Clark 1977 4/9 0/9 7.4 % 9.00 [ 0.55, 146.11 ]
Serafetinides 1972 7/14 1/13 15.3 % 6.50 [ 0.92, 45.90 ]
Subtotal (95% CI) 75 90 100.0 % 4.92 [ 2.32, 10.43 ]
Total events: 31 (Chlorpromazine), 7 (Placebo)
Heterogeneity: Chi2 = 1.13, df = 4 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 4.16 (P = 0.000032)
7 weight decrease
Clark 1968a 4/18 16/36 31.0 % 0.50 [ 0.20, 1.28 ]
Clark 1970a 0/15 5/14 16.5 % 0.09 [ 0.01, 1.41 ]
Clark 1972 2/19 8/18 23.9 % 0.24 [ 0.06, 0.97 ]
Clark 1977 0/9 1/9 4.4 % 0.33 [ 0.02, 7.24 ]
Serafetinides 1972 5/14 8/13 24.1 % 0.58 [ 0.25, 1.32 ]
Subtotal (95% CI) 75 90 100.0 % 0.38 [ 0.22, 0.66 ]
Total events: 11 (Chlorpromazine), 38 (Placebo)
Heterogeneity: Chi2 = 2.87, df = 4 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 3.42 (P = 0.00063)
8 nausea/vomiting
Cole 1964 25/88 3/74 20.4 % 7.01 [ 2.20, 22.29 ]
Hankoff 1962 0/25 3/72 11.5 % 0.40 [ 0.02, 7.51 ]
Kurland 1961 0/33 1/74 5.9 % 0.74 [ 0.03, 17.59 ]
Prien 1968 10/416 6/212 49.7 % 0.85 [ 0.31, 2.31 ]
Tetreault 1969 2/15 2/15 12.5 % 1.00 [ 0.16, 6.20 ]
Subtotal (95% CI) 577 447 100.0 % 2.07 [ 1.14, 3.73 ]
0.001 0.01 0.1 1 10 100 1000
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Study or subgroup Chlorpromazine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 37 (Chlorpromazine), 15 (Placebo)
Heterogeneity: Chi2 = 9.54, df = 4 (P = 0.05); I2 =58%
Test for overall effect: Z = 2.40 (P = 0.016)
9 salivation
Cole 1964 5/88 0/74 12.9 % 9.27 [ 0.52, 164.92 ]
Prien 1968 12/416 2/212 63.2 % 3.06 [ 0.69, 13.54 ]
Schiele 1961 1/20 1/20 23.9 % 1.00 [ 0.07, 14.90 ]
Subtotal (95% CI) 524 306 100.0 % 3.37 [ 1.07, 10.57 ]
Total events: 18 (Chlorpromazine), 3 (Placebo)
Heterogeneity: Chi2 = 1.27, df = 2 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 2.08 (P = 0.037)
10 menorrhagia / abnormal menstruation
Clark 1968b 8/12 4/9 81.5 % 1.50 [ 0.65, 3.45 ]
Clark 1970a 1/13 1/12 18.5 % 0.92 [ 0.06, 13.18 ]
Subtotal (95% CI) 25 21 100.0 % 1.39 [ 0.62, 3.13 ]
Total events: 9 (Chlorpromazine), 5 (Placebo)
Heterogeneity: Chi2 = 0.12, df = 1 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 0.80 (P = 0.42)
11 amenorrhea
Cole 1964 3/88 3/73 100.0 % 0.83 [ 0.17, 3.99 ]
Subtotal (95% CI) 88 73 100.0 % 0.83 [ 0.17, 3.99 ]
Total events: 3 (Chlorpromazine), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.23 (P = 0.82)
12 lactation
Clark 1970a 5/15 5/15 90.2 % 1.00 [ 0.36, 2.75 ]
Cole 1964 3/88 0/74 9.8 % 5.90 [ 0.31, 112.39 ]
Subtotal (95% CI) 103 89 100.0 % 1.48 [ 0.57, 3.81 ]
Total events: 8 (Chlorpromazine), 5 (Placebo)
Heterogeneity: Chi2 = 1.42, df = 1 (P = 0.23); I2 =30%
Test for overall effect: Z = 0.81 (P = 0.42)
0.001 0.01 0.1 1 10 100 1000
Favours CPZ Favours placebo
(1) N not reported, assumed to be N randomised.
(2) N not reported, assumed to be N randomised.
(3) N not reported, assumed to be N randomised.
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Review: Chlorpromazine versus placebo for schizophrenia
Comparison: 1 CHLORPROMAZINE versus PLACEBO
Outcome: 21 SUBGROUP ANALYSIS: 1. MEN vs WOMEN: Behaviour: Deteriorated/disturbed/un-cooperative
Study or subgroup Chlorpromazine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 only men
Schiele 1961 0/20 12/20 100.0 % 0.04 [ 0.00, 0.63 ]
Subtotal (95% CI) 20 20 100.0 % 0.04 [ 0.00, 0.63 ]
Total events: 0 (Chlorpromazine), 12 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.28 (P = 0.022)
2 only women
Clark 1970b 10/53 6/18 24.5 % 0.57 [ 0.24, 1.34 ]
Fleming 1959 5/21 13/21 35.5 % 0.38 [ 0.17, 0.89 ]
Somerville 1960 5/15 22/30 40.0 % 0.45 [ 0.22, 0.96 ]
Subtotal (95% CI) 89 69 100.0 % 0.46 [ 0.29, 0.73 ]
Total events: 20 (Chlorpromazine), 41 (Placebo)
Heterogeneity: Chi2 = 0.40, df = 2 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 3.29 (P = 0.0010)
Test for subgroup differences: Chi2 = 2.91, df = 1 (P = 0.09), I2 =66%
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Review: Chlorpromazine versus placebo for schizophrenia
Comparison: 1 CHLORPROMAZINE versus PLACEBO
Outcome: 22 SUBGROUP ANALYSIS: 2. ACUTE vs CHRONIC
Study or subgroup Chlorpromazine Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 acute - Relapse (9 wks - 6 months)
Rappaport 1978 38/53 44/74 100.0 % 1.21 [ 0.94, 1.55 ]
Subtotal (95% CI) 53 74 100.0 % 1.21 [ 0.94, 1.55 ]
Total events: 38 (Chlorpromazine), 44 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.45 (P = 0.15)
2 chronic - Relapse (9 wks - 6 months)
Nishikawa 1982 6/10 8/10 34.7 % 0.75 [ 0.41, 1.36 ]
Peet 1981 4/16 7/18 26.9 % 0.64 [ 0.23, 1.80 ]
Prien 1968 39/416 85/212 38.4 % 0.23 [ 0.17, 0.33 ]
Subtotal (95% CI) 442 240 100.0 % 0.46 [ 0.18, 1.15 ]
Total events: 49 (Chlorpromazine), 100 (Placebo)
Heterogeneity: Tau2 = 0.54; Chi2 = 13.80, df = 2 (P = 0.001); I2 =86%
Test for overall effect: Z = 1.66 (P = 0.097)
3 acute - Global state 1. No overall improvement (0-8 wks)
Chouinard 1990 9/21 13/21 52.0 % 0.69 [ 0.38, 1.26 ]
Kurland 1961 9/33 30/74 48.0 % 0.67 [ 0.36, 1.25 ]
Subtotal (95% CI) 54 95 100.0 % 0.68 [ 0.44, 1.05 ]
Total events: 18 (Chlorpromazine), 43 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 1.74 (P = 0.083)
4 chronic - Global state 1. No overall improvement (0-8 wks)
Baker 1959 7/7 6/7 13.9 % 1.15 [ 0.79, 1.68 ]
Cooper 2000 26/53 35/53 14.3 % 0.74 [ 0.53, 1.04 ]
Fink 1963 10/51 30/44 11.6 % 0.29 [ 0.16, 0.52 ]
Ramu 1999 6/27 18/27 9.9 % 0.33 [ 0.16, 0.71 ]
Shepherd 1956 3/8 10/16 7.9 % 0.60 [ 0.23, 1.59 ]
Somerville 1960 7/15 23/30 11.8 % 0.61 [ 0.34, 1.08 ]
Vaughan 1955 8/24 19/24 11.5 % 0.42 [ 0.23, 0.77 ]
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Study or subgroup Chlorpromazine Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Walsh 1959 2/22 8/22 4.9 % 0.25 [ 0.06, 1.05 ]
Weckowicz 1960 11/14 13/15 14.3 % 0.91 [ 0.65, 1.27 ]
Subtotal (95% CI) 221 238 100.0 % 0.57 [ 0.39, 0.84 ]
Total events: 80 (Chlorpromazine), 162 (Placebo)
Heterogeneity: Tau2 = 0.24; Chi2 = 35.30, df = 8 (P = 0.00002); I2 =77%
Test for overall effect: Z = 2.86 (P = 0.0043)
5 acute - Global state 2. No overall improvement (9 wks-6 months)
Reardon 1966 1/11 6/12 100.0 % 0.18 [ 0.03, 1.28 ]
Subtotal (95% CI) 11 12 100.0 % 0.18 [ 0.03, 1.28 ]
Total events: 1 (Chlorpromazine), 6 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.71 (P = 0.087)
6 chronic - Global state 2. No overall improvement (9 wks-6 months)
Bishop 1963 2/10 10/10 1.6 % 0.24 [ 0.08, 0.71 ]
Clark 1961 13/19 19/19 10.2 % 0.69 [ 0.51, 0.95 ]
Clark 1968a 10/18 30/36 6.9 % 0.67 [ 0.43, 1.03 ]
Clark 1970a 8/15 9/14 4.3 % 0.83 [ 0.45, 1.53 ]
Clark 1972 10/19 14/18 5.9 % 0.68 [ 0.41, 1.11 ]
Clark 1977 3/9 9/9 2.5 % 0.37 [ 0.16, 0.87 ]
Grygier 1958 13/15 13/15 11.2 % 1.00 [ 0.76, 1.32 ]
Hall 1955 56/87 72/88 14.8 % 0.79 [ 0.65, 0.95 ]
Hine 1958 6/11 11/11 5.3 % 0.57 [ 0.33, 0.96 ]
Prien 1968 330/416 192/212 18.9 % 0.88 [ 0.82, 0.94 ]
Ramu 1999a 10/23 18/20 6.0 % 0.48 [ 0.30, 0.79 ]
Serafetinides 1972 12/14 13/13 12.4 % 0.86 [ 0.67, 1.11 ]
Subtotal (95% CI) 656 465 100.0 % 0.74 [ 0.64, 0.86 ]
Total events: 473 (Chlorpromazine), 410 (Placebo)
Heterogeneity: Tau2 = 0.03; Chi2 = 26.86, df = 11 (P = 0.005); I2 =59%
Test for overall effect: Z = 4.05 (P = 0.000052)
7 acute - Behaviour deteriorated/disturbed/unco-operative
Chouinard 1990 14/21 16/21 100.0 % 0.88 [ 0.60, 1.29 ]
Subtotal (95% CI) 21 21 100.0 % 0.88 [ 0.60, 1.29 ]
Total events: 14 (Chlorpromazine), 16 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
8 chronic - Behaviour deteriorated/disturbed/unco-operative
Clark 1970a 2/15 5/14 8.4 % 0.37 [ 0.09, 1.62 ]
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Study or subgroup Chlorpromazine Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Clark 1970b 10/53 6/18 11.9 % 0.57 [ 0.24, 1.34 ]
Fleming 1959 5/21 13/21 12.0 % 0.38 [ 0.17, 0.89 ]
Hall 1955 65/87 70/88 15.0 % 0.94 [ 0.80, 1.10 ]
Prien 1968 37/416 70/212 14.5 % 0.27 [ 0.19, 0.39 ]
Schiele 1961 0/20 12/20 3.9 % 0.04 [ 0.00, 0.63 ]
Serafetinides 1972 6/14 3/13 10.1 % 1.86 [ 0.58, 5.94 ]
Smith 1961 4/13 10/15 11.7 % 0.46 [ 0.19, 1.12 ]
Somerville 1960 5/15 22/30 12.5 % 0.45 [ 0.22, 0.96 ]
Subtotal (95% CI) 654 431 100.0 % 0.49 [ 0.26, 0.92 ]
Total events: 134 (Chlorpromazine), 211 (Placebo)
Heterogeneity: Tau2 = 0.69; Chi2 = 72.28, df = 8 (P<0.00001); I2 =89%
Test for overall effect: Z = 2.21 (P = 0.027)
Test for subgroup differences: Chi2 = 20.53, df = 7 (P = 0.00), I2 =66%
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Review: Chlorpromazine versus placebo for schizophrenia
Comparison: 1 CHLORPROMAZINE versus PLACEBO
Outcome: 23 SUBGROUP ANALYSIS: 3. HIGH vs LOW DOSE
Study or subgroup Chlorpromazine Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 high - Relapse (9 wks-6 Months)
Prien 1968 (1) 12/208 85/212 100.0 % 0.14 [ 0.08, 0.26 ]
Subtotal (95% CI) 208 212 100.0 % 0.14 [ 0.08, 0.26 ]
Total events: 12 (Chlorpromazine), 85 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 6.63 (P < 0.00001)
2 low - Relapse (9 wks-6 Months)
Nishikawa 1982 6/10 8/10 35.3 % 0.75 [ 0.41, 1.36 ]
Peet 1981 4/16 7/18 22.5 % 0.64 [ 0.23, 1.80 ]
Prien 1968 (2) 27/208 85/212 42.2 % 0.32 [ 0.22, 0.48 ]
Subtotal (95% CI) 234 240 100.0 % 0.51 [ 0.26, 0.98 ]
Total events: 37 (Chlorpromazine), 100 (Placebo)
Heterogeneity: Tau2 = 0.23; Chi2 = 6.71, df = 2 (P = 0.03); I2 =70%
Test for overall effect: Z = 2.01 (P = 0.045)
3 high - Global state 1. No overall improvement (0-8 wks)
Cooper 2000 26/53 35/53 53.2 % 0.74 [ 0.53, 1.04 ]
Fink 1963 10/51 30/44 46.8 % 0.29 [ 0.16, 0.52 ]
Subtotal (95% CI) 104 97 100.0 % 0.48 [ 0.18, 1.25 ]
Total events: 36 (Chlorpromazine), 65 (Placebo)
Heterogeneity: Tau2 = 0.43; Chi2 = 8.10, df = 1 (P = 0.004); I2 =88%
Test for overall effect: Z = 1.51 (P = 0.13)
4 low - Global state 1. No overall improvement (0-8 wks)
Baker 1959 7/7 6/7 15.2 % 1.15 [ 0.79, 1.68 ]
Hankoff 1962 12/16 65/68 16.6 % 0.78 [ 0.59, 1.05 ]
Kurland 1961 9/33 30/74 11.4 % 0.67 [ 0.36, 1.25 ]
Ramu 1999 6/27 18/27 9.6 % 0.33 [ 0.16, 0.71 ]
Reschke 1974 7/10 4/11 8.2 % 1.93 [ 0.80, 4.64 ]
Shepherd 1956 3/8 10/16 7.3 % 0.60 [ 0.23, 1.59 ]
Vaughan 1955 8/24 19/24 11.7 % 0.42 [ 0.23, 0.77 ]
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Study or subgroup Chlorpromazine Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Walsh 1959 2/22 8/22 4.2 % 0.25 [ 0.06, 1.05 ]
Weckowicz 1960 11/14 13/15 15.8 % 0.91 [ 0.65, 1.27 ]
Subtotal (95% CI) 161 264 100.0 % 0.72 [ 0.52, 1.01 ]
Total events: 65 (Chlorpromazine), 173 (Placebo)
Heterogeneity: Tau2 = 0.15; Chi2 = 25.70, df = 8 (P = 0.001); I2 =69%
Test for overall effect: Z = 1.93 (P = 0.054)
5 high - Global state 1. No overall improvement (9 wks-6 months)
Bishop 1963 2/10 10/10 6.1 % 0.24 [ 0.08, 0.71 ]
Clark 1968a 10/18 30/36 17.8 % 0.67 [ 0.43, 1.03 ]
Clark 1972 10/19 14/18 16.2 % 0.68 [ 0.41, 1.11 ]
Clark 1977 3/9 9/9 8.8 % 0.37 [ 0.16, 0.87 ]
Prien 1968 (3) 187/208 205/212 27.5 % 0.93 [ 0.88, 0.98 ]
Serafetinides 1972 12/14 13/13 23.5 % 0.86 [ 0.67, 1.11 ]
Subtotal (95% CI) 278 298 100.0 % 0.69 [ 0.51, 0.94 ]
Total events: 224 (Chlorpromazine), 281 (Placebo)
Heterogeneity: Tau2 = 0.09; Chi2 = 23.08, df = 5 (P = 0.00033); I2 =78%
Test for overall effect: Z = 2.33 (P = 0.020)
6 low - Global state 1. No overall improvement (9 wks-6 months)
Grygier 1958 13/15 13/15 33.5 % 1.00 [ 0.76, 1.32 ]
Prien 1968 (4) 193/208 205/212 44.1 % 0.96 [ 0.92, 1.00 ]
Ramu 1999a 10/23 18/20 22.4 % 0.48 [ 0.30, 0.79 ]
Subtotal (95% CI) 246 247 100.0 % 0.83 [ 0.60, 1.16 ]
Total events: 216 (Chlorpromazine), 236 (Placebo)
Heterogeneity: Tau2 = 0.06; Chi2 = 9.92, df = 2 (P = 0.01); I2 =80%
Test for overall effect: Z = 1.08 (P = 0.28)
7 high - Behaviour 1. Deteriorated/disturbed/unco-operative
Prien 1968 (5) 10/208 70/212 51.9 % 0.15 [ 0.08, 0.27 ]
Serafetinides 1972 6/14 3/13 48.1 % 1.86 [ 0.58, 5.94 ]
Subtotal (95% CI) 222 225 100.0 % 0.50 [ 0.04, 6.21 ]
Total events: 16 (Chlorpromazine), 73 (Placebo)
Heterogeneity: Tau2 = 3.10; Chi2 = 14.58, df = 1 (P = 0.00013); I2 =93%
Test for overall effect: Z = 0.54 (P = 0.59)
8 low - Behaviour 1. Deteriorated/disturbed/unco-operative
Fleming 1959 5/21 13/21 18.7 % 0.38 [ 0.17, 0.89 ]
Prien 1968 (6) 27/208 70/212 81.3 % 0.39 [ 0.26, 0.59 ]
Subtotal (95% CI) 229 233 100.0 % 0.39 [ 0.27, 0.56 ]
Total events: 32 (Chlorpromazine), 83 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.96); I2 =0.0%
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Study or subgroup Chlorpromazine Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for overall effect: Z = 5.09 (P < 0.00001)
Test for subgroup differences: Chi2 = 35.21, df = 7 (P = 0.00), I2 =80%
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(1) Trial had a high dose and low dose arm.
(2) Trial had a high dose and low dose arm.
(3) Trial had a high dose and low dose arm. Data provided as percentages and numbers are calculated based on all participants randomised.
(4) Trial had a high dose and low dose arm. Data provided as percentages and numbers are calculated based on all participants randomised.
(5) Trial had a high dose and low dose arm.
(6) Trial had a high dose and low dose arm.
Analysis 1.24. Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 24 SUBGROUP
ANALYSIS: 4. DIAGNOSTIC CRITERIA vs NO DIAGNOSTIC CRITERIA.
Review: Chlorpromazine versus placebo for schizophrenia
Comparison: 1 CHLORPROMAZINE versus PLACEBO
Outcome: 24 SUBGROUP ANALYSIS: 4. DIAGNOSTIC CRITERIA vs NO DIAGNOSTIC CRITERIA
Study or subgroup Chlorpromazine Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 diagnostic criteria - Relapse (0-8 wks)
Peet 1981 4/16 6/18 100.0 % 0.75 [ 0.26, 2.19 ]
Subtotal (95% CI) 16 18 100.0 % 0.75 [ 0.26, 2.19 ]
Total events: 4 (Chlorpromazine), 6 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.53 (P = 0.60)
2 no diagnostic criteria - Relapse (0-8 wks)
Spohn 1977 0/20 10/20 100.0 % 0.05 [ 0.00, 0.76 ]
Subtotal (95% CI) 20 20 100.0 % 0.05 [ 0.00, 0.76 ]
Total events: 0 (Chlorpromazine), 10 (Placebo)
0.1 0.2 0.5 1 2 5 10
Favours CPZ Favours placebo
(Continued . . . )
188Chlorpromazine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Chlorpromazine Placebo Risk Ratio Weight Risk Ratio
n/N n/N
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Heterogeneity: not applicable
Test for overall effect: Z = 2.15 (P = 0.031)
3 diagnostic criteria - Relapse (9 wks-6 months)
Peet 1981 4/16 7/18 38.1 % 0.64 [ 0.23, 1.80 ]
Prien 1968 39/416 85/212 61.9 % 0.23 [ 0.17, 0.33 ]
Subtotal (95% CI) 432 230 100.0 % 0.34 [ 0.13, 0.90 ]
Total events: 43 (Chlorpromazine), 92 (Placebo)
Heterogeneity: Tau2 = 0.36; Chi2 = 3.36, df = 1 (P = 0.07); I2 =70%
Test for overall effect: Z = 2.17 (P = 0.030)
4 no diagnostic criteria - Relapse (9 wks-6 months)
Nishikawa 1982 6/10 8/10 33.4 % 0.75 [ 0.41, 1.36 ]
Rappaport 1978 38/53 44/74 66.6 % 1.21 [ 0.94, 1.55 ]
Subtotal (95% CI) 63 84 100.0 % 1.03 [ 0.66, 1.60 ]
Total events: 44 (Chlorpromazine), 52 (Placebo)
Heterogeneity: Tau2 = 0.06; Chi2 = 2.08, df = 1 (P = 0.15); I2 =52%
Test for overall effect: Z = 0.13 (P = 0.90)
5 diagnostic criteria - Global state 1. No overall improvement (0-8 wks)
Chouinard 1990 9/21 13/21 33.0 % 0.69 [ 0.38, 1.26 ]
Clark 1971 3/23 11/21 13.5 % 0.25 [ 0.08, 0.77 ]
Cooper 2000 26/53 35/53 53.5 % 0.74 [ 0.53, 1.04 ]
Subtotal (95% CI) 97 95 100.0 % 0.63 [ 0.40, 0.99 ]
Total events: 38 (Chlorpromazine), 59 (Placebo)
Heterogeneity: Tau2 = 0.07; Chi2 = 3.54, df = 2 (P = 0.17); I2 =43%
Test for overall effect: Z = 2.00 (P = 0.046)
6 no diagnostic criteria - Global state 1. No overall improvement (0-8 wks)
Baker 1959 7/7 6/7 11.7 % 1.15 [ 0.79, 1.68 ]
Fink 1963 10/51 30/44 9.6 % 0.29 [ 0.16, 0.52 ]
Hankoff 1962 12/16 65/68 12.5 % 0.78 [ 0.59, 1.05 ]
Kurland 1961 9/33 30/74 9.3 % 0.67 [ 0.36, 1.25 ]
Ramu 1999 6/27 18/27 8.1 % 0.33 [ 0.16, 0.71 ]
Reschke 1974 7/10 4/11 7.1 % 1.93 [ 0.80, 4.64 ]
Shepherd 1956 3/8 10/16 6.4 % 0.60 [ 0.23, 1.59 ]
Somerville 1960 7/15 23/30 9.8 % 0.61 [ 0.34, 1.08 ]
Vaughan 1955 8/24 19/24 9.5 % 0.42 [ 0.23, 0.77 ]
Walsh 1959 2/22 8/22 3.9 % 0.25 [ 0.06, 1.05 ]
Weckowicz 1960 11/14 13/15 12.0 % 0.91 [ 0.65, 1.27 ]
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M-
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CI
Subtotal (95% CI) 227 338 100.0 % 0.64 [ 0.46, 0.90 ]
Total events: 82 (Chlorpromazine), 226 (Placebo)
Heterogeneity: Tau2 = 0.22; Chi2 = 40.32, df = 10 (P = 0.00001); I2 =75%
Test for overall effect: Z = 2.58 (P = 0.0099)
7 diagnostic criteria - Global state 1. No overall improvement (9 wks-6 months)
Clark 1961 13/19 19/19 37.2 % 0.69 [ 0.51, 0.95 ]
Prien 1968 330/416 192/212 60.5 % 0.88 [ 0.82, 0.94 ]
Reardon 1966 1/11 6/12 2.3 % 0.18 [ 0.03, 1.28 ]
Subtotal (95% CI) 446 243 100.0 % 0.77 [ 0.57, 1.05 ]
Total events: 344 (Chlorpromazine), 217 (Placebo)
Heterogeneity: Tau2 = 0.04; Chi2 = 4.91, df = 2 (P = 0.09); I2 =59%
Test for overall effect: Z = 1.67 (P = 0.095)
8 no diagnostic criteria - Global state 1. No overall improvement (9 wks-6 months)
Ban 1975 6/10 8/10 6.5 % 0.75 [ 0.41, 1.36 ]
Bishop 1963 2/10 10/10 2.4 % 0.24 [ 0.08, 0.71 ]
Clark 1968a 10/18 30/36 9.5 % 0.67 [ 0.43, 1.03 ]
Clark 1970a 8/15 9/14 6.2 % 0.83 [ 0.45, 1.53 ]
Clark 1972 10/19 14/18 8.3 % 0.68 [ 0.41, 1.11 ]
Clark 1977 3/9 9/9 3.7 % 0.37 [ 0.16, 0.87 ]
Grygier 1958 13/15 13/15 14.3 % 1.00 [ 0.76, 1.32 ]
Hall 1955 56/87 72/88 17.7 % 0.79 [ 0.65, 0.95 ]
Hine 1958 6/11 11/11 7.5 % 0.57 [ 0.33, 0.96 ]
Ramu 1999a 10/23 18/20 8.4 % 0.48 [ 0.30, 0.79 ]
Serafetinides 1972 12/14 13/13 15.4 % 0.86 [ 0.67, 1.11 ]
Subtotal (95% CI) 231 244 100.0 % 0.71 [ 0.59, 0.85 ]
Total events: 136 (Chlorpromazine), 207 (Placebo)
Heterogeneity: Tau2 = 0.04; Chi2 = 19.93, df = 10 (P = 0.03); I2 =50%
Test for overall effect: Z = 3.71 (P = 0.00021)
9 diagnostic criteria - Global state 3. Severity of illness (9 wks-6 months)
Prien 1968 298/416 186/212 100.0 % 0.82 [ 0.75, 0.88 ]
Subtotal (95% CI) 416 212 100.0 % 0.82 [ 0.75, 0.88 ]
Total events: 298 (Chlorpromazine), 186 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 5.05 (P < 0.00001)
10 no diagnostic criteria - Global state 3. Severity of illness (9 wks-6 months)
Clark 1970a 3/15 6/14 17.0 % 0.47 [ 0.14, 1.52 ]
Clark 1972 9/19 14/18 83.0 % 0.61 [ 0.36, 1.04 ]
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Subtotal (95% CI) 34 32 100.0 % 0.58 [ 0.36, 0.95 ]
Total events: 12 (Chlorpromazine), 20 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.17, df = 1 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 2.18 (P = 0.029)
11 diagnostic criteria - Behaviour 1. deteriorated/disturbed/unco-operative
Chouinard 1990 14/21 16/21 49.9 % 0.88 [ 0.60, 1.29 ]
Prien 1968 37/416 70/212 50.1 % 0.27 [ 0.19, 0.39 ]
Subtotal (95% CI) 437 233 100.0 % 0.48 [ 0.14, 1.72 ]
Total events: 51 (Chlorpromazine), 86 (Placebo)
Heterogeneity: Tau2 = 0.80; Chi2 = 22.97, df = 1 (P<0.00001); I2 =96%
Test for overall effect: Z = 1.12 (P = 0.26)
12 no diagnostic criteria - Behaviour 1. deteriorated/disturbed/unco-operative
Clark 1970a 2/15 5/14 8.3 % 0.37 [ 0.09, 1.62 ]
Clark 1970b 10/53 6/18 13.9 % 0.57 [ 0.24, 1.34 ]
Fleming 1959 5/21 13/21 14.2 % 0.38 [ 0.17, 0.89 ]
Hall 1955 65/87 70/88 20.8 % 0.94 [ 0.80, 1.10 ]
Schiele 1961 0/20 12/20 3.3 % 0.04 [ 0.00, 0.63 ]
Serafetinides 1972 6/14 3/13 10.8 % 1.86 [ 0.58, 5.94 ]
Smith 1961 4/13 10/15 13.5 % 0.46 [ 0.19, 1.12 ]
Somerville 1960 5/15 22/30 15.2 % 0.45 [ 0.22, 0.96 ]
Subtotal (95% CI) 238 219 100.0 % 0.56 [ 0.33, 0.97 ]
Total events: 97 (Chlorpromazine), 141 (Placebo)
Heterogeneity: Tau2 = 0.36; Chi2 = 25.14, df = 7 (P = 0.00072); I2 =72%
Test for overall effect: Z = 2.06 (P = 0.039)
Test for subgroup differences: Chi2 = 16.01, df = 11 (P = 0.14), I2 =31%
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Analysis 1.25. Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 25 SUBGROUP
ANALYSIS: 5. STUDIES PRE-1990 vs STUDIES 1990-2007.
Review: Chlorpromazine versus placebo for schizophrenia
Comparison: 1 CHLORPROMAZINE versus PLACEBO
Outcome: 25 SUBGROUP ANALYSIS: 5. STUDIES PRE-1990 vs STUDIES 1990-2007
Study or subgroup Chlorpromazine Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Pre-1990 - Global state 1. No overall improvement (0-8 wks)
Baker 1959 7/7 6/7 12.0 % 1.15 [ 0.79, 1.68 ]
Clark 1971 3/23 11/21 5.6 % 0.25 [ 0.08, 0.77 ]
Fink 1963 10/51 30/44 9.9 % 0.29 [ 0.16, 0.52 ]
Hankoff 1962 12/16 65/68 12.8 % 0.78 [ 0.59, 1.05 ]
Kurland 1961 9/33 30/74 9.6 % 0.67 [ 0.36, 1.25 ]
Reschke 1974 7/10 4/11 7.3 % 1.93 [ 0.80, 4.64 ]
Shepherd 1956 3/8 10/16 6.6 % 0.60 [ 0.23, 1.59 ]
Somerville 1960 7/15 23/30 10.1 % 0.61 [ 0.34, 1.08 ]
Vaughan 1955 8/24 19/24 9.8 % 0.42 [ 0.23, 0.77 ]
Walsh 1959 2/22 8/22 4.1 % 0.25 [ 0.06, 1.05 ]
Weckowicz 1960 11/14 13/15 12.3 % 0.91 [ 0.65, 1.27 ]
Subtotal (95% CI) 223 332 100.0 % 0.64 [ 0.46, 0.91 ]
Total events: 79 (Chlorpromazine), 219 (Placebo)
Heterogeneity: Tau2 = 0.22; Chi2 = 39.82, df = 10 (P = 0.00002); I2 =75%
Test for overall effect: Z = 2.52 (P = 0.012)
2 1990 to 2002 - Global state 1. No overall improvement (0-8 wks)
Chouinard 1990 9/21 13/21 29.6 % 0.69 [ 0.38, 1.26 ]
Cooper 2000 26/53 35/53 48.4 % 0.74 [ 0.53, 1.04 ]
Ramu 1999 6/27 18/27 22.1 % 0.33 [ 0.16, 0.71 ]
Subtotal (95% CI) 101 101 100.0 % 0.61 [ 0.40, 0.94 ]
Total events: 41 (Chlorpromazine), 66 (Placebo)
Heterogeneity: Tau2 = 0.07; Chi2 = 3.83, df = 2 (P = 0.15); I2 =48%
Test for overall effect: Z = 2.25 (P = 0.024)
3 Pre-1990 - Global state 1. No overall improvement (9 wks-6 months)
Ban 1975 6/10 8/10 4.2 % 0.75 [ 0.41, 1.36 ]
Bishop 1963 2/10 10/10 1.4 % 0.24 [ 0.08, 0.71 ]
Clark 1961 13/19 19/19 10.1 % 0.69 [ 0.51, 0.95 ]
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Study or subgroup Chlorpromazine Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Clark 1968a 10/18 30/36 6.6 % 0.67 [ 0.43, 1.03 ]
Clark 1970a 8/15 9/14 4.0 % 0.83 [ 0.45, 1.53 ]
Clark 1972 10/19 14/18 5.6 % 0.68 [ 0.41, 1.11 ]
Clark 1977 3/9 9/9 2.2 % 0.37 [ 0.16, 0.87 ]
Grygier 1958 13/15 13/15 11.3 % 1.00 [ 0.76, 1.32 ]
Hall 1955 56/87 72/88 15.6 % 0.79 [ 0.65, 0.95 ]
Hine 1958 6/11 11/11 4.9 % 0.57 [ 0.33, 0.96 ]
Prien 1968 330/416 192/212 21.0 % 0.88 [ 0.82, 0.94 ]
Reardon 1966 1/11 6/12 0.5 % 0.18 [ 0.03, 1.28 ]
Serafetinides 1972 12/14 13/13 12.6 % 0.86 [ 0.67, 1.11 ]
Subtotal (95% CI) 654 467 100.0 % 0.77 [ 0.67, 0.88 ]
Total events: 470 (Chlorpromazine), 406 (Placebo)
Heterogeneity: Tau2 = 0.02; Chi2 = 24.25, df = 12 (P = 0.02); I2 =51%
Test for overall effect: Z = 3.89 (P = 0.000099)
4 1990 to 2002 - Global state 1. No overall improvement (9 wks-6 months)
Ramu 1999a 10/23 18/20 100.0 % 0.48 [ 0.30, 0.79 ]
Subtotal (95% CI) 23 20 100.0 % 0.48 [ 0.30, 0.79 ]
Total events: 10 (Chlorpromazine), 18 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.92 (P = 0.0035)
5 Pre-1990 - Behaviour 1. deteriorated/disturbed/unco-operative
Clark 1970a 2/15 5/14 8.4 % 0.37 [ 0.09, 1.62 ]
Clark 1970b 10/53 6/18 11.9 % 0.57 [ 0.24, 1.34 ]
Fleming 1959 5/21 13/21 12.0 % 0.38 [ 0.17, 0.89 ]
Hall 1955 65/87 70/88 15.0 % 0.94 [ 0.80, 1.10 ]
Prien 1968 37/416 70/212 14.5 % 0.27 [ 0.19, 0.39 ]
Schiele 1961 0/20 12/20 3.9 % 0.04 [ 0.00, 0.63 ]
Serafetinides 1972 6/14 3/13 10.1 % 1.86 [ 0.58, 5.94 ]
Smith 1961 4/13 10/15 11.7 % 0.46 [ 0.19, 1.12 ]
Somerville 1960 5/15 22/30 12.5 % 0.45 [ 0.22, 0.96 ]
Subtotal (95% CI) 654 431 100.0 % 0.49 [ 0.26, 0.92 ]
Total events: 134 (Chlorpromazine), 211 (Placebo)
Heterogeneity: Tau2 = 0.69; Chi2 = 72.28, df = 8 (P<0.00001); I2 =89%
Test for overall effect: Z = 2.21 (P = 0.027)
6 1990 to 2002 - Behaviour 1. deteriorated/disturbed/unco-operative
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Study or subgroup Chlorpromazine Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Chouinard 1990 14/21 16/21 100.0 % 0.88 [ 0.60, 1.29 ]
Subtotal (95% CI) 21 21 100.0 % 0.88 [ 0.60, 1.29 ]
Total events: 14 (Chlorpromazine), 16 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
Test for subgroup differences: Chi2 = 6.77, df = 5 (P = 0.24), I2 =26%
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Analysis 1.26. Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 26 SENSITIVITY
ANALYSIS: 1. RANDOMISATION.
Review: Chlorpromazine versus placebo for schizophrenia
Comparison: 1 CHLORPROMAZINE versus PLACEBO
Outcome: 26 SENSITIVITY ANALYSIS: 1. RANDOMISATION
Study or subgroup Chlorpromazine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 not stated - Global state: 1. No overall improvement (9 weeks - 6 months)
Ramu 1999a 10/23 18/20 100.0 % 0.48 [ 0.30, 0.79 ]
Subtotal (95% CI) 23 20 100.0 % 0.48 [ 0.30, 0.79 ]
Total events: 10 (Chlorpromazine), 18 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.92 (P = 0.0035)
2 stated - Global state: 1. No overall improvement (9 weeks - 6 months)
Ban 1975 6/10 8/10 1.7 % 0.75 [ 0.41, 1.36 ]
Bishop 1963 2/10 10/10 2.3 % 0.24 [ 0.08, 0.71 ]
Clark 1961 13/19 19/19 4.2 % 0.69 [ 0.51, 0.95 ]
Clark 1968a 10/18 30/36 4.3 % 0.67 [ 0.43, 1.03 ]
Clark 1970a 8/15 9/14 2.0 % 0.83 [ 0.45, 1.53 ]
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Study or subgroup Chlorpromazine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Clark 1972 10/19 14/18 3.1 % 0.68 [ 0.41, 1.11 ]
Clark 1977 3/9 9/9 2.1 % 0.37 [ 0.16, 0.87 ]
Grygier 1958 13/15 13/15 2.8 % 1.00 [ 0.76, 1.32 ]
Hall 1955 56/87 72/88 15.5 % 0.79 [ 0.65, 0.95 ]
Hine 1958 6/11 11/11 2.5 % 0.57 [ 0.33, 0.96 ]
Prien 1968 330/416 192/212 55.1 % 0.88 [ 0.82, 0.94 ]
Reardon 1966 1/11 6/12 1.2 % 0.18 [ 0.03, 1.28 ]
Serafetinides 1972 12/14 13/13 3.0 % 0.86 [ 0.67, 1.11 ]
Subtotal (95% CI) 654 467 100.0 % 0.80 [ 0.75, 0.85 ]
Total events: 470 (Chlorpromazine), 406 (Placebo)
Heterogeneity: Chi2 = 24.25, df = 12 (P = 0.02); I2 =51%
Test for overall effect: Z = 7.11 (P < 0.00001)
Test for subgroup differences: Chi2 = 3.99, df = 1 (P = 0.05), I2 =75%
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Analysis 1.27. Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 27 SENSITIVITY
ANALYSIS: 2. ASSUMPTIONS FOR LOST BINARY DATA.
Review: Chlorpromazine versus placebo for schizophrenia
Comparison: 1 CHLORPROMAZINE versus PLACEBO
Outcome: 27 SENSITIVITY ANALYSIS: 2. ASSUMPTIONS FOR LOST BINARY DATA
Study or subgroup Chlorpromazine Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 LOCF - Global state: 1. No overall improvement (0-8 weeks)
Chouinard 1990 9/21 13/21 60.4 % 0.69 [ 0.38, 1.26 ]
Clark 1971 3/23 11/21 39.6 % 0.25 [ 0.08, 0.77 ]
Subtotal (95% CI) 44 42 100.0 % 0.46 [ 0.17, 1.29 ]
Total events: 12 (Chlorpromazine), 24 (Placebo)
Heterogeneity: Tau2 = 0.36; Chi2 = 2.70, df = 1 (P = 0.10); I2 =63%
Test for overall effect: Z = 1.47 (P = 0.14)
2 not LOCF - Global state: 1. No overall improvement (0-8 weeks)
Baker 1959 7/7 6/7 10.8 % 1.15 [ 0.79, 1.68 ]
Cooper 2000 26/53 35/53 11.3 % 0.74 [ 0.53, 1.04 ]
Fink 1963 10/51 30/44 8.5 % 0.29 [ 0.16, 0.52 ]
Hankoff 1962 12/16 65/68 11.8 % 0.78 [ 0.59, 1.05 ]
Kurland 1961 9/33 30/74 8.2 % 0.67 [ 0.36, 1.25 ]
Ramu 1999 6/27 18/27 6.9 % 0.33 [ 0.16, 0.71 ]
Reschke 1974 7/10 4/11 5.9 % 1.93 [ 0.80, 4.64 ]
Shepherd 1956 3/8 10/16 5.2 % 0.60 [ 0.23, 1.59 ]
Somerville 1960 7/15 23/30 8.7 % 0.61 [ 0.34, 1.08 ]
Vaughan 1955 8/24 19/24 8.4 % 0.42 [ 0.23, 0.77 ]
Walsh 1959 2/22 8/22 3.1 % 0.25 [ 0.06, 1.05 ]
Weckowicz 1960 11/14 13/15 11.3 % 0.91 [ 0.65, 1.27 ]
Subtotal (95% CI) 280 391 100.0 % 0.66 [ 0.49, 0.88 ]
Total events: 108 (Chlorpromazine), 261 (Placebo)
Heterogeneity: Tau2 = 0.16; Chi2 = 38.45, df = 11 (P = 0.00007); I2 =71%
Test for overall effect: Z = 2.87 (P = 0.0041)
Test for subgroup differences: Chi2 = 0.42, df = 1 (P = 0.52), I2 =0.0%
0.5 0.7 1 1.5 2
Favours CPZ Favours placebo
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A D D I T I O N A L T A B L E S
Table 1. Mental state: 3. Average BPRS change score (large decline=best)
Study Chlorpro-
mazine mean
Chlorpro-
mazine SD
Chlorpro-
mazine N
Placebo mean Placebo SD Placebo N
Cooper 2000 -4.3 19.1 53 (LOCF) -2.9 16.3 53 (LOCF)
LOCF - last observation carried forward
A P P E N D I C E S
Appendix 1. Previous plain language summary
Chlorpromazine versus placebo for schizophrenia
Schizophrenia is a long-term illness with a worldwide lifetime prevalence of about one per cent. Many people who suffer from
schizophrenia live with considerable disability. Chlorpromazine was one of the first drugs discovered to be effective in its treatment
back in the 1950s - and is still used extensively today.This review updates the information available from trials in which chlorpromazine
was compared with placebo. In addition it attempts to look at outcomes in smaller sub-groups of people, by sex, by age, by length of
illness, by dose of chlorpromazine, by criteria of diagnosis or by whether they were diagnosed before or after 1990. This update adds
five studies giving a total of 55 studies and the included data have been divided as to whether they refer to short, medium or long-
term treatment. When looking at chlorpromazine versus placebo for schizophrenia since the first review in 1995, 370 trials have been
considered but 315 have been excluded, many because of flaws in the research methods or the reporting of the data. This is a shame
and much opportunity has been lost to report outcomes of interest to the reviewers and others.Chlorpromazine has been shown to
improve both a person’s symptoms and functioning in 14 trials containing 1164 people. Chlorpromazine reduces relapse in the short,
medium and long term. Many trials, however, have demonstrated that chlorpromazine has a number of adverse effects when compared
with placebo important ones being movement disorders, sleepiness, skin sensitivity to sunlight, low blood pressure and constipation.
The main weakness of these trials is that the majority are conducted on people who are in hospital. The results, therefore, may, at
best, be only partially applicable to people in the community.(Plain language summary prepared for this review by Janey Antoniou of
RETHINK, UK www.rethink.org).
Appendix 2. Previous search strategies
1.2 Details of previous electronic search:
1.2.1 We searched The Cochrane Schizophrenia Group Trials Register (June 2002) using the phrase:
{[(*anadep* or *chloractil* or *chlorazin* or *chlorpromados* or *chlorpromazine* or *chlorprom-ez-ets* or *(chlor p-z)* or
*chromedazine* or *cpz* or *elmarine* or *esmind* or *fenactil* or *hibanil* or *hibernal* or *klorazin* or *klorproman* or *klor-
promez* or *largactil* or *megaphen* or *neurazine* or *plegomazine* or *procalm* or *promachel* or *promacid* or *promapar*
or *promexin* or *promosol* or *prozil* or *psychozine* or *psylactil* or *serazone* or *sonazine* or *thoradex* or *thorazine* or
*tranzine*) in title, abstract, index terms of REFERENCE] or [chlorpromazine* in interventions of STUDY]}
Chlorpromazine is known by many names and we constructed the following search phrase in order to try to aid identification:
(chlorpromazine-phrase)=(anadep or chloractil or chlorazin or chlorpromados or chlorpromazine or chlorprom-ez-ets or (chlor p-z)
or chromedazine or cpz or elmarine or esmind or fenactil or hibanil or hibernal or klorazin or klorproman or klorpromez or largactil
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or megaphen or neurazine or plegomazine or procalm or promachel or promacid or promapar or promexin or promosol or prozil or
psychozine or psylactil or (RP near1 4560) or serazone or sonazine or thoradex or thorazine or tranzine).
1.2.2 We searched The Cochrane Schizophrenia Group Trials Register (October 1999) using the phrase:
(((chlorpromazine-phrase) or (#42=5)) and (placebo* or (#42=4)))
#42 is the ’Intervention’ field and 5 is the code for chlorpromazine; 4 is the code for placebo
1.2.3 We searched Biological Abstracts (January 1982 to May 1995) using The Cochrane Schizophrenia Group’s phrase for both
randomised controlled trials and schizophrenia (see: Group search strategy) combined with the phrase:
((chlorpromazine-phrase) and placebo*)
1.2.4 We searched The Cochrane Library (1999, Issue 2) using the phrase:
((chlorpromazine-phrase) and placebo)
1.2.5 We searched EMBASE (January 1980 to May 1995) using The Cochrane Schizophrenia Group’s phrase for both randomised
controlled trials and schizophrenia (see Group search strategy) combined with the phrase:
(and (chlorpromazine-phrase) and placebo*)
1.2.6 We searched MEDLINE (January 1966 to May 1995) using The Cochrane Schizophrenia Group’s phrase for both randomised
controlled trials and schizophrenia (see Group search strategy) combined with the phrase:
(and (chlorpromazine-phrase) and placebo*)
1.2.7 We searched PsycLIT (January 1974 to May 1995) using The Cochrane Schizophrenia Group’s phrase for both randomised
controlled trials and schizophrenia (see Group search strategy) combined with the phrase:
(and (chlorpromazine-phrase) and placebo*)
1.2.8 We searched local library listings of books/university series/dissertations relating to chlorpromazine using the phrase:
(and (chlorpromazine-phrase) and placebo*)
1.2.9 We searched Scisearch Citation Index database using each citation from the included studies. We inspected reports of articles
that had cited these studies in order to identify further trials.
1. Cochrane Schizophrenia Group Trials Register (January 2007)
We searched The Cochrane Schizophrenia Group Trials Register (January 2007) using the phrase:
{[((*anadep* or *chlora* or *chlorprom* or *(chlor p-z)* or *chromeda* or *cpz* or *elmarine* or *esmind* or *fenactil* or *hibanil* or
*hibernal* or *klorazin* or *klorpro* or *largactil* or *megaphen* or *neurazin* or *plegomaz* or *procalm* or *proma* or *promexin*
or *promosol* or *prozil* or *psychozin* or *psylactil* or *serazon* or *sonazin* or *thoradex* or *tranzine*) and placebo*) in title,
abstract, index terms of REFERENCE] or [)chlorpromazine* and placebo*) in interventions of STUDY]}
Appendix 3. Previous data collection
1. Study selection
We (BT, CEA and JR) independently inspected citations from the searches and identified relevant abstracts. GA independently re-
inspected a random 10% sample to ensure reliability. Where disputes arose, we acquired the full report for more detailed scrutiny. We
(BT and JR) obtained and inspected full reports of the abstracts meeting the review criteria. Again, a random 10% of reports were re-
inspected by CEA and GA in order to ensure reliable selection. Where it was not possible to resolve disagreement by discussion, an
attempt was made to contact the authors of the study for clarification. For the 2007 update, we independently inspected and selected
citations from the search results.
2. Assessment of methodological quality
We (BT, JR) assessed the methodological quality of included trials in this review using the criteria described in The Cochrane Handbook
(Higgins 2005). It is based on the evidence of a strong relationship between allocation concealment and direction of effect (Schulz
1995). When disputes arose as to which category a trial should be allocated, again we attempted resolution by discussion. When this
was not possible, we did not enter the data and added the trial to the list of those awaiting assessment until further information could
be obtained. The categories are defined below:
A. Low risk of bias (adequate allocation concealment)
B. Moderate risk of bias (some doubt about the results)
C. High risk of bias (inadequate allocation concealment).
In addition, for the first version of this review, we rated studies using the Jadad Scale (Jadad 1996) but this was not applied for the
updates, as it was found to add little to the initial version. The reliability of quality-rating was checked by CEA and GA who re-rated
a 10% sample of the selected studies.
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3. Data management
3.1. Data extraction
We (BT and JR) independently extracted data and, where further clarification was needed we contacted the authors of trials to provide
missing data. CEA and GA independently checked a 10% sample for reliability. Any disagreements were discussed and decisions
documented. For the 2007 update, JR independently extracted data and contacted authors of trials for missing data.
4. Data synthesis
4.1 Data types: We assessed outcomes using continuous (e.g. average changes on a behaviour scale), categorical (e.g. one of three
categories on a behaviour scale, such as ’little change’, ’moderate change’ or ’much change’) or dichotomous measures, e.g. either ’no
important change’ or ’important change’ in a person’s behaviour. RevMan software does not currently support categorical data, so we
only presented these in the text of the review.
4.2 Binary data
For binary outcomes we calculated the relative risk (RR) and its 95% confidence interval (CI) based on the fixed-effect model. Relative
Risk is more intuitive (Boissel 1999) than odds ratios and odds ratios tend to be interpreted as RR by clinicians (Deeks 2000). This
misinterpretation then leads to an overestimate of the impression of the effect. When the overall results were significant we calculated
the number needed to treat (NNT) and the number needed to harm (NNH). Where people were lost to follow-up at the end of the
study, we assumed that they had had a poor outcome and once they were randomised we included them in the analysis (intention-to-
treat /ITT analysis).
Where possible, we attempted to convert outcome measures to binary data. This can be done by identifying cut-off points on rating
scales and dividing participants accordingly into “clinically improved” or “not clinically improved”. It was generally assumed that if
there had been a 50% reduction in a scale-derived score such as the Brief Psychiatric Rating Scale (BPRS, Overall 1962) or the Positive
and Negative Syndrome Scale (PANSS, Kay 1986), this could be considered as a clinically significant response (Leucht 2005a; Leucht
2005b). It was recognised that for many people, especially those with chronic or severe illness, a less rigorous definition of important
improvement (e.g. 25% on the BPRS) would be equally valid. If individual patient data were available, we used the 50% cut-off for
the definition in the case of non-chronically ill people and 25% for those with chronic illness. If data based on these thresholds were
not available, we used the primary cut-off presented by the original authors.
4.3 Continuous data
4.3.1 Normal distribution
Continuous data on outcomes in trials relevant to mental health issues are often not normally distributed. To avoid the pitfall of
applying parametric tests to non-parametric data we applied the following standards to continuous final value endpoint data before
inclusion: (a) standard deviations and means were reported in the paper or were obtainable from the authors; (b) when a scale started
from zero, the standard deviation, when multiplied by two, should be less than the mean (otherwise the mean is unlikely to be an
appropriate measure of the centre of the distribution, Altman 1996); In cases with data that are greater than the mean we entered these
into ’Other data’ table as skewed data. If a scale starts from a positive value (such as PANSS, which can have values from 30 to 210) the
calculation described above in (b) should be modified to take the scale starting point into account. In these cases skewness is present if
2SD>(S-Smin), where S is the mean score and Smin is the minimum score.
For change data (mean change from baseline on a rating scale) it is impossible to tell whether or not data are non-normally distributed
(skewed) unless individual patient data are available. After consulting the ALLSTAT electronic statistics mailing list, we presented
change data in RevMan graphs to summarise available information. In doing this, we assumed either that data were not skewed or that
the analysis could cope with the unknown degree of skew.
4.3.2 Final endpoint value versus change data
Where both final endpoint data and change data were available for the same outcome category, we only presented endpoint data. We
acknowledge that by doing this much of the published change data may be excluded, but argue that endpoint data is more clinically
relevant and that if change data were to be presented along with endpoint data, it would be given undeserved equal prominence.
4.4 Rating scales: A wide range of instruments are available to measure mental health outcomes. These instruments vary in quality and
many are not valid, and are known to be subject to bias in trials of treatments for schizophrenia (Marshall 2000). Therefore we only
included continuous data from rating scales if the measuring instrument had been described in a peer-reviewed journal.
4.5 Cross-over design
We expected that some trials would use a cross-over design. In order to exclude the potential additive effect in the second or later stages
in these trials we only analysed data from the first stage.
4.6 Cluster trials
Studies increasingly employ “cluster randomisation” (such as randomisation by clinician or practice) but analysis and pooling of clustered
data poses problems. Firstly, authors often fail to account for intra class correlation in clustered studies, leading to a “unit of analysis”
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error (Divine 1992) whereby P values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated.
This causes type 1 errors (Bland 1997; Gulliford 1999).
Where clustering was not accounted for in primary studies, we presented the data in a table, with a (*) symbol to indicate the presence
of a probable unit of analysis error. in subsequent versions of this review we will seek to contact first authors of studies to obtain intra-
class correlation co-efficients of their clustered data and to adjust for this using accepted methods (Gulliford 1999). Where clustering
has been incorporated into the analysis of primary studies, we will also present these data as if from a non-cluster randomised study,
but adjusted for the clustering effect.
We have sought statistical advice and have been advised that the binary data as presented in a report should be divided by a “design
effect”. This is calculated using themean number of participants per cluster (m) and the intraclass correlation co-efficient (ICC) [Design
effect=1+ (m-1)*ICC] (Donner 2002). If the ICC was not reported it was assumed to be 0.1 (Ukoumunne 1999).
If cluster studies had been appropriately analysed taking into account intra-class correlation coefficients and relevant data documented
in the report, synthesis with other studies would have been possible using the generic inverse variance technique.
5. Investigation for heterogeneity
Firstly, we considered all the included studies within any comparison to judge for clinical heterogeneity then we visually inspected
the graphs to investigate the possibility of statistical heterogeneity. This was supplemented using, primarily, the I-squared statistic.
This provides an estimate of the percentage of variability due to heterogeneity rather than chance alone. Where the I-squared estimate
was greater than or equal to 75%, we interpreted this as indicating the presence of high levels of heterogeneity (Higgins 2003). If
heterogeneity was found, we re-analysed the data using a random-effects model to see if this made a substantial difference. If it did,
we did not add the studies responsible for heterogeneity to the main body of homogeneous trials, but summated and presented them
separately and investigated reasons for heterogeneity.
6. Addressing publication bias
We undertook funnel plots (trial affect versus trial size) for outcomes where more than five trials reported usable data and no clear
asymmetry was apparent.
7. Sensitivity analysis
We anticipated that this would be a large review in comparison to many within the field of mental health. As a result this gave an
opportunity for several sensitivity analyses to be undertaken. These sensitivity analyses are listed (see: in Objectives). BT, CEA and JR
selected relevant trials at the data extraction stage of the review. The synthesised results of the groups of trials were inspected for overlap
of the 95% confidence intervals.
8. General
Where possible we presented data so that results shown to the left of the line of no effect favoured chlorpromazine.
F E E D B A C K
Methods and results
Summary
Methods - summary statistic
I think it would be helpful if you were to include in your review additional measures of effect size. While you report the relative risk and
number needed to treat, many of us not in medical or epidemiological fields tend to use effect size analysis (Cohen 1983), in standard
deviation, units to evaluate strength of effect. For binary outcomes, we also tend to use the difference in the percentage of those having
the desired outcome in the experimental treatment minus the percentage having the desired effect in the control treatment. Using your
study to illustrate, if the percentage of the placebo treated group showing symptomatic remission is 40 and the NNT is 7, then the
percentage of drug treated participants showing symptom remission is 52.5 (100/(7+1)=.125+.40 =.525). Then the effect size is 12.5
percent, or a small to moderate effect size. I think that adding this type of layman-accessible translation will enhance the utility and
breadth of appeal of your analysis.
Results - sensitivity analysis
Are there differences between early (first and second) episode patients and those with a more chronic course? I think it reasonable to
expect a higher proportion of placebo remissions in early episodes, and perhaps a different (smaller or larger) effect size for the drugs.
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In looking through the titles of the articles included in your review, it seems that most studies are of the more chronic group. If you
can segregate the early episode studies form the more chronic ones, I think the field could learn a great deal about whether the drug
has different effects at these different stages of illness. In relation to the Rappaport (1978) first episode study, you might consider a
comment on the portion of the placebo treated group that appeared to do better without drugs. If there is such a subgroup, this would
be important to know.
Results and conclusions - the interaction of drug effects and study design
From what we know of the conventional antipsychotic effect, there is a dopamine blocking action that appears correlated with the effect.
The body responds to this blocking by generating additional dopamine receptors. Subsequent withdrawing of antipsychotics can thus
increase the likelihood of a subsequent episode of psychosis to be greater than if drugs were never given (Chouinard 1978, Chouinard
1980, Warner 1985). In relation to study design, this effect can operate in a number of ways, potentially introducing bias into study
results. If the study is of first episode patients and the control group does not receive antipsychotics, then there is no problem. Warner
(1985) calls this design ’initial assignment’. But if, while waiting for participants to be collected, early recruits are given medication that
for some of them (subsequently assigned to the control group) is later withdrawn, effect size estimates, particularly those using ’relapse’
as the dependent variable, will be biased in favour of the drug treated group. This is due to the increased likelihood of ’supersensitivity’
psychosis (Chouinard 1978, Chouinard 1980) associated with drug withdrawal. Warner (1985) calls this design ’drug withdrawal’.
These issues become more complex when studying a more chronic population (virtually all of whom have been previously medicated).
Certainly a sudden drug withdrawal will insert this bias, but most studies you cite seem to use ’wash-out periods’ of varying lengths.
The real question here is whether the length of the wash out period is sufficient to conduct a fair test. If it’s not, there is a bias favouring
the drug treatment group in the design. If there is a way, in your analysis, to control for length of wash-out period, it might produce
’clean’ estimates of drug-effect for chronically ill people. It would also help to clarify empirically whether the length of the wash-out
period is a significant issue (by whether the effect size changes when length of wash-out is included as a control variable).
Reply
The reviewers would first like to thank Dr Bola for his detailed comment and patience. It has taken us a shamefully long time to address
the issues he raised.
Methods - summary statistic
We have taken advice on this comment as regards the use of an additional effect size statistic. The two statisticians consulted suggested
that accessibility is best served by the NNT statistic and the effect size adds little. Although it is now well recognised that there are
difficulties with the NNT in meta-analysis it is still thought to be of use. The reviewers have tried to reword were necessary and clarify
the numbers without decreasing readability.
Results - sensitivity analysis
Dr Bola highlighted that we had not completed the review. We had intended to undertake several additional sensitivity analyses. One
of these was to compare, for primary outcomes, if any clear differences were suggested for the effect of chlorpromazine compared with
placebo, when a group of people whose illnesses were not chronic were included in the study, as against people with more chronic
illnesses. We too expected to see a difference but data were so limited that nothing could be said with confidence. For the outcome of
medium term relapse the results of the Rappaport 1978 study (acutely ill people) are different from the synthesised findings of three
studies dealing with a more chronic population. This difference was not, however, statistically significant. The other outcomes in this
sensitivity analysis do not show any suggestion of a difference. We agree that it would have been important to know with certainty if
a portion of the placebo treated group that appeared to do better without drugs. This review generates some hypotheses that could be
worth testing. The data are very far from being strong enough to all any clear conclusions to be drawn.
Results and conclusions - the interaction of drug effects and study design
We completely accept Dr Bola’s comment about the possible interaction of length of washout and effect of chlorpromazine. There is
just not enough data to be able to control for this in the current analyses. Taking this into account, along with the other potential biases
that could be operating, often favouring the chlorpromazine group, gives all the more reason to treat the current estimates of the size
of the effect of this drug with caution.
Contributors
Comment by John Bola, Los Angeles, CA, USA, March 2000.
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Feedback received, 18 August 2015
Summary
Comment #1: The authors mention in the abstract of this huge review ((55 trials and 5,506 patients) without any reservation that
akathisia didn’t occur more often in the chlorpromazine group than in the placebo group. The largest trial that contributed data to
this outcome even found significantly less akathisia in the active group than in the placebo group, relative risk 0.57, 95% CI 0.37 to
0.88. Since we know that antipsychotics cause akathisia and that placebo cannot cause akathisia, this result speaks volumes about how
flawed trials in schizophrenia generally are. What was seen in the placebo group were cold turkey symptoms caused by withdrawal of
the antipsychotics the patients had received before randomisation.
Comment #2: I [Professor Gøtzsche] believe this fundamental problem renders the review unreliable
Comment #3 : I [Professor Gøtzsche] refer readers to another review. The most reliable placebo controlled trials are those of first
episode schizophrenia where none of the patients have ever received drugs before. There is a Cochrane review that approaches this
ideal, but even this review is biased, as the trials are not limited to first episode patients; the review includes studies “with a majority
of first and second episode schizophrenia spectrum disorders” (4). The authors of that Cochrane review pointed out that the available
evidence doesn’t support a conclusion that antipsychotic treatment in an acute early episode of schizophrenia is effective. They felt
this was worrying given the widespread use of antipsychotics in the acute treatment of early episode schizophrenia-type psychoses, and
also because the use of antipsychotics for millions of people with an early episode appears based on the trials for those with multiple
previous episodes (which we know are highly flawed). What does this mean for use of antipsychotics more generally, also for multiple
episodes of psychoses? Doesn’t it mean that we don’t have the evidence to support using antipsychotics at all? In fact, despite the trials
being flawed by the cold turkey design, what was seen in recent placebo controlled trials in submissions to the FDA was only a 6 point
improvement on the Positive and Negative Syndrome Scale (PANSS) (5,6), far below the minimally relevant clinical effect on this scale,
which is about 15 points (7).
Reply
Response #1: Thank you for this comment. The abstract is accurate in that we found, for akathisia, for these trials RR was 0.78 (CI
0.54 to 1.11, 9 RCTs, n=1164). Professor Gøtzsche says that “we know that that antipsychotics cause akathisia and that placebo cannot
cause akathisia.” Antipsychotics can cause akathisia, but these symptoms are well recognised to also occur in people who have never
been on medication. Even a cursory search of the literature highlights study after study illustrating this odd fact 1−3. It is indeed possible
that the akathisia people displayed in these trials was due to preceding medications, but also a whole raft of other factors that are not
speculated upon in a balanced argument. Professor Gøtzsche goes on to say that his statement “speaks volumes” about how flawed trials
in schizophrenia generally are”. Professor Gøtzsche’s statement is poorly-supported and - even if it had been supported - generalising
his perception of nine trials conducted between 1961 and 1970 to all of trials in schizophrenia is unscientific and not appropriate.
Response #2: The authors of the review make effort to provide a balanced appraisal of the best available evidence and have made efforts
within the review to be transparent. Every one of the studies has been rated in detail regarding risk of bias and pre-defined outcomes
given particular scrutiny for the Summary of Findings table. Professor Gøtzsche has selected one outcome which he finds fault with,
speculates as to its cause, generalises to all of trials relevant to people with schizophrenia, and dismisses the review. We feel this is
unwarranted.
Response #3: There is much in this comment that does not relate to this review. Important for this review is the statement “The most
reliable placebo controlled trials are those of first episode schizophrenia where none of the patients have ever received drugs before.”
Professor Gøtzsche does not explain what he means by reliable. It seems likely that he is suggesting the explanatory exploration of the
effects of medications - and is right in saying that trials in the group of people who have not had any medication before may help this
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exploration. It does not, however, help exploration of the effects of drugs for the great majority of people who have the illness in real-
world circumstances. Professor Gøtzsche goes on to make statements about another review which we also feel are equally unwarranted
but are not relevant to this evidence within the Chlorpromazine versus placebo review. Professor Gøtzsche is right in saying that the
Chlorpromazine versus placebo review was “huge”. He has chosen to comment on one outcome amongst hundreds, has not evidence
to support his speculative interpretation of the finding and then used this as a basis for developing the argument across another review
and well beyond. His final statements are a rallying call and not relevant to the Chlorpromazine versus placebo review and consistent
with his recent statements to the press where he advertises his book attempting to discredit all psychiatry drugs ( Daily Mail) to which
others have reacted ( Royal College of Psychiatrists 2015).
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Contributors
Feedback comment: Peter C Gøtzsche: Director Nordic Cochrane Centre.
Reply: Clive E Adams. Author, Cochrane Schizophrenia Group.
WH A T ’ S N E W
Date Event Description
30 October 2015 Amended Reply to Feedback received 18 August 2015
H I S T O R Y
Protocol first published: Issue 3, 1996
Review first published: Issue 1, 1998
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Date Event Description
7 September 2015 Amended New Feedback received.
3 December 2013 New citation required but conclusions have not
changed
Results of update search added to review, no substantial
change to overall conclusions
5 November 2012 New search has been performed Update search carried out November 2012. Five new
trials added to the review
15 May 2012 Amended Update search of Cochrane Schizophrenia
Group’s Trial Register (see Search methods for
identification of studies), 26 studies added to awaiting
classification.
14 March 2012 Amended Additional table(s) linked to text.
18 January 2012 Amended Contact details updated.
24 April 2009 Amended New plain language summary added.
23 April 2008 Amended Converted to new review format.
30 January 2007 New citation required and conclusions have changed Substantive amendment
C O N T R I B U T I O N S O F A U T H O R S
Clive Adams - protocol development, searching, data extraction, analysis, data interpretation, writing the final report and maintaining
the review.
John Rathbone - study selection, data extraction, analysis, writing the report for the update of 2002. Update 2007, study selection,
data extraction, data analysis, writing final report.
George Awad - protocol development, data interpretation.
Ben Thornley - completion of earlier versions of this review.
Karla Soares-Weiser - completion of 2012 update.
Nicola Maayan - completion of 2012 update.
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D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
Internal sources
• University of Toronto, Canada.
• University of Leeds, UK.
External sources
• NHS Executive Anglia and Oxford R&D Directorate, UK.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We have updated the methods section since the last publication of this review to reflect changes in the Cochrane Schizophrenia Group’s
methodology.
We have re-ordered some of the outcomes.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Antipsychotic Agents [adverse effects; ∗therapeutic use]; Chlorpromazine [adverse effects; ∗therapeutic use]; PlaceboEffect; Randomized
Controlled Trials as Topic; Schizophrenia [∗drug therapy; prevention & control]; Secondary Prevention
MeSH check words
Humans
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